Compounds having T-structure formed by at least four rings for treatment of cancer and other indications

By developing compounds that can disrupt the interaction between PI3Kα and small GTPase, the problems of existing PI3K inhibitors in the treatment of cancer toxicity and drug resistance are solved, and effective inhibition of tumor cells is achieved without affecting the metabolism of normal cells. Safer treatment options.

CN118946555APending Publication Date: 2024-11-12THERAS INC +2
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202380027562.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-10-17
Filing Date
2023-02-07
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

Existing PI3K inhibitors have intolerable toxicity and drug resistance problems in the treatment of cancer, especially leading to hyperglycemia and hyperinsulinemia, limiting their therapeutic efficacy and patient tolerance.

Method used

Develop a compound that can disrupt or inhibit the interaction between PI3Kα protein and small GTPase, specifically by binding to PI3Kα protein without significantly affecting its kinase activity, thereby preventing PI3Kα:RAS interaction, providing a new Treatment strategies to avoid hyperglycemia and insulin-driven resistance.

Benefits of technology

This compound can effectively inhibit signaling in tumor cells without affecting glucose metabolism in normal cells, providing multiple therapeutic advantages, including reducing side effects and improving treatment tolerance, significantly inhibiting tumor growth without causing hyperglycemia or hyperinsulinemia.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118946555A_ABST
    Figure CN118946555A_ABST
Patent Text Reader

Abstract

Provided herein are compounds and compositions thereof that can be capable of disrupting, disrupting, and / or preventing interactions between small GTPase proteins and PI3K proteins (e.g., PI3Ka). The disclosure also provides methods of treating cancer and other indications with such compounds or compositions thereof. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Government support

[0002] This invention was made with government support under Contract No. DE-AC52-07NA27344 awarded by the U.S. Department of Energy. The government has certain rights in this invention.

[0003] Related applications

[0004] This application claims priority to and the benefit of U.S. Application No. 63 / 307,882, filed on February 8, 2022, and U.S. Application No. 63 / 416,772, filed on October 17, 2022, the entire contents of each of which are hereby incorporated by reference. Background Art

[0005] It is estimated that over 600,000 Americans will die from cancer in 2021, equivalent to more than 1,600 deaths per day (Cancer Facts and Figures 2021). The leading causes of death are lung, prostate, and colorectal cancers among men, and lung, breast, and colorectal cancers among women. Lung cancer causes almost a quarter of all cancer deaths, 82% of which are directly attributable to smoking. The five-year survival rate for lung cancer patients is only around 20%.

[0006] Aberrant activation of phosphoinositide 3-kinase (PI3K) is one of the most common oncogenic events in human cancers, and its inhibition is an attractive therapeutic approach for treating cancer. PI3K signals downstream of receptor tyrosine kinases (RTKs), G protein-coupled receptors (GPCRs), and RAS proteins to regulate a wide range of cellular activities, including metabolism, proliferation, and migration.

[0007] The frequency of PI3K oncogenic events has driven the development and testing of PI3K inhibitors. To date, most PI3K inhibitors that have entered clinical development are reversible, ATP-competitive kinase inhibitors. Despite considerable effort, clinical results of PI3K inhibitor-based therapies for solid tumors have been disappointing, primarily due to intolerable toxicity and drug resistance. Summary of the Invention

[0008] The present disclosure provides new treatment modalities for treating cancer and other indications (e.g., cancers and other indications associated with and / or characterized by abnormal activation of PI3K). The present disclosure encompasses the recognition that therapeutic agents (e.g., therapeutic agents comprising small molecules, such as compounds provided herein) that disrupt, inhibit and / or prevent the interaction between a PI3K protein (e.g., PI3Kα) and a small GTPase (e.g., Rac1, CDC42 or a RAS protein, such as KRAS, NRAS, HRAS, RRAS, RRAS2, MRAS or RIT1) may be particularly useful for treating, ameliorating cancer and / or other indications (e.g., indications associated with and / or characterized by abnormal activation of PI3K), delaying the progression of the cancer and / or other indications, improving or eliminating the symptoms of the cancer and / or other indications, and / or inhibiting the cancer and / or other indications. Without wishing to be bound by theory, the therapeutic agents provided herein (e.g., therapeutic agents comprising small molecules, e.g., compounds provided herein) may be able to bind to a PI3K protein (e.g., PI3Kα) while exhibiting (i) no or minimal binding to a small GTPase (e.g., Racl, CDC42, or RAS protein, such as KRAS, NRAS, HRAS, RRAS, RRAS2, MRAS, or RIT1) and / or (ii) no substantial effect on the kinase activity of the PI3K protein (e.g., PI3Kα). In some embodiments, such therapeutic agents may provide advantages such as improved efficacy or reduced side effects compared to, for example, an ATP-competitive PI3K kinase inhibitor as described herein. For example, in some embodiments, such therapeutic agents may reduce hyperglycemia and / or hyperinsulinemia relative to PI3K kinase inhibitors.

[0009] The present disclosure provides compounds (including any available form, such as salt form) that can be used to destroy, inhibit and / or prevent the interaction between PI3K protein (e.g., PI3Kα) and small GTPase (e.g., Rac1, CDC42 or RAS protein, such as KRAS, NRAS, HRAS, RRAS, RRAS2, MRAS or RIT1). In some embodiments, the present disclosure provides compounds that can bind to PI3Kα protein so as to achieve the following effects: (i) the interaction between small GTPase (e.g., Rac1, CDC42 or RAS protein, such as KRAS, NRAS, HRAS, RRAS, RRAS2, MRAS or RIT1) and PI3Kα protein is destroyed, inhibited and / or prevented; and / or (ii) the kinase activity of PI3Kα protein is not inhibited. In some embodiments, such compounds can be used to treat cancer or other indications, as described herein.

[0010] In one aspect, the present disclosure provides compounds of Formula I:

[0011]

[0012] or a salt thereof (eg, a pharmaceutically acceptable salt), wherein Ring A, Ring B, Ring C, Ring D, R 1 、R 2 、R 3 、R 4 、R 5 , m, n, p, q, and r are as defined herein. In some embodiments, the compound of Formula I is capable of binding to the PI3Kα protein such that (i) the interaction between a small GTPase (e.g., Rac1, CDC42, or a RAS protein, such as KRAS, NRAS, HRAS, RRAS, RRAS2, MRAS, or RIT1) and the PI3Kα protein is disrupted, inhibited, and / or prevented; and / or (ii) the kinase activity of the PI3Kα protein is not inhibited.

[0013] In another aspect, the present disclosure provides a pharmaceutical composition comprising a compound provided herein (eg, a compound of Formula I) or a salt thereof (eg, a pharmaceutically acceptable salt) and a pharmaceutically acceptable carrier.

[0014] In another aspect, the present disclosure provides a method of inhibiting, disrupting and / or preventing the interaction between a PI3Kα protein and a small GTPase (e.g., Rac1, CDC42 or a RAS protein, such as KRAS, NRAS, HRAS, RRAS, RRAS2, MRAS or RIT1) such that the kinase activity of the PI3Kα protein is not inhibited. In some embodiments, the PI3Kα protein is in a cell, such as in a cell of a human or animal subject (e.g., as described herein).

[0015] In another aspect, the present disclosure provides a method for treating, ameliorating, delaying progression of, improving or eliminating symptoms of, and / or inhibiting cancer and / or other indications (e.g., indications associated with and / or characterized by abnormal activation of PI3K), comprising administering a compound provided herein (e.g., a compound of Formula I) or a salt thereof (e.g., a pharmaceutically acceptable salt).

[0016] In a related aspect, the present disclosure provides the use of a compound (e.g., a compound of Formula I) or a salt thereof (e.g., a pharmaceutically acceptable salt) as provided herein in the manufacture of a medicament for treating, ameliorating, or inhibiting cancer or other indications (e.g., indications associated with and / or characterized by abnormal activation of PI3K). The present disclosure also provides a compound (e.g., a compound of Formula I) or a salt thereof (e.g., a pharmaceutically acceptable salt) for use as a medicament, which can be used to treat, ameliorate, or inhibit cancer or other indications (e.g., indications associated with and / or characterized by abnormal activation of PI3K). BRIEF DESCRIPTION OF THE DRAWINGS

[0017] Figure 1 The effect of inhibiting PI3Kα using a PI3Kα kinase inhibitor such as alpelisib in normal cells (left panel) and tumor cells (right panel) is shown. In normal cells, inhibiting PI3Kα blocks normal cell signaling, leading to dose-limiting hyperglycemia and insulin-driven resistance. The right panel shows an alternative approach to inhibiting PI3Kα:RAS protein:protein interactions in tumor cells using PI3Kα disruptors. This mechanism should avoid hyperglycemia and insulin-driven resistance by selectively targeting tumor cells and may provide multiple therapeutic advantages. The observation that mutations in the RAS binding domain that impair the PI3Kα:RAS interaction block oncogene-driven non-small cell lung cancer (NSCLC) tumor growth in vivo and have no effect on glucose metabolism supports the potential of this mechanism.

[0018] Figure 2A and 2B It was shown that PI3Kα disruptors can have broad in vitro activity. Figure 2A It was shown that one-third of the human tumor cell lines tested had a pAKT IC50 < 100 nanomolar (nM) and depended on the RAS:PI3Kα interaction to activate Akt signaling. Specifically, 29 of the 50 G12X cell lines (58%) had a pAKT IC50 < 100 nM. Figure 2B Bioinformatic analysis in the present study showed that cell lines with PIK3CA helical mutations were particularly sensitive to PI3Kα-disrupting agents without inducing hyperglycemia; in addition, 78% of HER2-amplified lines were sensitive to PI3Kα-disrupting agents.

[0019] Figures 3A-3D PI3Kα disrupting agents were shown to be orally bioavailable and to achieve near-complete inhibition of signaling in tumors without the risk of hyperglycemia or hyperinsulinemia. Figure 3A Shown are the pharmacokinetics of PI3Kα disruptor compounds in mice. Figure 3BShown are the dose-response pharmacodynamics of a PI3Kα disruptor ("BBO") and the PI3Kα kinase domain inhibitor apellix in a BT474 cell line-derived xenograft model. Dose-response pharmacodynamics demonstrates near-complete target inhibition at 100 mg / kg of the PI3Kα disruptor. (One-way ANOVA with Dunnett's test versus vehicle; *=p<0.01; **=p<0.0001). Figure 3B From left to right along the x-axis: vehicle, 30 mg / kg BBO, 100 mg / kg BBO, 300 mg / kg BBO, 50 mg / kg apellisil. Figure 3C and 3D It was shown that unlike PI3Kα kinase domain inhibitors, PI3Kα disruptor compounds did not affect glucose metabolism. Figure 3C Figure 2 shows blood glucose levels in fasted male mice after a single dose of vehicle, the PI3Kα kinase domain inhibitor apellix, and a PI3Kα disruptor (Compound 58, "BBO") administered after an oral glucose tolerance test. Hyperglycemia was observed in apellix, but not in mice treated with the PI3Kα disruptor. (One-way ANOVA with Dunnett's test vs. vehicle, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001) Figure 3D Shown are insulin levels at and 240 minutes after administration of a single oral dose of vehicle, 50 mg / kg apellisor, or 300 mg / kg compound 58 ("BBO") in fed male mice. Hyperinsulinemia was observed with apellisor, but not with mice treated with a PI3Kα disruptor. (One-way ANOVA with Tukey's multiple comparison test vs. all other groups: *p<0.0001) (IV = intravenous administration; PO = oral or per os; ng / mL = nanograms per milliliter; mg / kg = milligrams per kilogram; mg / dL = milligrams per liter; min = minute; CDX = cell line-derived xenograft; QD = daily or once daily, PK = pharmacokinetics)

[0020] Figures 4A-4D It was shown that strong efficacy was observed in xenograft models with KRAS G12X mutation, with or without PIK3CA mutation. Figure 4A Shown are changes in tumor volume in a KYSE-410 cell line-derived xenograft model characterized by KRAS G12C mutation and HER2 amplification. Dose-dependent significant efficacy was observed with tumor regression at 100 mg / kg of PI3Kα disruptor ("BBO"). Figure 4BShown are changes in tumor volume in a GP2d cell line-derived xenograft model characterized by KRAS G12D mutation and PIK3CA H1047L mutation. Significant tumor volume reduction was observed at 10 mg / kg and higher doses of PI3Kα disruptor ("BBO"). Figure 4C Shown are changes in tumor volume in a SNU-601 cell line-derived xenograft model characterized by KRAS G12D mutation and PIK3CA E542K mutation. Significant tumor volume reduction was observed at 10 mg / kg and higher doses of PI3Kα disruptor ("BBO"). Figure 4D Figure 2 shows changes in tumor volume in a xenograft model derived from the SNU-16 cell line characterized by the KRAS G12D mutation. Significant tumor volume reduction was observed at 10 mg / kg and higher doses of a PI3Kα disruptor ("BBO"). (p<0.0005, two-way repeated measures ANOVA vs. vehicle; all groups were dosed once daily (QD) orally (PO, oral) (mm 3 = cubic millimeter; mg / kg = milligrams per kilogram) DETAILED DESCRIPTION

[0021] Compounds and Definitions

[0022] The compounds of the present disclosure include those generally described above and are further illustrated by the classes, subclasses, and species disclosed herein. As used herein, unless otherwise indicated, the following definitions shall apply. For the purposes of this disclosure, chemical elements are identified according to the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75th edition. In addition, the general principles of organic chemistry are described in "Organic Chemistry", Thomas Sorrell, University Science Books, Sausalito: 1999 and "March's Advanced Organic Chemistry", 5th edition, Smith, MB and March, J. ed., John Wiley & Sons, New York: 2001, the entire contents of which are hereby incorporated by reference.

[0023] Unless otherwise indicated, the structures depicted herein are intended to include all stereoisomeric (e.g., enantiomeric, diastereomeric, atropisomeric or epimeric) forms of the structure, as well as all geometric or conformational isomeric forms of the structure. For example, the R and S configurations of each stereocenter are expected to be part of this disclosure; and the D and L isomers of each compound are expected to be part of this disclosure. Therefore, single stereochemical isomers of the provided compounds, as well as enantiomeric, diastereomeric, atropisomeric and geometric (or conformational) mixtures are within the scope of this disclosure. For example, in some cases, Tables 1 and 2 show one or more stereoisomers of a compound, and unless otherwise indicated, each stereoisomer is represented individually and / or as a mixture. The present disclosure includes all cis, trans, cis, trans, entgegen (E) and zusammen (Z) isomers and mixtures thereof. Individual stereoisomers of compounds can be prepared synthetically from commercially available starting materials containing chiral centers, or by preparing a mixture of enantiomeric products followed by separation, such as conversion into a mixture of diastereomers followed by separation via, for example, recrystallization, chromatographic techniques, direct separation of enantiomers on a chiral chromatographic column, or any other appropriate method. Starting compounds of specific stereochemistry are commercially available or can be prepared and resolved by various techniques. Unless otherwise stated, all tautomeric forms (e.g., rapidly interconverting forms) of the provided compounds are within the scope of the present disclosure.

[0024] Unless otherwise indicated, structures depicted herein are intended to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, structures having the present invention and including the replacement of hydrogen with deuterium or tritium, or the replacement of hydrogen with 13 C or 14 C-enriched carbon-substituted carbon compounds are within the scope of the present disclosure.

[0025] Aliphatic: As used herein, the term "aliphatic" or "aliphatic group" means a straight (i.e., unbranched) or branched, substituted or unsubstituted hydrocarbon chain that is fully saturated or contains one or more unsaturated units (e.g., multiple bonds, such as double bonds or triple bonds). Unless otherwise specified, an aliphatic group contains 1-12 aliphatic carbon atoms. In some embodiments, an aliphatic group contains 1-6 aliphatic carbon atoms. In some embodiments, an aliphatic group contains 1-5 aliphatic carbon atoms. In other embodiments, an aliphatic group contains 1-4 aliphatic carbon atoms. In other embodiments, an aliphatic group contains 1-3 aliphatic carbon atoms, and in other embodiments, an aliphatic group contains 1-2 aliphatic carbon atoms.

[0026] Alkyl: The term "alkyl" used alone or as part of a larger moiety refers (unless otherwise indicated) to a group having 1-12, 1-10, 1-8, 1-6, 1-4, 1-3, or 1-2 carbon atoms (e.g., C 1-12 、C 1-10 、C 1-8 、C 1-6 、C 1-4 、C 1-3 or C 1-2 ) is a saturated, optionally substituted, straight or branched chain hydrocarbon group. Examples of alkyl groups include methyl, ethyl, propyl (e.g., n-propyl), isopropyl, n-butyl, tert-butyl, isobutyl, sec-butyl, pentyl, isopentyl, hexyl, heptyl, octyl, and nonyl. The term "alkylene," as used herein, alone or in combination, refers to a divalent, saturated, optionally substituted, straight or branched chain hydrocarbon group, such as methylene (-CH2-).

[0027] Alkenyl: The term "alkenyl," used alone or as part of a larger moiety, refers to a group having at least one double bond and (unless otherwise indicated) 2-12, 2-10, 2-8, 2-6, 2-4, or 2-3 carbon atoms (e.g., C 2-12 、C 2-10 、C 2-8 、C 2-6 、C 2-4 or C 2-3 ) is an optionally substituted straight or branched hydrocarbon chain of . Examples of the alkenyl group include ethenyl, propenyl, 2-methylpropenyl, 1,4-butadienyl, butenyl, pentenyl, hexenyl and heptenyl.

[0028] Alkynyl: The term "alkynyl," used alone or as part of a larger moiety, refers to a group having at least one triple bond and, unless otherwise indicated, 2-12, 2-10, 2-8, 2-6, 2-4, or 2-3 carbon atoms (e.g., C 2-12 、C 2-10 、C 2-8 、C 2-6 、C 2-4 or C 2-3 ) is an optionally substituted straight or branched hydrocarbon group. Examples of alkynyl groups include ethynyl, propynyl, 1-butynyl, 2-butynyl, butadiynyl, 1-pentynyl, 2-pentynyl, isopentenyl, 1,3-pentadiynyl, 1,4-pentadiynyl, 1-hexynyl, 2-hexynyl, 3-hexynyl, 1,3-hexadiynyl, 1,4-hexadiynyl, 1,5-hexadiynyl, 2,4-hexadiynyl, and 1,3,5-hexatriynyl.

[0029] Aryl: The term "aryl" used alone or as part of a larger moiety such as "aralkyl," "aralkoxy," or "aryloxyalkyl" refers to a monocyclic or bicyclic ring system having a total of six to fourteen ring members, wherein at least one ring in the system is aromatic and wherein each ring in the system contains 3 to 7 ring members. A bicyclic ring system may comprise a first and second ring that are fused together and / or share one or more atoms. The term "aryl" is used interchangeably with the term "aromatic ring." In certain embodiments of the present invention, "aryl" refers to an aromatic ring system. Examples of aryl groups include phenyl, biphenyl, naphthyl, anthracenyl, and the like, which may bear one or more substituents as defined herein. As used herein, the term "aryl" also includes within its scope groups in which an aromatic ring is fused to one or more non-aromatic rings, such as indanyl or tetrahydronaphthyl. Unless otherwise indicated, an "aryl" group is a hydrocarbon.

[0030] Carbocyclyl: As used herein, the terms "carbocyclyl," "carbocycle," and "carbocyclic ring" refer to a saturated or partially unsaturated cyclic aliphatic monocyclic, bicyclic, or polycyclic ring system as described herein having from 3 to 14 members, wherein the aliphatic ring system is optionally substituted as described herein. The carbocycle may comprise a fused ring system, a bridged ring system, and / or a spirocyclic ring system (e.g., a system comprising two rings sharing a single carbon atom). Carbocyclic groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cycloheptenyl, cyclooctyl, cyclooctenyl, norbornyl, adamantyl, and cyclooctadienyl. In some embodiments, "carbocyclyl" (or "alicyclic") refers to an optionally substituted monocyclic C3-C8 hydrocarbon or an optionally substituted C6-C8 hydrocarbon that is fully saturated or contains one or more unsaturated units but is not aromatic. 10 Bicyclic hydrocarbons. The term "cycloalkyl" refers to an optionally substituted saturated ring system having from about 3 to about 10 ring carbon atoms. In some embodiments, the cycloalkyl group has 3–6 carbon atoms. Examples of monocyclic cycloalkyl rings include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl. The term "cycloalkenyl" refers to an optionally substituted non-aromatic monocyclic or polycyclic ring system containing at least one carbon-carbon double bond and having from about 3 to about 10 carbon atoms. Examples of monocyclic cycloalkenyl rings include cyclopentenyl, cyclohexenyl, and cycloheptenyl.

[0031] Halogen: The term "halogen" or "halo" means F, Cl, Br, or I.

[0032] Heteroaryl: The terms "heteroaryl," "heteroaromatic," and "heteroar-," used alone or as part of a larger moiety such as "heteroaralkyl" or "heteroaralkoxy," refer to groups having 5 to 14 ring atoms (e.g., a 5- to 6-membered monocyclic heteroaryl or a 9- to 10-membered bicyclic heteroaryl); sharing 6, 10, or 14 pi electrons in the cyclic array; and having one to five heteroatoms in addition to carbon atoms. Examples of heteroaryl groups include thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolizinyl, purinyl, naphthyridinyl, and pteridinyl. As used herein, the terms "heteroaryl" and "heteroar-" also include groups in which a heteroaromatic ring is fused to one or more aryl, cycloaliphatic, or heterocyclyl rings. Examples of bicyclic heteroaromatic groups include indolyl, isoindolyl, benzothienyl, benzofuranyl, indazolyl, indolizinyl, benzimidazolyl, benzothiazolyl, benzotriazolyl, benzoxazolyl, benzoxadiazolyl, benzothiadiazolyl, tetrazolopyridazinyl, thienopyridinyl, furopyridinyl, pyrrolopyridinyl, chromonyl, coumarinyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 4H-quinolizinyl, tetrahydroquinolyl, and tetrahydroisoquinolyl. Examples of tricyclic heterocyclic groups include carbazolyl, phenanthroline, dibenzofuranyl, acridinyl, phenazinyl, phenanthridinyl, phenothiazinyl, phenoxazinyl and xanthenyl. Heteroaryl groups may be monocyclic or bicyclic. The term "heteroaryl" may be used interchangeably with the terms "heteroaromatic ring," "heteroaryl group," or "heteroaromatics," any of which includes optionally substituted rings. The term "heteroaralkyl" refers to an alkyl group substituted with a heteroaryl group, wherein the alkyl and heteroaryl moieties are independently optionally substituted. It should be understood that certain tautomeric forms of heteroaromatic rings may exist and are encompassed by the term "heteroaryl." Such tautomeric forms include, for example, pyridin-2(1H)-one.

[0033] Heteroatom: The term "heteroatom" means one or more of oxygen, sulfur, nitrogen, phosphorus, or silicon (including any oxidized form of nitrogen, sulfur, phosphorus, or silicon; the quaternized form of any basic nitrogen; or a substitutable nitrogen of a heterocyclic ring, for example, N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl), or NR + (As in N-substituted pyrrolidinyl). In some embodiments, the heteroatom is selected from oxygen, sulfur, and nitrogen.

[0034] Heterocycle: As used herein, the terms "heterocycle," "heterocyclyl," "heterocyclic group," and "heterocyclic ring" are used interchangeably and refer to a stable 3- to 8-membered monocyclic or 5- to 10-membered bicyclic heterocyclic moiety that is saturated or partially unsaturated and has, in addition to one or more carbon atoms, one or more, preferably one to four, heteroatoms as defined above. The term "nitrogen" when used to refer to the ring atoms of a heterocycle includes substituted nitrogens. The heterocycle may be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure, and any of the ring atoms may be unsubstituted or substituted with one or more substituents (e.g., as described herein). Examples of such saturated or partially unsaturated heterocyclic groups include tetrahydrofuranyl, tetrahydrothienylpyrrolidinyl, piperidinyl, pyrrolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, oxazolidinyl, piperazinyl, dioxanyl, dioxolane, diazepine The terms "heterocycle," "heterocyclyl," "heterocyclyl ring," "heterocyclic group," "heterocyclic moiety," and "heterocyclic radical" are used interchangeably herein and also include groups in which the heterocyclyl ring is fused to one or more aryl, heteroaryl, or cycloaliphatic rings, such as indolinyl, 3H-indolyl, chromanyl, phenanthridinyl, or tetrahydroquinolinyl. The heterocyclyl group may be monocyclic or bicyclic. The term "heterocycloalkyl" refers to an alkyl group substituted with a heterocyclyl, wherein the alkyl and heterocyclyl moieties are independently unsubstituted or substituted with one or more substituents (e.g., as described herein).

[0035] Partially unsaturated: As used herein, the term "partially unsaturated," when referring to a ring moiety, means a ring moiety that includes at least one double or triple bond between ring atoms. The term "partially unsaturated" is intended to encompass rings having multiple sites of unsaturation, but is not intended to include aryl or heteroaryl moieties as defined herein.

[0036] Patient or subject: As used herein, the term "patient" or "subject" refers to any organism to which a provided composition is or may be administered, e.g., for experimental, diagnostic, preventive, cosmetic, and / or therapeutic purposes. Typical patients or subjects include animals (e.g., mammals such as mice, rats, rabbits, hamsters, guinea pigs, cats, dogs, goats, pigs, sheep, cows, deer, horses, non-human primates, and / or humans). In some embodiments, the patient or subject is human. In some embodiments, the patient or subject suffers from or is susceptible to one or more conditions or illnesses. In some embodiments, the patient or subject shows one or more symptoms of a condition or illness. In some embodiments, the patient or subject has been diagnosed as suffering from one or more conditions or illnesses. In some embodiments, the patient or subject is receiving or has received certain therapies to diagnose and / or treat a disease, condition, or illness.

[0037] Prevent or prevention: As used herein, when used in conjunction with the occurrence of a disease, condition, and / or illness, "Prevent" or "prevention" refers to reducing the risk of developing a disease, condition, or illness; delaying the onset of one or more characteristics or symptoms of a disease, condition, or illness; and / or preventing the escalation of a disease, condition, or illness. Prevention of a disease, condition, or illness can provide complete protection from the disease and / or prevent the progression of the disease (e.g., to an advanced stage of the disease, condition, or illness). For example, prevention of a disease may not mean the complete elimination of any effects associated with the disease at any level, but rather may mean preventing the symptoms of the disease, condition, or illness to a clinically significant or detectable level. Prevention may be considered complete when the onset of a disease, condition, or illness has been delayed for a predetermined period of time.

[0038] Substituted or optionally substituted: As described herein, compounds of the present disclosure may contain "optionally substituted" moieties (e.g., moieties bearing one or more substituents). In general, the term "substituted," whether preceded by the term "optionally" or not, means that one or more hydrogens of the designated moiety are replaced with a suitable substituent. "Substituted" applies to the replacement of one or more hydrogens in a structure, whether explicit or implicit (e.g., means at least and means at least ). Unless otherwise indicated, an "optionally substituted" group may have a suitable substituent at each substitutable position of the group, and when more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituent may be the same or different at each position. The combination of substituents contemplated by the present invention is preferably such that a stable or chemically feasible compound is formed. As used herein, the term "stable" refers to a compound that is substantially unchanged when subjected to conditions that allow its production, detection, and in certain embodiments, its recovery, purification, and use for one or more purposes provided herein. A group described as "substituted" preferably has between 1 and 4 substituents, more preferably 1 or 2 substituents. A group described as "optionally substituted" may be unsubstituted or "substituted" as described above.

[0039] Suitable monovalent substituents on a substitutable carbon atom of an "optionally substituted" group are independently halogen; -(CH2) 0–4 R o ; –(CH2) 0–4 OR o ;-O(CH2) 0-4 R o ;–O–(CH2) 0–4 C(O)OR o ; –(CH2) 0–4 CH(OR o )2;–(CH2) 0– 4SR o ; –(CH2) 0–4 Ph, which can be o Substitution; –(CH2) 0–4 O(CH2) 0–1 Ph, which can be o Substitution; -CH=CHPh, which can be R o Substitution; –(CH2) 0–4 O(CH2) 0–1 -pyridyl, which may be R o Substitution; –NO2; –CN; –N3; -(CH2) 0–4 N(R o )2;–(CH2) 0–4 N(R o )C(O)R o ;–N(R o )C(S)R o ; –(CH2) 0–4 N(R o )C(O)NR o 2;-N(R o )C(S)NR o 2;–(CH2)0–4 N(R o )C(O)OR o ;-N(R o )N(R o )C(O)R o ;-N(R o )N(R o )C(O)NR o 2;-N(R o )N(R o )C(O)OR o ;–(CH2) 0–4 C(O)R o ;–C(S)R o ;–(CH2) 0–4 C(O)OR o ;–(CH2) 0–4 C(O)SR o ;-(CH2) 0–4 C(O)OSiR o 3;–(CH2) 0–4 OC(O)R o ;–OC(O)(CH2) 0–4 SR o ;–(CH2) 0–4 SC(O)R o ;–(CH2) 0–4 C(O)NR o 2;–C(S)NR o 2;–C(S)SR o ;–SC(S)SR o ;-(CH2) 0– 4OC(O)NR o 2;-C(O)N(OR o )R o ;–C(O)C(O)R o ;–C(O)CH2C(O)R o ;–C(NOR o )R o ;-(CH2) 0–4 SSR o ;-(CH2) 0–4 S(O)2R o ;–(CH2) 0–4 S(O)2OR o ;–(CH2) 0–4 OS(O)2R o ;–S(O)2NR o 2;-(CH2) 0–4 S(O)R o ;-N(Ro )S(O)2NR o 2;–N(R o )S(O)2R o ;–N(OR o )R o ;–C(NH)NR o 2;–P(O)2R o ;-P(O)R o 2;-OP(O)R o 2;–OP(O)(OR o )2;–SiR o 3;–(C 1–4 linear or branched alkylene)O–N(R o )2; or –(C 1–4 linear or branched alkylene) C(O)O–N(R o )2, where each R o may be substituted as defined below and are independently hydrogen, C 1-6 Aliphatic, -CH2Ph, -O(CH2) 0-1 Ph, -CH2-(5- to 6-membered heteroaromatic ring), or a 3- to 6-membered saturated, partially unsaturated or aromatic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur, or, notwithstanding the above definitions, two independent occurrences of R o Together with their intervening atoms they form a 3- to 12-membered saturated, partially unsaturated or aryl monocyclic or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur which may be substituted as defined below.

[0040] R o (or by two independent occurrences of R o Suitable monovalent substituents on the ring formed by the ring and its intervening atoms are independently halogen, -(CH2) 0–2 R ● 、–(halogen R ● ),–(CH2) 0–2 OH, –(CH2) 0–2 OR ● 、–(CH2) 0–2 CH(OR ● )2、-O(halogen R ● ), –CN, –N3, –(CH2) 0–2 C(O)R ● 、–(CH2) 0–2 C(O)OH, –(CH2) 0–2 C(O)OR ● 、–(CH2) 0–2 SR ● 、–(CH2) 0–2SH, –(CH2) 0–2 NH2, –(CH2) 0–2 NHR ● 、–(CH2) 0–2 NR ● 2. –NO2, –SiR ● 3. –OSiR ● 3. -C(O)SR ● 、–(C 1–4 linear or branched alkylene)C(O)OR ● or –SSR ● , where each R ● unsubstituted or, when preceded by "halo", substituted only with one or more halogens, and independently selected from C 1-4 Aliphatic, -CH2Ph, -O(CH2) 0-1 Ph, or a 3- to 6-membered saturated, partially unsaturated or aromatic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur. o Suitable divalent substituents on a saturated carbon atom of include =0 and =S.

[0041] Suitable divalent substituents on a saturated carbon atom of an "optionally substituted" group include the following: =0 ("oxo"), =S, =NNR * 2. =NNHC(O)R * 、=NNHC(O)OR * 、=NNHS(O)2R * 、=NR * 、=NOR * 、–O(C(R * 2)) 2–3 O–or–S(C(R * 2)) 2–3 S–, where R * Each independent occurrence is selected from hydrogen, C 1-6 An aliphatic or unsubstituted 3- to 6-membered saturated, partially unsaturated, or aromatic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. Suitable divalent substituents bound to an ortho-substitutable carbon of an "optionally substituted" group include: -O(CR * 2) 2–3 O–, where R * Each independent occurrence is selected from hydrogen, C 1–6 an aliphatic or unsubstituted 5-6 membered saturated, partially unsaturated or aromatic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur.

[0042] R * Suitable substituents on the aliphatic group include halogen, –R● 、-(halogen R ● ),-OH, –OR ● 、–O(halogen R ● ), –CN, –C(O)OH, –C(O)OR ● , –NH2, –NHR ● ,–NR ● 2 or –NO2, where each R ● is unsubstituted or, when preceded by "halo", is substituted only with one or more halogens, and is independently C 1-4 Aliphatic, -CH2Ph, -O(CH2) 0-1 Ph or a 3- to 6-membered saturated, partially unsaturated or aromatic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur.

[0043] Suitable substituents on a substitutable nitrogen of an "optionally substituted" group include Among them are independently hydrogen, C 1-6 an aliphatic or unsubstituted 3- to 6-membered saturated, partially unsaturated or aromatic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur, or, notwithstanding the above definition, two independent occurrences of Together with its intervening atoms, it forms an unsubstituted 3- to 12-membered saturated, partially unsaturated or aryl monocyclic or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur.

[0044] Suitable substituents on the aliphatic group of are independently halogen, -R ● 、-(halogen R ● ),–OH,–OR ● 、–O(halogen R ● ), –CN, –C(O)OH, –C(O)OR ● , –NH2, –NHR ● ,–NR ● 2 or -NO2, where each R ● is unsubstituted or, when preceded by "halo", is substituted only with one or more halogens, and is independently C 1-4 Aliphatic, -CH2Ph, -O(CH2) 0-1 Ph or a 3- to 6-membered saturated, partially unsaturated or aromatic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur.

[0045] Treatment: As used herein, the term "treat" (also referred to as "treatment" or "treating") refers to any administration of a therapy that partially or completely alleviates, ameliorates, relieves, inhibits, delays the onset of, reduces the severity of, and / or reduces the incidence of one or more symptoms, features, and / or causes of a particular disease, disorder, and / or condition. Treatment may also refer to any other marker of success in treating or ameliorating an injury, pathology, disease, disorder, or condition, including any objective or subjective parameter, such as alleviation; remission; elimination of symptoms or rendering the patient more tolerant of the injury, pathology, disease, disorder, or condition; slowing the rate of degeneration or decline; rendering the final moments of degeneration less debilitating; and / or improving the patient's physical or mental health. Treatment or amelioration of symptoms may be based on objective or subjective parameters, including the results of a physical examination, neuropsychiatric examination, and / or psychiatric assessment. In some embodiments, such treatment may be directed to subjects who do not exhibit signs of the relevant disease, disorder, and / or condition and / or subjects who exhibit only early signs of a disease, disorder, and / or condition. Alternatively or additionally, such treatment may be directed to a subject who exhibits one or more established signs of the relevant disease, disorder, and / or condition. In some embodiments, treatment may be directed to a subject who has been diagnosed with the relevant disease, disorder, and / or condition.

[0046] Composition: As used herein, the term "composition" refers to a discrete physical entity comprising one or more specified components (e.g., a product comprising one or more specified ingredients (e.g., in specified amounts) or a product consisting directly or indirectly of specified ingredients in combination in specified amounts). Unless otherwise indicated, a composition can be in any form, e.g., a gas, a gel, a liquid, a solid, etc. A composition can contain one or more pharmaceutically acceptable components, such as a carrier, a diluent, or an excipient. "Pharmaceutically acceptable" generally means that the carrier, diluent, or excipient must be compatible with the other ingredients of the formulation and not deleterious to the recipient thereof. For example, a "pharmaceutically acceptable excipient" refers to a substance that facilitates the administration of the active agent and absorption by the subject.

[0047] PI3K and small GTPase proteins

[0048] Aberrant activation of phosphoinositide 3-kinase (PI3K) is one of the most common oncogenic events in human cancer, and its inhibition is an attractive therapeutic approach for treating cancer. PI3K signals downstream of receptor tyrosine kinases (RTKs), G protein-coupled receptors (GPCRs), and RAS proteins to regulate a wide range of cellular activities, including metabolism, proliferation, and migration. Upon activation, PI3K catalyzes the synthesis of a secondary messenger, phosphatidylinositol (3,4,5)-triphosphate (PIP3), by phosphorylating phosphatidylinositol 4,5-bisphosphate (PIP2). Signaling proteins such as the Ser / Thr kinase AKT (e.g., protein kinase B (PKB)) can bind to PIP3, thereby localizing it to the cell membrane. Phospho-AKT activates or inhibits several signaling proteins through direct phosphorylation, including mammalian target of rapamycin complex 1 (mTORC1), which acts as a regulator of cell growth and survival pathways, cyclin D1, GSK3(B), BAD, MDM2, FOXO, TSC1 / 2, and PRAS40. Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) regulates this pathway by dephosphorylating PIP3 to PIP2, thereby preventing the activation of downstream kinases.

[0049] Based on sequence homology and substrate preference, PI3Ks have been divided into three separate classes (e.g., class I, class II, and class III). Class I PI3Ks are further divided into two subclasses, IA and IB, depending on their regulatory profile. Class IA PI3Ks are heterodimers comprising the p110 catalytic subunit and the p85 regulatory subunit and are most prominently implicated in human cancers. Class IA PI3Ks contain the p110α, p110β, and p110δ catalytic subunits, produced by distinct genes (PIK3CA, PIK3CB, and PIK3CD, respectively), while p110γ, produced by PIK3CG, represents the only catalytic subunit in class IB PI3Ks. The expression of PI3K isoforms (e.g., PI3Kα, PI3Kβ, PI3Kδ, and PI3Kγ) is cell type specific. The p110α and β isoforms are expressed in all cell types, whereas p110δ expression is primarily restricted to leukocytes. The p110γ isoform is primarily expressed in myeloid cell lineages.

[0050] The PIK3CA gene encodes a 1068-amino acid p110α protein containing five domains: an N-terminal adaptor binding domain (ABD) that binds to the regulatory subunit p85α, a RAS binding domain (RBD), a C2 domain, a helical domain, and a kinase catalytic domain. RAS directly contributes to the activation of the PI3K pathway by directly binding RAS proteins (e.g., HRAS, NRAS, and KRAS) to the RAS binding domain (RBD) in the p110α catalytic subunit of PI3Kα. Activating mutations in the KRAS and PIK3CA genes are frequently detected in cancer, making these two proteins important targets for drug discovery. Somatic missense mutations in the PIK3CA gene have been reported in many human cancer types, including breast, colon, liver, gastric, endometrial, bladder, and lung cancers. The most common hotspot mutations in PIK3CA are E542K, E545K, H1047R, and H1047L, and they account for 80-90% of all PIK3CA mutations detected in human malignancies. These PIK3CA mutations result in increased catalytic activity of p110α, leading to downstream effects such as unregulated cell growth, proliferation, and survival.

[0051] Mutations in RAS proteins are seen in more than 20% of all human cancers. RAS proteins act as molecular switches that cycle between an active GTP-bound state and an inactive GDP-bound state. In the active state, RAS proteins interact with various effector proteins including PI3K, RAF kinases, and RalGDS, thereby activating multiple downstream signaling pathways. Oncogenic RAS mutations are primarily found at amino acid positions G12, G13, and Q61, and these mutations impair GTPase activity, leading to the accumulation of active RAS proteins. The most common oncogenic RAS mutations are G12C, G12D, G12S, G12V, G12R, G13D, and Q61H.

[0052] RAS signaling through PI3K is essential for normal lymphoid development and RAS-induced transformation, particularly in lung cancer, where the interaction between mutant RAS and p110a-RBD is crucial for tumor initiation and maintenance. The interaction of RAS with p110α-RBD has been shown to be essential for epidermal growth factor (EGF) signaling to PI3K. Recent studies have shown that disruption of the RAS-PI3K interaction inhibits AKT and RAC1 activation in EGFR mutant lung cancer cells, leading to reduced growth and survival and suppressing the onset of tumors induced by EGFR mutants. These results suggest that in EGFR-driven lung adenocarcinomas, the binding of p110α to endogenous RAS proteins is crucial for tumors driven by upstream activators of the RAS pathway, not just those in which RAS is activated by mutations.

[0053] Small GTPases (e.g., other than RAS) are also expected to bind to the RBD of PI3Kα, resulting in activation of signal transduction. The small GTPases Rac1 and CDC42 have been shown to bind to the RBD of PI3Kβ, and it is hypothesized that they can also bind to the RBD of PI3Kα. Therefore, in some embodiments, the present disclosure encompasses the recognition that disrupting the interaction between PI3Kα and any small GTPase that binds to the RBD of PI3Kα may be a useful therapeutic strategy for treating cancer and other indications. In some embodiments, the small GTPase is selected from Rac1, CDC42, and RAS proteins (including HRAS, NRAS, KRAS, RRAS, RRAS2, MRAS, and RIT1).

[0054] The frequency of oncogenic PIK3CA hotspot mutations in cancer has driven the development and testing of numerous PI3K (e.g., PI3Kα) inhibitors. To date, most PI3K inhibitors that have entered clinical development are reversible, ATP-competitive kinase inhibitors. Despite considerable effort, clinical results for PI3K inhibitor-based therapies for solid tumors have been disappointing, primarily due to intolerable toxicity and drug resistance. In 2019, the US Food and Drug Administration (FDA) approved apellisib (BYL719; Novartis Pharma AG), a PI3Kα isoform-specific inhibitor, in combination with fulvestrant for the treatment of patients diagnosed with HR+ / HER2- PIK3CA mutations. The therapeutic window of PI3K inhibitors is primarily limited by isoform selectivity and off-tumor toxicity. Furthermore, hyperglycemia and hyperinsulinemia have been observed as the major dose-limiting toxicities of p110α inhibitors, which preclude the use of sufficiently high doses to fully inhibit PI3Kα signaling in tumors. Hyperglycemia and hyperinsulinemia are considered target effects of PI3Kα inhibition because inhibition of the PI3K / AKT pathway reduces glucose uptake, leading to increased insulin secretion and subsequent activation of insulin / insulin-like growth factor I receptors in tumor cells, providing a survival mechanism for tumor cells and limiting the therapeutic efficacy of PI3Kα inhibitors. In fact, in the Phase III clinical trial of apellis, hyperglycemia was observed in 65% of patients, leading to significant dose interruptions.

[0055] In order to overcome the limitations of current PI3Kα inhibitors, it is necessary to explore new strategies for targeting PI3Kα. Previous studies have shown that inhibiting the RAS-p110α (RBD) interaction is minimally toxic to adult animals while effectively causing tumor regression. The present disclosure encompasses the recognition that this treatment approach may be effective for various cancers, including cancers driven by RAS mutants and / or those driven by mutations or amplifications of receptor tyrosine kinases (RTKs). The present disclosure also recognizes that this treatment approach may provide certain advantages over known PI3Kα inhibitors (e.g., inhibitors targeting the ATP binding pocket of PI3Kα). For example, the technology provided can avoid hyperglycemia and insulin-driven resistance common to PI3Kα inhibitors, for example, because such technology targets the activation of PI3Kα by RAS, which is primarily present in transformed cells.

[0056] The provided compounds

[0057] In some embodiments, the present disclosure provides compounds that can be used to destroy, inhibit and / or prevent the interaction between a small GTPase (e.g., a RAS protein as described herein) and a PI3Kα protein. In some embodiments, the present disclosure provides compounds that can bind to PI3Kα so that the following effects are achieved: (i) the interaction between a small GTPase (e.g., a RAS protein as described herein) and PI3Kα is destroyed, inhibited or prevented; and / or (ii) the kinase activity of PI3Kα is not significantly inhibited. In some embodiments, such compounds reversibly bind to PI3Kα. As used herein, a "reversibly" bound compound refers to a compound that can bind to and dissociate from a target protein kinase (e.g., PI3Kα). Typically, but not always, a reversible inhibitor cannot form a covalent bond with a target protein kinase. In some embodiments, such compounds irreversibly bind to PI3Kα. As used herein, an "irreversibly" bound compound refers to a compound that can interact (e.g., form a covalent bond) with a target protein kinase (e.g., PI3Kα) in a substantially non-reversible manner. In some embodiments, the reversible or irreversible inhibitor may be capable of covalently interacting with PI3Kα. For example, in some embodiments, the present disclosure provides compounds comprising an electrophilic moiety (e.g., a Michael acceptor, etc.) capable of binding (e.g., reversibly or irreversibly) to, for example, a cysteine ​​residue in the catalytic subunit of PI3Kα (e.g., C242). In some embodiments, the provided compound that covalently interacts with PI3Kα is a compound of Formula I, wherein -LW comprises an electrophilic moiety (e.g., a Michael acceptor, etc.) capable of binding (e.g., reversibly or irreversibly) to, for example, a cysteine ​​residue in PI3Kα (e.g., C242).

[0058] In some embodiments, the present disclosure provides compounds of Formula I:

[0059]

[0060] or a salt (e.g., a pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer thereof, wherein:

[0061] Ring A is selected from phenyl and a 5- to 6-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur;

[0062] Ring B is selected from phenyl, a 6-membered heteroaromatic ring having 1-2 nitrogen atoms, and a 9- to 10-membered bicyclic ring containing at least one 5- or 6-membered heteroaromatic ring;

[0063] Ring C is selected from phenyl; a 5- to 6-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5- to 8-membered bicyclic carbocyclic ring; a 4- to 8-membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and a 7- to 10-membered spiro-fused heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein the phenyl, heteroaromatic, and heterocyclic rings are each optionally fused to Ring E;

[0064] Ring D is selected from phenyl and a 5- to 6-membered heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein the phenyl and heteroaryl ring are each optionally fused to Ring F;

[0065] Ring E is selected from a 5- to 6-membered carbocyclic ring; a 5- to 7-membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 7- to 10-membered spirofused heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and a 5- to 6-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein Ring E is substituted by s R 5′ Instance replacement;

[0066] Ring F is selected from phenyl; 5- to 6-membered carbocyclic rings; 5- to 7-membered heterocyclic rings having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and 5- to 6-membered heteroaromatic rings having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein Ring F is substituted by u instances of -LW and y instances of R 2’ Instance replacement;

[0067] R 1 Selected from -LW, ring D' or a divalent C substituted by ring D' 1-6 aliphatic chains;

[0068] Each –LW is –CN, or:

[0069] Each L is independently a divalent linear or branched C 1-8an aliphatic chain, wherein one or more methylene units of the aliphatic chain are optionally and independently replaced by a group selected from the group consisting of: -N(R)-, -O-, -S-, -C(O)-, -SO2-, -CH(X)-, -C(X)2-, -C(O)N(R)-, -N(R)C(O)-, -C(O)O-, -OC(O)-, -SO2N(R)-, and -N(R)SO2-;

[0070] each W is independently hydrogen, halogen, -CN, or an optionally substituted 3-10 membered monocyclic or bicyclic, saturated, partially unsaturated, or aromatic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

[0071] Each X is independently halogen, -OR or -CN;

[0072] each ring D' is independently a 4- to 6-membered carbocyclic ring or a 4- to 6-membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein ring D' is substituted with t instances of -LW;

[0073] Each R 2 and R 2’ are independently selected from oxo, halogen, -CN, -OR and C 1-6 alkyl;

[0074] Each R 3 Independently selected from oxo, halogen, -CN, -OR, -O(CH2) v Cy, -OCH2CH2OR and optionally substituted C 1-6 aliphatic;

[0075] Each Cy is independently a 5- to 6-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3- to 6-membered carbocyclic ring; or a 4- to 6-membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein Cy is optionally substituted with 0-2 R 6 Instance replacement;

[0076] Each R 4 independently selected from halogen and optionally substituted C 1-6 aliphatic;

[0077] R 5 and R 5’ are each independently selected from oxo, =NH, -CN, halogen, -OR, -N(R)2, -SR, -C(O)R, -N(R)C(O)R, -(CH2) x C(O)N(R)2, -C(O)N(R)2, -C(O)N(R)(CH2) x Cy, -(CH2) xC(O)Cy, -OC(O)R, -C(O)OR, -SO2R, -N(R)SO2R, -N=S(O)(R)2, -SO2N(R)2, -P(O)R2, -(CH2) x Cy, -O(CH2) x Cy and optionally substituted C 1-6 aliphatic;

[0078] Each R 6 independently selected from oxo, -CN, halogen, -OR, -N(R)2, -SR, -C(O)R, -N(R)C(O)R, -C(O)N(R)2, -OC(O)R, -C(O)OR, -SO2R, -N(R)SO2R, -SO2N(R)2, and an optionally substituted group selected from: C 1-6 aliphatic; 3- to 6-membered carbocyclic ring; phenyl; 3- to 6-membered heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; 5- to 6-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; 10-membered aromatic ring; and 9- to 10-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;

[0079] Each R is independently hydrogen or an optionally substituted group selected from: C 1-6 aliphatic; 3- to 6-membered carbocyclic ring; phenyl; 3- to 6-membered heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; 5- to 6-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; 10-membered aromatic ring; and 9- to 10-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;

[0080] m is 0, 1, 2, or 3;

[0081] n is 0, 1, or 2;

[0082] p is 0, 1, 2, or 3;

[0083] q is 0 or 1;

[0084] r is 0, 1, or 2;

[0085] s is 0, 1, 2, or 3;

[0086] t is 0, 1, or 2;

[0087] u is 0 or 1;

[0088] Each v is independently 0, 1 or 2;

[0089] Each x is independently 0, 1 or 2; and

[0090] y is 0, 1, or 2.

[0091] In some embodiments, the present disclosure provides a compound of Formula I or a pharmaceutically acceptable salt thereof.

[0092] In some embodiments, the present disclosure provides a compound of Formula I, or a salt (e.g., a pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer thereof, wherein:

[0093] Ring A is selected from phenyl and a 5- to 6-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur;

[0094] Ring B is selected from phenyl, a 6-membered heteroaromatic ring having 1-2 nitrogen atoms, and a 9- to 10-membered bicyclic ring containing at least one 5- or 6-membered heteroaromatic ring;

[0095] Ring C is selected from phenyl; a 5- to 6-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5- to 6-membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and a 9- to 10-membered spiro-fused heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein the phenyl, heteroaromatic, and heterocyclic rings are each optionally fused to Ring E;

[0096] Ring D is selected from phenyl and a 5- to 6-membered heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein the phenyl and heteroaryl ring are each optionally fused to Ring F;

[0097] Ring E is selected from 5 to 6 membered carbocyclic rings; 5 to 7 membered heterocyclic rings having 1-2 heteroatoms independently selected from nitrogen, oxygen and sulfur; and 5 to 6 membered heteroaromatic rings having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur, wherein Ring E is substituted by s R 5′ Instance replacement;

[0098] Ring F is selected from phenyl; a 5- to 6-membered carbocyclic ring; a 5- to 6-membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and a 5- to 6-membered heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein Ring F is substituted with u instances of -LW;

[0099] R 1 Selected from -LW, ring D' or a divalent C substituted by ring D' 1-6 aliphatic chains;

[0100] Each L is independently a divalent linear or branched C 1-8 an aliphatic chain, wherein one or more methylene units of the aliphatic chain are optionally and independently replaced by a group selected from the group consisting of: -N(R)-, -O-, -S-, -C(O)-, -SO2-, -CH(X)-, -C(X)2-, -C(O)N(R)-, -N(R)C(O)-, -C(O)O-, -OC(O)-, -SO2N(R)-, and -N(R)SO2-;

[0101] each W is independently hydrogen, halogen, -CN, or an optionally substituted 3-10 membered monocyclic or bicyclic, saturated, partially unsaturated, or aromatic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

[0102] Each X is independently halogen or -CN;

[0103] each ring D' is independently a 4- to 6-membered carbocyclic ring or a 4- to 6-membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein ring D' is substituted with t instances of -LW;

[0104] Each R 2 are independently selected from oxo, halogen, -CN, -OR and C 1-6 alkyl;

[0105] Each R 3 Independently selected from oxo, halogen, -CN, -OR, -O(CH2) v Cy, -OCH2CH2OR and optionally substituted C 1-6 aliphatic;

[0106] Each Cy is independently a 5- to 6-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3- to 6-membered carbocyclic ring; or a 4- to 6-membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein Cy is optionally substituted with 0-2 R 6 Instance replacement;

[0107] Each R 4 independently selected from halogen and optionally substituted C 1-6 aliphatic;

[0108] R 5 and R 5’ each independently selected from oxo, =NH, -CN, halogen, -OR, -N(R)2, -SR, -C(O)R, -N(R)C(O)R, -C(O)N(R)2, -OC(O)R, -C(O)OR, -SO2R, -N(R)SO2R, -SO2N(R)2, -(CH2) x Cy and optionally substituted C 1-6 aliphatic;

[0109] Each R 6 independently selected from oxo, -CN, halogen, -OR, -N(R)2, -SR, -C(O)R, -N(R)C(O)R, -C(O)N(R)2, -OC(O)R, -C(O)OR, -SO2R, -N(R)SO2R, -SO2N(R)2, and an optionally substituted group selected from: C 1-6aliphatic; 3- to 6-membered carbocyclic ring; phenyl; 3- to 6-membered heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; 5- to 6-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; 10-membered aromatic ring; and 9- to 10-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;

[0110] Each R is independently hydrogen or an optionally substituted group selected from: C 1-6 aliphatic; 3- to 6-membered carbocyclic ring; phenyl; 3- to 6-membered heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; 5- to 6-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; 10-membered aromatic ring; and 9- to 10-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;

[0111] m is 0, 1, 2, or 3;

[0112] n is 0, 1, or 2;

[0113] p is 0, 1, or 2;

[0114] q is 0 or 1;

[0115] r is 0, 1, or 2;

[0116] s is 0, 1, or 2;

[0117] t is 0, 1, or 2;

[0118] u is 0 or 1;

[0119] each v is independently 0, 1 or 2; and

[0120] Each x is independently 0, 1 or 2.

[0121] In some embodiments, the present disclosure provides a compound of Formula I, or a salt (e.g., a pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer thereof, wherein:

[0122] Ring A is phenyl;

[0123] Ring B is selected from a 9- to 10-membered bicyclic ring containing at least one 5- or 6-membered heteroaromatic ring;

[0124] Ring C is selected from phenyl; a 5- to 6-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5- to 8-membered bicyclic carbocyclic ring; a 4- to 8-membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and a 7- to 10-membered spiro-fused heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein the phenyl, heteroaromatic, and heterocyclic rings are each optionally fused to Ring E;

[0125] Ring D is selected from phenyl and a 5- to 6-membered heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein the phenyl and heteroaryl ring are each optionally fused to Ring F;

[0126] Ring E is selected from a 5- to 6-membered carbocyclic ring; a 5- to 7-membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 7- to 10-membered spirofused heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and a 5- to 6-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein Ring E is substituted by s R 5′ Instance replacement;

[0127] Ring F is selected from phenyl; 5- to 6-membered carbocyclic rings; 5- to 7-membered heterocyclic rings having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and 5- to 6-membered heteroaromatic rings having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein Ring F is substituted by u instances of -LW and y instances of R 2’ Instance replacement;

[0128] R 1 Selected from -LW, ring D' or a divalent C substituted by ring D' 1-6 aliphatic chains;

[0129] Each –LW is –CN, or:

[0130] Each L is independently a divalent linear or branched C 1-8 an aliphatic chain, wherein one or more methylene units of the aliphatic chain are optionally and independently replaced by a group selected from the group consisting of: -N(R)-, -O-, -S-, -C(O)-, -SO2-, -CH(X)-, -C(X)2-, -C(O)N(R)-, -N(R)C(O)-, -C(O)O-, -OC(O)-, -SO2N(R)-, and -N(R)SO2-;

[0131] each W is independently hydrogen, halogen, -CN, or an optionally substituted 3-10 membered monocyclic or bicyclic, saturated, partially unsaturated, or aromatic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

[0132] Each X is independently halogen, -OR or -CN;

[0133] each ring D' is independently a 4- to 6-membered carbocyclic ring or a 4- to 6-membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein ring D' is substituted with t instances of -LW;

[0134] Each R 2 and R 2’ are independently selected from oxo, halogen, -CN, -OR and C 1-6 alkyl;

[0135] Each R3 Independently selected from oxo, halogen, -CN, -OR, -O(CH2) v Cy, -OCH2CH2OR and optionally substituted C 1-6 aliphatic;

[0136] Each Cy is independently a 5- to 6-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3- to 6-membered carbocyclic ring; or a 4- to 6-membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein Cy is optionally substituted with 0-2 R 6 Instance replacement;

[0137] Each R 4 independently selected from halogen and optionally substituted C 1-6 aliphatic;

[0138] R 5 and R 5’ are each independently selected from oxo, =NH, -CN, halogen, -OR, -N(R)2, -SR, -C(O)R, -N(R)C(O)R, -(CH2) x C(O)N(R)2, -C(O)N(R)2, -C(O)N(R)(CH2) x Cy, -(CH2) x C(O)Cy, -OC(O)R, -C(O)OR, -SO2R, -N(R)SO2R, -N=S(O)(R)2, -SO2N(R)2, -P(O)R2, -(CH2) x Cy, -O(CH2) x Cy and optionally substituted C 1-6 aliphatic;

[0139] Each R 6 independently selected from oxo, -CN, halogen, -OR, -N(R)2, -SR, -C(O)R, -N(R)C(O)R, -C(O)N(R)2, -OC(O)R, -C(O)OR, -SO2R, -N(R)SO2R, -SO2N(R)2, and an optionally substituted group selected from: C 1-6 aliphatic; 3- to 6-membered carbocyclic ring; phenyl; 3- to 6-membered heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; 5- to 6-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; 10-membered aromatic ring; and 9- to 10-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;

[0140] Each R is independently hydrogen or an optionally substituted group selected from the following: C 1-6aliphatic; 3- to 6-membered carbocyclic ring; phenyl; 3- to 6-membered heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; 5- to 6-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; 10-membered aromatic ring; and 9- to 10-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;

[0141] m is 2 or 3;

[0142] n is 0, 1, or 2;

[0143] p is 0, 1, 2, or 3;

[0144] q is 0 or 1;

[0145] r is 0, 1, or 2;

[0146] s is 0, 1, 2, or 3;

[0147] t is 0, 1, or 2;

[0148] u is 0 or 1;

[0149] Each v is independently 0, 1 or 2;

[0150] Each x is independently 0, 1 or 2; and

[0151] y is 0, 1, or 2.

[0152] In some embodiments, the present disclosure provides a compound of Formula I, or a salt (e.g., a pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer thereof, wherein:

[0153] Ring A is phenyl;

[0154] Ring B is selected from a 9- to 10-membered bicyclic ring containing at least one 5- or 6-membered heteroaromatic ring;

[0155] Ring C is selected from phenyl; a 5- to 6-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5- to 8-membered bicyclic carbocyclic ring; a 4- to 8-membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and a 7- to 10-membered spiro-fused heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein the phenyl, heteroaromatic, and heterocyclic rings are each optionally fused to Ring E;

[0156] Ring D is selected from phenyl and a 5- to 6-membered heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein the phenyl and heteroaryl rings are each fused to Ring F;

[0157] Ring E is selected from a 5- to 6-membered carbocyclic ring; a 5- to 7-membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 7- to 10-membered spirofused heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and a 5- to 6-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein Ring E is substituted by s R 5′ Instance replacement;

[0158] Ring F is selected from phenyl; 5- to 6-membered carbocyclic rings; 5- to 7-membered heterocyclic rings having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and 5- to 6-membered heteroaromatic rings having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein Ring F is substituted by u instances of -LW and y instances of R 2’ Instance replacement;

[0159] Each –LW is –CN, or:

[0160] Each L is independently a divalent linear or branched C 1-8 an aliphatic chain, wherein one or more methylene units of the aliphatic chain are optionally and independently replaced by a group selected from the group consisting of: -N(R)-, -O-, -S-, -C(O)-, -SO2-, -CH(X)-, -C(X)2-, -C(O)N(R)-, -N(R)C(O)-, -C(O)O-, -OC(O)-, -SO2N(R)-, and -N(R)SO2-;

[0161] each W is independently hydrogen, halogen, -CN, or an optionally substituted 3-10 membered monocyclic or bicyclic, saturated, partially unsaturated, or aromatic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

[0162] Each X is independently halogen, -OR or -CN;

[0163] Each R 2 and R 2’ are independently selected from oxo, halogen, -CN, -OR and C 1-6 alkyl;

[0164] Each R 3 Independently selected from oxo, halogen, -CN, -OR, -O(CH2) v Cy, -OCH2CH2OR and optionally substituted C 1-6 aliphatic;

[0165] Each Cy is independently a 5- to 6-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3- to 6-membered carbocyclic ring; or a 4- to 6-membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein Cy is optionally substituted with 0-2 R 6 Instance replacement;

[0166] Each R4 independently selected from halogen and optionally substituted C 1-6 aliphatic;

[0167] R 5 and R 5’ are each independently selected from oxo, =NH, -CN, halogen, -OR, -N(R)2, -SR, -C(O)R, -N(R)C(O)R, -(CH2) x C(O)N(R)2, -C(O)N(R)2, -C(O)N(R)(CH2) x Cy, -(CH2) x C(O)Cy, -OC(O)R, -C(O)OR, -SO2R, -N(R)SO2R, -N=S(O)(R)2, -SO2N(R)2, -P(O)R2, -(CH2) x Cy, -O(CH2) x Cy and optionally substituted C 1-6 aliphatic;

[0168] Each R 6 independently selected from oxo, -CN, halogen, -OR, -N(R)2, -SR, -C(O)R, -N(R)C(O)R, -C(O)N(R)2, -OC(O)R, -C(O)OR, -SO2R, -N(R)SO2R, -SO2N(R)2, and an optionally substituted group selected from: C 1-6 aliphatic; 3- to 6-membered carbocyclic ring; phenyl; 3- to 6-membered heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; 5- to 6-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; 10-membered aromatic ring; and 9- to 10-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;

[0169] Each R is independently hydrogen or an optionally substituted group selected from the following: C 1-6 aliphatic; 3- to 6-membered carbocyclic ring; phenyl; 3- to 6-membered heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; 5- to 6-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; 10-membered aromatic ring; and 9- to 10-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;

[0170] m is 2 or 3;

[0171] n is 0, 1, or 2;

[0172] p is 0, 1, 2, or 3;

[0173] q is 0;

[0174] r is 0, 1, or 2;

[0175] s is 0, 1, 2, or 3;

[0176] u is 0 or 1;

[0177] Each v is independently 0, 1 or 2;

[0178] Each x is independently 0, 1 or 2; and

[0179] y is 0, 1, or 2.

[0180] In some embodiments, the present disclosure provides a compound of Formula I, or a salt (e.g., a pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer thereof, wherein:

[0181] Ring A is phenyl;

[0182] Ring B is selected from a 9- to 10-membered bicyclic ring containing at least one 5- or 6-membered heteroaromatic ring;

[0183] Ring C is selected from phenyl; a 5- to 6-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5- to 8-membered bicyclic carbocyclic ring; a 4- to 8-membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and a 7- to 10-membered spiro-fused heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein the phenyl, heteroaromatic, and heterocyclic rings are each fused to Ring E;

[0184] Ring D is selected from phenyl and a 5- to 6-membered heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein the phenyl and heteroaryl rings are each fused to Ring F;

[0185] Ring E is selected from a 5- to 6-membered carbocyclic ring; a 5- to 7-membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 7- to 10-membered spirofused heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and a 5- to 6-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein Ring E is substituted by s R 5′ Instance replacement;

[0186] Ring F is selected from phenyl; 5- to 6-membered carbocyclic rings; 5- to 7-membered heterocyclic rings having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and 5- to 6-membered heteroaromatic rings having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein Ring F is substituted by u instances of -LW and y instances of R 2’ Instance replacement;

[0187] Each –LW is –CN, or:

[0188] Each L is independently a divalent linear or branched C 1-8an aliphatic chain, wherein one or more methylene units of the aliphatic chain are optionally and independently replaced by a group selected from the group consisting of: -N(R)-, -O-, -S-, -C(O)-, -SO2-, -CH(X)-, -C(X)2-, -C(O)N(R)-, -N(R)C(O)-, -C(O)O-, -OC(O)-, -SO2N(R)-, and -N(R)SO2-;

[0189] each W is independently hydrogen, halogen, -CN, or an optionally substituted 3-10 membered monocyclic or bicyclic, saturated, partially unsaturated, or aromatic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

[0190] Each X is independently halogen, -OR or -CN;

[0191] Each R 2 and R 2’ are independently selected from oxo, halogen, -CN, -OR and C 1-6 alkyl;

[0192] Each R 3 Independently selected from oxo, halogen, -CN, -OR, -O(CH2) v Cy, -OCH2CH2OR and optionally substituted C 1-6 aliphatic;

[0193] Each Cy is independently a 5- to 6-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3- to 6-membered carbocyclic ring; or a 4- to 6-membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein Cy is optionally substituted with 0-2 R 6 Instance replacement;

[0194] Each R 4 independently selected from halogen and optionally substituted C 1-6 aliphatic;

[0195] R 5 and R 5’ are each independently selected from oxo, =NH, -CN, halogen, -OR, -N(R)2, -SR, -C(O)R, -N(R)C(O)R, -(CH2) x C(O)N(R)2, -C(O)N(R)2, -C(O)N(R)(CH2) x Cy, -(CH2) x C(O)Cy, -OC(O)R, -C(O)OR, -SO2R, -N(R)SO2R, -N=S(O)(R)2, -SO2N(R)2, -P(O)R2, -(CH2) x Cy, -O(CH2) xCy and optionally substituted C 1-6 aliphatic;

[0196] Each R 6 independently selected from oxo, -CN, halogen, -OR, -N(R)2, -SR, -C(O)R, -N(R)C(O)R, -C(O)N(R)2, -OC(O)R, -C(O)OR, -SO2R, -N(R)SO2R, -SO2N(R)2, and an optionally substituted group selected from: C 1-6 aliphatic; 3- to 6-membered carbocyclic ring; phenyl; 3- to 6-membered heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; 5- to 6-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; 10-membered aromatic ring; and 9- to 10-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;

[0197] Each R is independently hydrogen or an optionally substituted group selected from: C 1-6 aliphatic; 3- to 6-membered carbocyclic ring; phenyl; 3- to 6-membered heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; 5- to 6-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; 10-membered aromatic ring; and 9- to 10-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;

[0198] m is 2 or 3;

[0199] n is 0, 1, or 2;

[0200] p is 0, 1, 2, or 3;

[0201] q is 0;

[0202] r is 0, 1, or 2;

[0203] s is 0, 1, 2, or 3;

[0204] u is 0 or 1;

[0205] Each v is independently 0, 1 or 2;

[0206] Each x is independently 0, 1 or 2; and

[0207] y is 0, 1, or 2.

[0208] In some embodiments, the present disclosure provides a compound selected from Formula Ia, Ib, Ic, Id, Ie, If, Ig, Ih, Ii, Ij, and Ik:

[0209]

[0210]

[0211] or a salt (eg, a pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form or stereoisomer thereof, wherein Ring A, Ring C, Ring D, R 1 、R 2 、R 3 、R 4 、R 5 , m, n, p, q, and r are as defined above for Formula I and described individually and in combination in the classes and subclasses herein. In some embodiments, the present disclosure provides a compound of Formula Ia, or a pharmaceutically acceptable salt thereof. In some embodiments, the present disclosure provides a compound of Formula Ib, or a pharmaceutically acceptable salt thereof. In some embodiments, the present disclosure provides a compound of Formula Ic, or a pharmaceutically acceptable salt thereof. In some embodiments, the present disclosure provides a compound of Formula Id, or a pharmaceutically acceptable salt thereof. In some embodiments, the present disclosure provides a compound of Formula Ie, or a pharmaceutically acceptable salt thereof. In some embodiments, the present disclosure provides a compound of Formula If, or a pharmaceutically acceptable salt thereof. In some embodiments, the present disclosure provides a compound of Formula Ig, or a pharmaceutically acceptable salt thereof. In some embodiments, the present disclosure provides a compound of Formula Ih, or a pharmaceutically acceptable salt thereof. In some embodiments, the present disclosure provides a compound of Formula Ii, or a pharmaceutically acceptable salt thereof. In some embodiments, the present disclosure provides a compound of Formula Ij, or a pharmaceutically acceptable salt thereof. In some embodiments, the present disclosure provides a compound of Formula Ik, or a pharmaceutically acceptable salt thereof.

[0212] In some embodiments, the present disclosure provides a compound selected from Formula Iai, Ibi, Ici, Idi, Iei, Ifi, Igi, Ihi, Iii, Iji, and Iki:

[0213]

[0214]

[0215] or a salt (eg, a pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form or stereoisomer thereof, wherein Ring A, Ring C, Ring D, Ring E, R 1 、R 2 、R 3 、R 4 、R 5 、R 5’, m, n, p, q, r, and s are as defined above for Formula I and described individually and in combination in the classes and subclasses herein. In some embodiments, the present disclosure provides a compound of Formula Iai, or a pharmaceutically acceptable salt thereof. In some embodiments, the present disclosure provides a compound of Formula Ibi, or a pharmaceutically acceptable salt thereof. In some embodiments, the present disclosure provides a compound of Formula Ici, or a pharmaceutically acceptable salt thereof. In some embodiments, the present disclosure provides a compound of Formula Idi, or a pharmaceutically acceptable salt thereof. In some embodiments, the present disclosure provides a compound of Formula Iei, or a pharmaceutically acceptable salt thereof. In some embodiments, the present disclosure provides a compound of Formula Ifi, or a pharmaceutically acceptable salt thereof. In some embodiments, the present disclosure provides a compound of Formula Igi, or a pharmaceutically acceptable salt thereof. In some embodiments, the present disclosure provides a compound of Formula Ihi, or a pharmaceutically acceptable salt thereof. In some embodiments, the present disclosure provides a compound of Formula Iii, or a pharmaceutically acceptable salt thereof. In some embodiments, the present disclosure provides a compound of Formula Iji, or a pharmaceutically acceptable salt thereof. In some embodiments, the present disclosure provides a compound of Formula Iki, or a pharmaceutically acceptable salt thereof.

[0216] In some embodiments, the present disclosure provides a compound selected from Formula Ia-ii, Ib-ii, Ic-ii, Id-ii, Ie-ii, If-ii, Ig-ii, Ih-ii, Ii-ii, Ij-ii, and Ik-ii:

[0217]

[0218]

[0219] or a salt (eg, a pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer thereof, wherein Ring A, Ring C, Ring D, Ring F, R 2 、R 3 、R 4 、R 5, L, W, m, n, p, r, and u are as defined above for Formula I and described individually and in combination in the classes and subclasses herein. In some embodiments, the present disclosure provides compounds of Formula Ia-ii, or pharmaceutically acceptable salts thereof. In some embodiments, the present disclosure provides compounds of Formula Ib-ii, or pharmaceutically acceptable salts thereof. In some embodiments, the present disclosure provides compounds of Formula Ic-ii, or pharmaceutically acceptable salts thereof. In some embodiments, the present disclosure provides compounds of Formula Id-ii, or pharmaceutically acceptable salts thereof. In some embodiments, the present disclosure provides compounds of Formula Ie-ii, or pharmaceutically acceptable salts thereof. In some embodiments, the present disclosure provides compounds of Formula If-ii, or pharmaceutically acceptable salts thereof. In some embodiments, the present disclosure provides compounds of Formula Ig-ii, or pharmaceutically acceptable salts thereof. In some embodiments, the present disclosure provides compounds of Formula Ih-ii, or pharmaceutically acceptable salts thereof. In some embodiments, the present disclosure provides compounds of Formula Ii-ii, or pharmaceutically acceptable salts thereof. In some embodiments, the present disclosure provides compounds of Formula Ij-ii, or pharmaceutically acceptable salts thereof. In some embodiments, the present disclosure provides a compound of Formula Ik-ii or a pharmaceutically acceptable salt thereof.

[0220] In some embodiments, the present disclosure provides a compound selected from Formula Ia-ii', Ib-ii', Ic-ii', Id-ii', Ie-ii', If-ii', Ig-ii', Ih-ii', Ii-ii', Ij-ii', and Ik-ii':

[0221]

[0222]

[0223] or a salt (eg, a pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer thereof, wherein Ring A, Ring C, Ring D, Ring F, R 2 、R 2’ 、R 3 、R 4 、R 5, L, W, m, n, p, r, u and y are as defined above for Formula I and described individually and in combination in the classes and subclasses herein. In some embodiments, the present disclosure provides compounds of Formula Ia-ii' or pharmaceutically acceptable salts thereof. In some embodiments, the present disclosure provides compounds of Formula Ib-ii' or pharmaceutically acceptable salts thereof. In some embodiments, the present disclosure provides compounds of Formula Ic-ii' or pharmaceutically acceptable salts thereof. In some embodiments, the present disclosure provides compounds of Formula Id-ii' or pharmaceutically acceptable salts thereof. In some embodiments, the present disclosure provides compounds of Formula Ie-ii' or pharmaceutically acceptable salts thereof. In some embodiments, the present disclosure provides compounds of Formula If-ii' or pharmaceutically acceptable salts thereof. In some embodiments, the present disclosure provides compounds of Formula Ig-ii' or pharmaceutically acceptable salts thereof. In some embodiments, the present disclosure provides compounds of Formula Ih-ii' or pharmaceutically acceptable salts thereof. In some embodiments, the present disclosure provides compounds of Formula Ii-ii' or pharmaceutically acceptable salts thereof. In some embodiments, the present disclosure provides a compound of Formula Ij-ii' or a pharmaceutically acceptable salt thereof. In some embodiments, the present disclosure provides a compound of Formula Ik-ii' or a pharmaceutically acceptable salt thereof.

[0224] In some embodiments, the present disclosure provides a compound selected from Formula Ia-iii, Ib-iii, Ic-iii, Id-iii, Ie-iii, If-iii, Ig-iii, Ih-iii, Ii-iii, Ij-iii, and Ik-iii:

[0225]

[0226]

[0227] or a salt (eg, a pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer thereof, wherein Ring A, Ring C, Ring D, Ring D', L, R 2 、R 3 、R 4 、R 5, W, m, n, p, r, and t are as defined above for Formula I and described individually and in combination in the classes and subclasses herein. In some embodiments, the present disclosure provides compounds of Formulas Ia-iii, or pharmaceutically acceptable salts thereof. In some embodiments, the present disclosure provides compounds of Formulas Ib-iii, or pharmaceutically acceptable salts thereof. In some embodiments, the present disclosure provides compounds of Formulas Ic-iii, or pharmaceutically acceptable salts thereof. In some embodiments, the present disclosure provides compounds of Formulas Id-iii, or pharmaceutically acceptable salts thereof. In some embodiments, the present disclosure provides compounds of Formulas Ie-iii, or pharmaceutically acceptable salts thereof. In some embodiments, the present disclosure provides compounds of Formulas If-iii, or pharmaceutically acceptable salts thereof. In some embodiments, the present disclosure provides compounds of Formulas Ig-iii, or pharmaceutically acceptable salts thereof. In some embodiments, the present disclosure provides compounds of Formulas Ih-iii, or pharmaceutically acceptable salts thereof. In some embodiments, the present disclosure provides compounds of Formulas Ii-iii, or pharmaceutically acceptable salts thereof. In some embodiments, the present disclosure provides compounds of Formulas Ij-iii, or pharmaceutically acceptable salts thereof. In some embodiments, the present disclosure provides a compound of Formula Ik-iii or a pharmaceutically acceptable salt thereof.

[0228] In some embodiments, the present disclosure provides a compound selected from Formula Ia-iv, Ib-iv, Ic-iv, Id-iv, Ie-iv, If-iv, Ig-iv, Ih-iv, Ii-iv, Ij-iv, and Ik-iv:

[0229]

[0230]

[0231] or a salt (eg, a pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer thereof, wherein Ring A, Ring C, Ring D', L, R 2 、R 3 、R 4 、R 5, W, m, n, p, r, and t are as defined above for Formula I and described individually and in combination in the classes and subclasses herein. In some embodiments, the present disclosure provides compounds of Formulas Ia-iv, or pharmaceutically acceptable salts thereof. In some embodiments, the present disclosure provides compounds of Formulas Ib-iv, or pharmaceutically acceptable salts thereof. In some embodiments, the present disclosure provides compounds of Formulas Ic-iv, or pharmaceutically acceptable salts thereof. In some embodiments, the present disclosure provides compounds of Formulas Id-iv, or pharmaceutically acceptable salts thereof. In some embodiments, the present disclosure provides compounds of Formulas Ie-iv, or pharmaceutically acceptable salts thereof. In some embodiments, the present disclosure provides compounds of Formulas If-iv, or pharmaceutically acceptable salts thereof. In some embodiments, the present disclosure provides compounds of Formulas Ig-iv, or pharmaceutically acceptable salts thereof. In some embodiments, the present disclosure provides compounds of Formulas Ih-iv, or pharmaceutically acceptable salts thereof. In some embodiments, the present disclosure provides compounds of Formulas Ii-iv, or pharmaceutically acceptable salts thereof. In some embodiments, the present disclosure provides compounds of Formulas Ij-iv, or pharmaceutically acceptable salts thereof. In some embodiments, the present disclosure provides a compound of Formula Ik-iv or a pharmaceutically acceptable salt thereof.

[0232] In some embodiments, the present disclosure provides a compound selected from Formulas Iav, Ibv, Icv, Idv, Iev, Ifv, Igv, Ihv, Iiv, Ijv, and Ikv:

[0233]

[0234]

[0235] or a salt (e.g., a pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form or stereoisomer thereof, wherein Ring A, Ring C, Ring D, Ring E, Ring F, R 2 、R 3 、R 4 、R 5 、R 5’, L, W, m, n, p, r, s, and u are as defined above for Formula I and described individually and in combination in the classes and subclasses herein. In some embodiments, the present disclosure provides a compound of Formula Iav, or a pharmaceutically acceptable salt thereof. In some embodiments, the present disclosure provides a compound of Formula Ibv, or a pharmaceutically acceptable salt thereof. In some embodiments, the present disclosure provides a compound of Formula Icv, or a pharmaceutically acceptable salt thereof. In some embodiments, the present disclosure provides a compound of Formula Idv, or a pharmaceutically acceptable salt thereof. In some embodiments, the present disclosure provides a compound of Formula Ifv, or a pharmaceutically acceptable salt thereof. In some embodiments, the present disclosure provides a compound of Formula Igv, or a pharmaceutically acceptable salt thereof. In some embodiments, the present disclosure provides a compound of Formula Ihv, or a pharmaceutically acceptable salt thereof. In some embodiments, the present disclosure provides a compound of Formula Iiv, or a pharmaceutically acceptable salt thereof. In some embodiments, the present disclosure provides a compound of Formula Ijv, or a pharmaceutically acceptable salt thereof. In some embodiments, the present disclosure provides a compound of Formula Ikv or a pharmaceutically acceptable salt thereof.

[0236] In some embodiments, the present disclosure provides a compound selected from Formula Ia-v', Ib-v', Ic-v', Id-v', Ie-v', If-v', Ig-v', Ih-v', Ii-v', Ij-v', and Ik-v':

[0237]

[0238]

[0239]

[0240] or a salt (e.g., a pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form or stereoisomer thereof, wherein Ring A, Ring C, Ring D, Ring E, Ring F, R 2 、R 2’ 、R 3 、R 4 、R 5 、R 5’, L, W, m, n, p, r, s, u, and y are as defined above for Formula I and described individually and in combination in the classes and subclasses herein. In some embodiments, the present disclosure provides compounds of Formulas Ia-v', or pharmaceutically acceptable salts thereof. In some embodiments, the present disclosure provides compounds of Formulas Ib-v', or pharmaceutically acceptable salts thereof. In some embodiments, the present disclosure provides compounds of Formulas Ic-v', or pharmaceutically acceptable salts thereof. In some embodiments, the present disclosure provides compounds of Formulas Id-v', or pharmaceutically acceptable salts thereof. In some embodiments, the present disclosure provides compounds of Formulas Ie-v', or pharmaceutically acceptable salts thereof. In some embodiments, the present disclosure provides compounds of Formulas If-v', or pharmaceutically acceptable salts thereof. In some embodiments, the present disclosure provides compounds of Formulas Ig-v', or pharmaceutically acceptable salts thereof. In some embodiments, the present disclosure provides compounds of Formulas Ih-v', or pharmaceutically acceptable salts thereof. In some embodiments, the present disclosure provides compounds of Formulas Ii-v', or pharmaceutically acceptable salts thereof. In some embodiments, the present disclosure provides compounds of Formula Ij-v' or pharmaceutically acceptable salts thereof. In some embodiments, the present disclosure provides compounds of Formula Ik-v' or pharmaceutically acceptable salts thereof.

[0241] In some embodiments, the present disclosure provides a compound selected from Formula II, Im, In, Ip, Iq, and Ir:

[0242]

[0243] or a salt (eg, a pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer thereof, wherein Ring A, Ring B, Ring C, Ring D', L, R 3 、R 4 、R 5 , W, m, n, p, and t are as defined above for Formula I and described individually and in combination in the classes and subclasses herein. In some embodiments, the present disclosure provides a compound of Formula II or a pharmaceutically acceptable salt thereof. In some embodiments, the present disclosure provides a compound of Formula Im or a pharmaceutically acceptable salt thereof. In some embodiments, the present disclosure provides a compound of Formula In or a pharmaceutically acceptable salt thereof. In some embodiments, the present disclosure provides a compound of Formula Ip or a pharmaceutically acceptable salt thereof. In some embodiments, the present disclosure provides a compound of Formula Iq or a pharmaceutically acceptable salt thereof. In some embodiments, the present disclosure provides a compound of Formula Ir or a pharmaceutically acceptable salt thereof.

[0244] In some embodiments, the present disclosure provides compounds of Formula IA:

[0245]

[0246] or a salt (eg, a pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer thereof, wherein Ring B, Ring C, Ring D, R 1 、R 2 、R 3 、R 4 、R 5 , m, n, p, q, and r are as defined above for Formula I and described herein, individually and in combination, in classes and subclasses. In some embodiments, the disclosure provides a compound of Formula IA, or a pharmaceutically acceptable salt thereof.

[0247] In some embodiments, the present disclosure provides compounds of Formula IA1:

[0248]

[0249] or a salt (eg, a pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer thereof, wherein Ring B, Ring C, Ring D, R 1 、R 2 、R 3 、R 4 、R 5 , n, p, q, and r are as defined above for Formula I and described in classes and subclasses herein, individually and in combination. In some embodiments, the disclosure provides a compound of Formula IA1 or a pharmaceutically acceptable salt thereof.

[0250] In some embodiments, the present disclosure provides compounds of Formula IB:

[0251]

[0252] or a salt (eg, a pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer thereof, wherein Ring C, Ring D, R 1 、R 2 、R 3 、R 4 、R 5 , m, n, p, q, and r are as defined above for Formula I and described herein, individually and in combination, in classes and subclasses. In some embodiments, the disclosure provides a compound of Formula IB or a pharmaceutically acceptable salt thereof.

[0253] In some embodiments, the present disclosure provides compounds of Formula IB1:

[0254]

[0255] or a salt (eg, a pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer thereof, wherein Ring C, Ring D, R 1 、R 2 、R 3 、R 4 、R 5 , n, p, q, and r are as defined above for Formula I and described in classes and subclasses herein, both individually and in combination. In some embodiments, the disclosure provides a compound of Formula IBl or a pharmaceutically acceptable salt thereof.

[0256] In some embodiments, the present disclosure provides compounds of Formula IC:

[0257]

[0258] or a salt (eg, a pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer thereof, wherein Ring B, Ring C, L, R 2’ 、R 3 、R 4 、R 5 , W, m, n, p, and y are as defined above for Formula I and described herein, individually and in combination, in classes and subclasses. In some embodiments, the disclosure provides a compound of Formula IC, or a pharmaceutically acceptable salt thereof.

[0259] In some embodiments, the present disclosure provides compounds of Formula IC1:

[0260]

[0261] or a salt (eg, a pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer thereof, wherein Ring B, Ring C, L, R 2’ 、R 3 、R 4 、R 5 , W, n, p, and y are as defined above for Formula I and described herein, individually and in combination, in classes and subclasses. In some embodiments, the disclosure provides a compound of Formula IC1 or a pharmaceutically acceptable salt thereof.

[0262] In some embodiments, the present disclosure provides compounds of Formula ID:

[0263]

[0264] or a salt (eg, a pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer thereof, wherein ring C, L, R 2’ 、R 3 、R 4 、R5 , W, m, n, p, and y are as defined above for Formula I and described herein, individually and in combination, in classes and subclasses. In some embodiments, the disclosure provides a compound of Formula ID, or a pharmaceutically acceptable salt thereof.

[0265] In some embodiments, the present disclosure provides compounds of Formula ID1:

[0266]

[0267] or a salt (eg, a pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer thereof, wherein ring C, L, R 2’ 、R 3 、R 4 、R 5 , W, n, p, and y are as defined above for Formula I and described in classes and subclasses herein, both individually and in combination. In some embodiments, the disclosure provides a compound of Formula ID1 or a pharmaceutically acceptable salt thereof.

[0268] In some embodiments, the present disclosure provides compounds of Formula IE:

[0269]

[0270] or a salt (eg, a pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer thereof, wherein Ring B, Ring C, Ring E, L, R 2’ 、R 3 、R 4 、R 5 、R 5’ , W, m, n, p, s, and y are as defined above for Formula I and described herein, individually and in combination, in classes and subclasses. In some embodiments, the disclosure provides a compound of Formula IE or a pharmaceutically acceptable salt thereof.

[0271] In some embodiments, the present disclosure provides compounds of Formula IE1:

[0272]

[0273] or a salt (eg, a pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer thereof, wherein Ring B, Ring C, Ring E, L, R 2’ 、R 3 、R 4 、R 5 、R 5’, W, n, p, s, and y are as defined above for Formula I and described in classes and subclasses herein, both individually and in combination. In some embodiments, the present disclosure provides a compound of Formula IE1 or a pharmaceutically acceptable salt thereof.

[0274] In some embodiments, the present disclosure provides compounds of Formula IF:

[0275]

[0276] or a salt (eg, a pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer thereof, wherein Ring C, Ring E, L, R 2’ 、R 3 、R 4 、R 5 、R 5’ , W, m, n, p, s, and y are as defined above for Formula I and described herein, individually and in combination, in classes and subclasses. In some embodiments, the present disclosure provides a compound of Formula IF, or a pharmaceutically acceptable salt thereof.

[0277] In some embodiments, the present disclosure provides compounds of Formula IF1:

[0278]

[0279] or a salt (eg, a pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer thereof, wherein Ring C, Ring E, L, R 2’ 、R 3 、R 4 、R 5 、R 5’ , W, n, p, s, and y are as defined above for Formula I and described herein, individually and in combination, in classes and subclasses. In some embodiments, the present disclosure provides a compound of Formula IF1 or a pharmaceutically acceptable salt thereof.

[0280] In some embodiments of any of the formulae described herein, Ring A is phenyl or a 5- to 6-membered heteroaromatic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, Ring A is phenyl or a 6-membered heteroaromatic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0281] In some embodiments of any of the formulae described herein, Ring A is phenyl. In some embodiments, Ring A is In some embodiments, Ring A is In some embodiments, Ring A is In some embodiments, Ring A is selected from In some embodiments, Ring A is selected from In some embodiments, Ring A is

[0282] In some embodiments of any of the formulas described herein, Ring A is a 5- to 6-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, Ring A is a 5- to 6-membered heteroaromatic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, Ring A is a 5-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, Ring A is pyrazole. In some embodiments, Ring A is a 6-membered heteroaromatic ring having 1-3 nitrogen atoms. In some embodiments, Ring A is pyridine or pyridone.

[0283] In some embodiments of any of the formulae described herein, 3 Example substituted ring A is selected from

[0284]

[0285] In some embodiments of any of the formulas described herein, each R 3 independently selected from oxo, halogen (such as F or Cl), -CN, -OR, -O(CH2) v Cy, -O-(C 1-4 Alkylene) -OR (e.g. -OCH2CH2OR), -CH2CH2OR, C 1-6 Aliphatic and C 1-6 In some embodiments, each R 3 independently selected from oxo, halogen (such as F or Cl), -CN, -OR, -O(CH2) v Cy, -OCH2CH2OR, -CH2CH2OR, C 1-6 Aliphatic and C 1-6 In some embodiments, each R 3 Independently selected from halogen, -CN, -OR, -O(CH2) v Cy, -OCH2CH2OR and optionally substituted C 1-6 In some embodiments, each R 3 Independently selected from oxo, halogen, -CN, -OR, -O(CH2) v Cy, -OCH2CH2OR and optionally substituted C 1-6 In some embodiments, each R 3 Independently selected from oxo, halogen, -CN, -OR, -O(CH2) v Cy, -OCH2CH2OR and optionally substituted with one or more halogens or -ORo Substituted C 1-6 In some such embodiments, R o C 1-4 Thus, in some embodiments, each R 3 Independently selected from oxo, halogen, -CN, -OR, -O(CH2) v Cy, -OCH2CH2OR and optionally one or more halogen or -O(C 1-4 Alkyl) substituted C 1-6 In some embodiments, each R 3 Independently selected from oxo, halogen, -CN, -OR, -O(CH2) v Cy, -OCH2CH2OR and optionally one or more halogen or -O(C 1-4 Alkyl) substituted C 1-6 In some embodiments, at least one R 3 Selected from halogen, -OR, -O(CH2) v Cy and -OCH2CH2OR. In some embodiments, at least one R 3 Selected from -OR, -O(CH2) v Cy and -OCH2CH2OR. In some embodiments, Ring A is Among them, each R 3 independently selected from halogen, -OR, -O(CH2) v Cy and -OCH2CH2OR. In some embodiments, Ring A is Among them, each R 3 independently selected from halogen, -OR, -O(CH2) v Cy and -O-(C 1-4 In some embodiments, ring A is where R 3 Selected from -OR, -O(CH2) v Cy and -OCH2CH2OR. In some embodiments, Ring A is where R 3 Selected from -OR, -O(CH2) v Cy and -O-(C 1-4 Alkylene)-OR.

[0286] In some embodiments of any of the formulas described herein, each R 3 independently selected from halogen, -OR, -OCH2CH2OR and optionally substituted with one or more halogen or -O(C 1-4 Alkyl) substituted C 1-6 In some embodiments, at least one R 3is selected from halogen (eg, F). In some embodiments, at least one R 3 Selected from -OCH2CH2OR and optionally substituted with one or more halogens or -O(C 1-4 Alkyl) substituted C 1-6 In some embodiments, at least one R 3 Selected from -OCH3, -OCH2CH3, -OCH(CH3)2, -OCHF2, -OCH2CHF2, -OCH(CH2F)2, -OCH2CH2OH, -OCH2CH2OCH3, -OCH2CH(CH3)OH, -OCH2C(CH3)2OH, -OCH(CH3)CH2OH and -O(cyclopropyl).

[0287] In some embodiments of any of the formulae described herein, R 3 is oxo (eg, when Ring A is not phenyl). In some embodiments, R 3 is halogen (eg, fluorine or chlorine). In some embodiments, R 3 In some embodiments, R 3 In some embodiments, R 3 In some embodiments, R 3 In some embodiments, R 3 is -O (optionally substituted with -OH) 1-4 alkyl) or –O(C 1-4 In some embodiments, R 3 In some embodiments, R 3 For –O(C 1-4 alkyl) or –O(C 1-4 In some embodiments, R 3 is -OCH3, -OCH2CH3, -OCH(CH3)2, -OCHF2 or -OCH2CHF2. In some embodiments, R 3 -O(CH2) v Cy. In some embodiments, R 3 In some embodiments, R 3 -O(CH2) v Cy, wherein Cy is a 5- to 6-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur, 6In some embodiments, R 3 -O(CH2) v Cy, where Cy is 0-2 R 6 Examples include substituted 3- to 6-membered carbocyclic rings (eg, Cy is cyclopropane or cyclobutane substituted with one or more halogens). In some embodiments, R 3 -O(CH2) v Cy, wherein Cy is a 3- to 6-membered carbocyclic ring (eg, Cy is cyclopropane). In some embodiments, R 3 -O(CH2) v Cy, wherein Cy is a 4- to 6-membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur (e.g., Cy is optionally C 1-6 In some embodiments, R 3 -O-(C 1-4 In some embodiments, R 3 For –O-(C 1-4 In some embodiments, R 3 is -OCH2CH2OH, -OCH(CH3)CH2OH, -OCH2CH(CH3)OH, -OCH2C(CH3)2OH, -OCH2CH2O(C 1-4 Alkyl) or -OCH2CH2O(C 1-4 In some embodiments, R 3 In some embodiments, R 3 -OCH2CH2OH or -OCH2CH2O(C 1-4 In some embodiments, R 3 In some embodiments, R 3 is –CH2CH2O(C 1-4 In some embodiments, R 3 is an optionally substituted C 1-6 In some embodiments, R 3 is an optionally substituted C 1-6 In some embodiments, R 3 is optionally substituted with one or more halogens (eg, fluorine) or -OR o (For example –O(C 1-4 Alkyl)) substituted C 1-6 In some embodiments, R 3 is optionally substituted with one or more halogens (eg, fluorine) or -OR o (For example –O(C1-4 Alkyl)) substituted C 1-6 In some embodiments, R 3 C 1-6 In some embodiments, R 3 C 1-6 Haloalkyl.

[0288] In some embodiments of any of the formulas described herein, each R 3 independently selected from oxo, fluorine, chlorine, -CN, -OH, -OCH3, -OCH2CH3, -OCH(CH3)2, -OCHF2, -OCH2CHF2, -OCH(CH2F)2, -OCH2CH2OH, -OCH2CH2OCH3, -OCH2CH2OCD3, -OCH(CH3)CH2OH, -OCH2CH(CH3)OH, -OCH2C(CH3)2OH, -OCH2CH2OCHF2, -CH3, -CHF2, -CH2CH2OCH3,

[0289] In some embodiments of any of the formulae described herein, m is 1, 2, or 3. In some embodiments, m is 1 or 2. In some embodiments, m is 0. In some embodiments, m is 1. In some embodiments, m is 2. In some embodiments, m is 3.

[0290] In some embodiments of any of the formulas described herein, Ring B is selected from a 6-membered heteroaromatic ring having 1-3 nitrogen atoms and a 9- to 10-membered bicyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein the bicyclic ring contains at least one 5- or 6-membered heteroaromatic ring having at least one nitrogen atom. In some embodiments, Ring B is selected from a 6-membered heteroaromatic ring having 1-2 nitrogen atoms and a 9- to 10-membered bicyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein the bicyclic ring contains at least one 5- or 6-membered heteroaromatic ring having at least one nitrogen atom. In some embodiments, Ring B is selected from a 6-membered heteroaromatic ring having 1-2 nitrogen atoms and a 9-membered bicyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein the bicyclic ring contains at least one 5- or 6-membered heteroaromatic ring having at least one nitrogen atom.

[0291] In some embodiments of any of the formulae described herein, Ring B is phenyl.

[0292] In some embodiments of any of the formulae described herein, Ring B is a 6-membered heteroaromatic ring having 1-2 nitrogen atoms. In some embodiments, Ring B is pyridine. In some embodiments, Ring B is pyrazine. In some embodiments, Ring B is pyrimidine. In some embodiments, Ring B is pyridazine.

[0293] In some embodiments of any of the formulas described herein, Ring B is a 9- to 10-membered bicyclic ring containing at least one 5- or 6-membered heteroaromatic ring. In some embodiments, Ring B is a 9- to 10-membered bicyclic ring containing at least one 5- or 6-membered heteroaromatic ring containing at least one nitrogen atom. In some embodiments, Ring B is a 9- to 10-membered bicyclic ring containing one 5- or 6-membered heteroaromatic ring containing at least one nitrogen atom. In some embodiments, Ring B is a 9- to 10-membered bicyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein the bicyclic ring contains at least one 5- or 6-membered heteroaromatic ring containing at least one nitrogen atom. In some embodiments, Ring B is a 9- to 10-membered bicyclic ring containing at least one 6-membered heteroaromatic ring. In some embodiments, Ring B is a 9- to 10-membered bicyclic ring containing at least one 6-membered heteroaromatic ring containing at least one nitrogen atom. In some embodiments, Ring B is a 9- to 10-membered bicyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein the bicyclic ring contains at least one 6-membered heteroaromatic ring containing at least one nitrogen atom. In some embodiments, Ring B is a 9-membered bicyclic ring containing at least one 5- or 6-membered heteroaromatic ring. In some embodiments, Ring B is a 9-membered bicyclic ring containing at least one 5- or 6-membered heteroaromatic ring containing at least one nitrogen atom. In some embodiments, Ring B is a 9- to 10-membered bicyclic ring containing at least one 5- or 6-membered heteroaromatic ring containing at least one nitrogen atom. In some embodiments, Ring B is a 9- to 10-membered bicyclic ring containing a pyridine ring. In some embodiments, Ring B is a 9- to 10-membered bicyclic ring containing a pyrazine ring. In some embodiments, Ring B is a 9- to 10-membered bicyclic ring containing a pyrazole ring. In some embodiments, Ring B is a 9- to 10-membered bicyclic ring containing a thiazole ring. In some embodiments, Ring B is a 9- to 10-membered bicyclic ring containing a thiophene ring. In some embodiments, Ring B is a 9- to 10-membered bicyclic ring containing a furan ring. In some embodiments, Ring B is a 9- to 10-membered bicyclic ring containing a cyclopentane or cyclopentene ring. In some embodiments, Ring B is thieno[3,2-c]pyridine, thieno[2,3-c]pyridine, thiazolo[4,5-c]pyridine, pyrazolo[1,5-a]pyrazine, furo[3,2-c]pyridine, or 6,7-dihydro-5H-cyclopenta[c]pyridine. In some embodiments, Ring B is a 10-membered bicyclic ring containing at least one 6-membered heteroaromatic ring. In some embodiments, Ring B is a 10-membered bicyclic ring containing at least one 6-membered heteroaromatic ring containing at least one nitrogen atom.

[0294] In some embodiments of any of the formulae described herein, 4 Example substituted ring B is selected from

[0295] In some embodiments of any of the formulae described herein, 4 Example substituted ring B is selected from In some embodiments, through n R 4 Example substituted ring B is

[0296] In some embodiments of any of the formulas described herein, each R 4 independently selected from halogen, C 1-6 Aliphatic and C 1-6 In some embodiments, each R 4 independently selected from halogen and C 1-6 In some embodiments, each R 4 independently selected from halogen and optionally substituted C 1-6 In some embodiments, R 4 is halogen (eg, fluorine or chlorine). In some embodiments, R 4 In some embodiments, R 4 In some embodiments, R 4 is an optionally substituted C 1-6 In some embodiments, R 4 C 1-6 In some embodiments, R 4 C 1-6 In some embodiments, R 4 is an optionally substituted C 1-6 In some embodiments, R 4 C 1-6 In some embodiments, R 4 In some embodiments, R 4 C 1-6 In some embodiments, R 4 It is a methyl group.

[0297] In some embodiments of any of the formulae described herein, n is 0 or 1. In some embodiments, n is 0. In some embodiments, n is 1. In some embodiments, n is 2.

[0298] In some embodiments of any of the formulae described herein, Ring C is selected from phenyl; a 5- to 6-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5- to 8-membered bicyclic carbocyclic ring; a 4- to 8-membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and a 7- to 10-membered saturated or partially unsaturated spiro-fused heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein each of the phenyl, heteroaromatic, and heterocyclic ring is optionally fused to Ring E. In some embodiments, Ring C is selected from phenyl; a 5- to 6-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5- to 6-membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and a 9- to 10-membered saturated or partially unsaturated spiro-fused heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein each of the phenyl, heteroaromatic, and heterocyclic ring is optionally fused to Ring E. In some embodiments, ring C is phenyl; a 5- to 6-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5- to 8-membered bicyclic carbocyclic ring; a 4- to 8-membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and a 7- to 10-membered spiro-fused heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, ring C is phenyl; a 5- to 6-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5- to 6-membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and a 9- to 10-membered spiro-fused heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, Ring C is phenyl; a 5- to 6-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 4- to 8-membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and a 7- to 10-membered spiro-fused heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein Ring C is fused to Ring E. In some embodiments, Ring C is phenyl; a 5- to 6-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5- to 6-membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and a 9- to 10-membered spiro-fused heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein Ring C is fused to Ring E.

[0299] In some embodiments of any of the formulae described herein, Ring C is not fused to Ring E. In some embodiments, Ring C is fused to Ring E. In some embodiments, when Ring C is fused to Ring E, only one of Ring C and Ring E is aromatic.

[0300] It should be understood that throughout this disclosure, when a ring is described as being fused to another ring, one skilled in the art will understand that such fusion may or may not result in additional unsaturation in one or both of the rings, which is not individually accounted for in the designation of each ring. For example, a cyclopentane ring fused to a benzene ring has the following structure: And the benzene ring fused with the pyrrole ring has the following structure:

[0301] In some embodiments of any of the formulae described herein, Ring C is phenyl. In some embodiments, Ring C is phenyl that is not fused to Ring E. In some embodiments, Ring C is phenyl that is fused to Ring E.

[0302] In some embodiments of any of the formulas described herein, Ring C is a 5- to 6-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, Ring C is a 5- to 6-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein Ring C is not fused to Ring E. In some embodiments, Ring C is a 5- to 6-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein Ring C is fused to Ring E. In some embodiments, Ring C is a 5-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, Ring C is pyrazole, imidazole, or triazole. In some embodiments, Ring C is pyrazole, imidazole, triazole, oxazole, thiazole, or oxadiazole. In some embodiments, Ring C is a 6-membered heteroaromatic ring having 1-3 nitrogen atoms. In some embodiments, Ring C is pyridine, pyridone, pyrimidine, or pyridazinone. In some embodiments, Ring C is pyridine, pyridone, pyrazine, pyrimidine, pyridazine, or pyridazinone.

[0303] In some embodiments of any of the formulae described herein, Ring C is a 5- to 8-membered bicyclic carbocycle. In some embodiments, Ring C is a 5- to 8-membered bridged bicyclic carbocycle. In some embodiments, Ring C is a bridged cyclobutane (e.g., bicyclo[1.1.1]pentane).

[0304] In some embodiments of any of the formulas described herein, Ring C is a 4- to 8-membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, Ring C is a 5- to 6-membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, Ring C is a 4- to 8-membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein Ring C is not fused to Ring E. In some embodiments, Ring C is a 4- to 8-membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein Ring C is fused to Ring E. In some embodiments, Ring C is a 4- to 8-membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, Ring C is a 5- to 6-membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, Ring C is a 4-membered heterocyclic ring having 1 heteroatom independently selected from nitrogen, oxygen, and sulfur. In some embodiments, Ring C is azetidine. In some embodiments, Ring C is a 5-membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, Ring C is pyrrolidine. In some embodiments, Ring C is a 6-membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, Ring C is piperidine, tetrahydropyridine, piperazine, piperazinone, or thiomorpholine-1,1-dioxide. In some embodiments, Ring C is a 7- to 8-membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, Ring C is a bridged ring system. In some embodiments, Ring C is a 7- to 8-membered bridged heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, Ring C is a bridged piperazine (eg, 3,8-diazabicyclo[3.2.1]octane). In some embodiments, Ring C is a bridged piperidine (eg, 3-azabicyclo[3.1.1]heptane).

[0305] In some embodiments of any of the formulas described herein, Ring C is a 7- to 10-membered spiro-fused heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, Ring C is a 9- to 10-membered spiro-fused heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, Ring C is a 7- to 10-membered saturated or partially unsaturated spiro-fused heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein Ring C is not fused to Ring E. In some embodiments, Ring C is a 7- to 10-membered saturated or partially unsaturated spiro-fused heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein Ring C is fused to Ring E. In some embodiments, Ring C is a 7- to 10-membered saturated or partially unsaturated spiro-fused heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, Ring C is a 9- to 10-membered saturated or partially unsaturated spiro-fused heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, Ring C is a 7-membered spiro-fused heterocyclic ring having two 4-membered rings. In some embodiments, Ring C is 2-azaspiro[3.3]heptane or 2,6-diazaspiro[3.3]heptane. In some embodiments, Ring C is an 8-membered spiro-fused heterocyclic ring having a 4-membered ring and a 5-membered ring. In some embodiments, Ring C is 2,6-diazaspiro[3.4]octane. In some embodiments, Ring C is a 9-membered spiro-fused heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, Ring C is a 9-membered spiro-fused heterocyclic ring having a 4-membered ring and a 6-membered ring. In some embodiments, ring C is 2-azaspiro[3.5]nonane, 2-azaspiro[3.5]non-6-ene, 2,7-diazaspiro[3.5]nonane, 2-oxa-7-azaspiro[3.5]nonane, or 2-thio-7-azaspiro[3.5]nonane-2,2-dioxide. In some embodiments, ring C is a 10-membered spiro-fused heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, ring C is 2,8-diazaspiro[4.5]decan-3-one or 2,8-diazaspiro[4.5]decane.

[0306] In some embodiments of any of the formulas described herein, Ring C is not fused to Ring E and is fused to Ring E via p R 5 Example substituted ring C is selected from

[0307] In some embodiments of any of the formulae described herein, Ring E is selected from a 5- to 6-membered saturated or partially unsaturated carbocyclic ring; a 5- to 7-membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 7- to 10-membered saturated or partially unsaturated spirofused heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and a 5- to 6-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein Ring E is substituted by s R 5′ In some embodiments, ring E is selected from a 5- to 6-membered saturated or partially unsaturated carbocyclic ring; a 5- to 7-membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and a 5- to 6-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein ring E is substituted by s R 5′ Instance replacement.

[0308] In some embodiments of any of the formulae described herein, Ring E is substituted with s R 5’ In some embodiments, Ring E is substituted with 5 to 6 membered carbocyclic rings. 5′ In some embodiments, Ring E is substituted with 5 to 6 membered saturated or partially unsaturated carbocyclic rings. 5’ In some embodiments, Ring E is substituted with 5 members of carbon ring. 5’ In some embodiments, ring E is substituted with 5 R 5′ In some embodiments, Ring E is substituted with 5 R 5′ Examples are substituted cyclohexanes.

[0309] In some embodiments of any of the formulae described herein, Ring E is a 5- to 7-membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein Ring E is substituted by s R 5’ In some embodiments, Ring E is a 5- to 7-membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein Ring E is substituted by s R 5′ In some embodiments, Ring E is a 5-membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein Ring E is substituted by s R 5′ In some embodiments, ring E is pyrrolidine, pyrrolidone, 1-iminotetrahydro-1H-1λ 6 -thiophene-1-oxide or tetrahydrothiophene-1,1-dioxide, each of which is substituted by s R 5’ In some embodiments, ring E is pyrrolidine, pyrrolidone, imidazolidin-2-one, 1-iminotetrahydro-1H-1λ 6 -thiophene-1-oxide or tetrahydrothiophene-1,1-dioxide, each of which is substituted by s R 5′In some embodiments, Ring E is a 6-membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein Ring E is substituted by s R 5′ In some embodiments, ring E is piperidine, piperidone, hexahydropyrimidine, piperazine, or piperazinone, each of which is substituted with s R 5’ In some embodiments, Ring E is a 7-membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein Ring E is substituted by s R 5′ In some embodiments, Ring E is substituted with 5 R 5′ In some embodiments, Ring E is azepane or 1,4-diazepan-2-one, each substituted with 5 R 5’ Instance replacement.

[0310] In some embodiments of any of the formulae described herein, Ring E is a 7- to 10-membered spirofused heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein Ring E is fused to a ring having 5 R 5′ In some embodiments, Ring E is an 8-membered spiro-fused heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein Ring E is substituted by s R 5′ In some embodiments, ring E is 5-azaspiro[2.5]octane or 5-azaspiro[2.5]octan-4-one, each substituted with s R 5’ Instance replacement.

[0311] In some embodiments of any of the formulae described herein, Ring E is a 5- to 6-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein Ring E is substituted by s R 5′ In some embodiments, Ring E is a 5-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein Ring E is substituted by s R 5′ In some embodiments, Ring E is pyrazole or triazole, each substituted with s R 5’ In some embodiments, ring E is pyrazole, imidazole, oxazole, or triazole, each substituted with s R 5’ In some embodiments, Ring E is a 6-membered heteroaromatic ring having 1-3 nitrogen atoms, substituted by s R 5′ In some embodiments, Ring E is substituted with 5 R 5′ In some embodiments, ring E is pyridone, pyrazine, pyrimidine, pyridazine, pyrazinone, pyrimidone or pyridazinone, with s R 5’ Instance replacement.

[0312] In some embodiments of any of the formulas described herein, Ring C is fused to Ring E, and Selected from

[0313] In some embodiments of any of the formulas described herein, Ring C is fused to Ring E and is fused to Ring E via s R 5’ Example substituted ring E is selected from

[0314] In some embodiments of any of the formulas described herein, Ring C is fused to Ring E, and Selected from

[0315] In some embodiments of any of the formulas described herein, each R 5 independently selected from oxo, =NH, -CN, halogen, -OR, -N(R)2, -SR, -C(O)R, -N(R)C(O)R, -(CH2) x C(O)N(R)2, -C(O)N(R)(CH2) x Cy, -(CH2) x C(O)Cy, -OC(O)R, -C(O)OR, -SO2R, -N(R)SO2R, -N=S(O)(R)2, -SO2N(R)2, -P(O)(R)2, -(CH2) x Cy, -O(CH2) x Cy and C 1-6 Aliphatic, C 1-6 The aliphatic group is unsubstituted or substituted with one or more halogens, -CN, -N(R)C(O)R, -N(R)2, or -OR. In some embodiments, each R 5 independently selected from oxo, =NH, -CN, halogen, -OR, -N(R)2, -SR, -C(O)R, -N(R)C(O)R, -(CH2) x C(O)N(R)2, -OC(O)R, -C(O)OR, -SO2R, -N(R)SO2R, -SO2N(R)2, -(CH2) x Cy and C 1-6 Aliphatic, C 1-6 Aliphatic is unsubstituted or substituted with one or more halogens or -OR. In some embodiments, each R 5independently selected from -CN, halogen, -OR, -N(R)2, -SR, -C(O)R, -N(R)C(O)R, -C(O)N(R)2, -OC(O)R, -C(O)OR, -SO2R, -N(R)SO2R, -SO2N(R)2, -(CH2) x Cy and optionally substituted C 1-6 Aliphatic (e.g., C substituted with one or more substituents selected from 1-6 Aliphatic: halogen, -OR, -C(O)NR2, and -N(R)2). In some embodiments, each R 5 independently selected from oxo, =NH, -CN, halogen, -OR, -N(R)2, -SR, -C(O)R, -N(R)C(O)R, -C(O)N(R)2, -OC(O)R, -C(O)OR, -SO2R, -N(R)SO2R, -SO2N(R)2, -(CH2) x Cy and optionally substituted C 1-6 Alkyl (e.g., C substituted with one or more substituents selected from 1-6 Alkyl: halogen, -OR, -C(O)NR2, and -N(R)2). In some embodiments, each R 5 independently selected from oxo, -CN, halogen, -N(R)2, -C(O)R, -C(O)N(R)2, -SO2R, -SO2N(R)2, -(CH2) x Cy and optionally substituted C 1-6 Aliphatic (e.g., C substituted with one or more substituents selected from 1-6 Aliphatic: halogen, -OR, -C(O)NR2, and -N(R)2). In some embodiments, each R 5 independently selected from oxo, -CN, halogen, -OR, -N(R)2, -C(O)R, -(CH2) x C(O)N(R)2, -C(O)N(R)(CH2) x Cy, -(CH2) x C(O)Cy, -SO2R, -N=S(O)(R)2, -SO2N(R)2, -P(O)(R)2, -(CH2) x Cy, -O(CH2) x Cy and C 1-6 Aliphatic, C 1-6 The aliphatic group is unsubstituted or substituted with one or more halogens, -CN, -N(R)C(O)R, -N(R)2, or -OR. In some embodiments, each R 5 are independently selected from oxo, -CN, halogen, -NH2, -N(C 1-4Alkyl)2, -C(O)(C 1-4 alkyl), -C(O)NH2, -SO2(C 1-4 alkyl), -SO2NH2, -SO2N(H)(C 1-4 alkyl), -CH2 (3 to 6 membered carbocyclic ring optionally substituted with one or more halogens), 4 to 6 membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen and sulfur, and optionally substituted with one or more halogens, -OR o and –C(O)NR o 2 substituted C 1-6 In some such embodiments, R o is hydrogen. Thus, in some embodiments, each R 5 are independently selected from oxo, -CN, halogen, -NH2, -N(C 1-4 Alkyl)2, -C(O)(C 1-4 alkyl), -C(O)NH2, -SO2(C 1-4 alkyl), -SO2NH2, -SO2N(H)(C 1-4 alkyl), -CH2 (3 to 6 membered carbocyclic ring optionally substituted with one or more halogens), 4 to 6 membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen and sulfur, and C optionally substituted with one or more halogens, -OH and -CO2NH2 1-6 alkyl.

[0316] In some embodiments of any of the formulae described herein, R 5 In some embodiments, R 5 =NH. In some embodiments, R 5 In some embodiments, R 5 is halogen (eg, fluorine or chlorine). In some embodiments, R 5 In some embodiments, R 5 In some embodiments, R 5 In some embodiments, R 5 is -O(optionally substituted with one or more -N(C 1-4 Alkyl)2 substituted C 1-4 In some embodiments, R 5 is -N(R)2. In some embodiments, R 5 is -NH2. In some embodiments, R 5 =–N(C 1-4 In some embodiments, R 5 In some embodiments, R 5 is -C(O)R. In some embodiments, R 5-C(O)(C 1-4 In some embodiments, R 5 is -N(R)C(O)R. In some embodiments, R 5 -(CH2) x C(O)N(R)2. In some embodiments, R 5 -(CH2) x C(O)NH2, -(CH2) x C(O)NH(C 1-4 alkyl), -(CH2) x C(O)NH(C 1-4 Haloalkyl), -(CH2) x C(O)N(C 1-4 alkyl)2 or -(CH2) x C(O)N(C 1-4 In some embodiments, R 5 is -C(O)N(R)2. In some embodiments, R 5 -C(O)NH2、-C(O)NH(C 1-4 alkyl), -C(O)NH(C 1-4 Haloalkyl), –C(O)N(C 1-4 alkyl)2 or –C(O)N(C 1-4 In some embodiments, R 5 -C(O)N(R)(CH2) x Cy (e.g. -C(O)NH(CH2) x Cy). In some embodiments, R 5 -(CH2) x C(O)Cy. In some embodiments, R 5 is -OC(O)R. In some embodiments, R 5 In some embodiments, R 5 In some embodiments, R 5 For –SO2(C 1-4 In some embodiments, R 5 is -N(R)SO2R. In some embodiments, R 5 is -N=S(O)(R)2. In some embodiments, R 5 is -SO2N(R)2. In some embodiments, R 5 is –SO2NH2 or –SO2NH(C 1-4 In some embodiments, R 5 is -P(O)R2. In some embodiments, R5 -(CH2) x Cy. In some embodiments, R 5 -(CH2) x Cy, wherein Cy is a 3- to 6-membered carbocyclic ring optionally substituted with one or more halogens. 5 -(CH2) x Cy, wherein Cy is a 4- to 6-membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. 5 -(CH2) x Cy, and x is 0. In some embodiments, R 5 -(CH2) x Cy, wherein x is 0 and Cy is a 3- to 6-membered carbocyclic ring optionally substituted with one or more halogens. 5 -(CH2) x Cy, wherein x is 0 and Cy is a 4- to 6-membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen and sulfur, substituted by 0-2 R 6 In some embodiments, R 5 -O(CH2) x Cy. In some embodiments, R 5 is an optionally substituted C 1-6 Aliphatic (e.g., C substituted with one or more substituents selected from 1-6 Aliphatic: halogen, -OR, -CN, -N(R)C(O)R, -C(O)NR2, and -N(R)2). In some embodiments, R 5 is C optionally substituted with one or more of the following groups 1-6 Aliphatic: halogen, -OR o (e.g. -OH) and –C(O)NR o 2 (e.g., -CO2NH2). In some embodiments, R 5 is an optionally substituted C 1-6 Alkyl (e.g., C substituted with one or more substituents selected from 1-6 Alkyl: halogen, -OR, -CN, -N(R)C(O)R, -C(O)NR2, and -N(R)2). In some embodiments, R 5 is C optionally substituted with one or more of the following groups 1-6 Alkyl: halogen, -OH and -CO2NH2.

[0317] In some embodiments of any of the formulas described herein, each R 5independently selected from oxo, -CN, fluorine, chlorine, -NH2, -N(CH3)2, -OCH3, -C(O)CH3, -C(O)N(CH3)2, -C(O)N(H)CH3, -CH2C(O)N(H)CH3, -CH2C(O)N(CH3)2, -C(O)N(H)CH2CH2N(CH3)2, -CO2NH2, -SO2CH3, -SO2NH2, -SO2N(H)CH3, -N=S(O)(CH3)2, -P(O)(CH3)2, -CH3, -CH2F, -CHF2, -CH2CHF2, -CH2OH, -CH2CH2OH, -CH2CH2OCH3, -CH2C(CH3)2OH, -C(CH3)2CH2OH, -C(CH3)2OH, -C(CH3)2NH2, -C(CH3)2CN, -CH2N(CH3)2, -CH2CH2N(CH3)2, -CH2C(CH3)2NH2, -CH2N(H)C(O)CH3, -OCH 2CH2N(CH3)2, -CH2CH2N(CH3)2, -C(O)N(CH3)2, -CH2C(O)NH2, -CH2C(O)N(H)(CH3), -CH2 C(O)N(CH3)2, -CH(CH3)2, -CH(CF3)N(H)CH3, -CH(CF3)N(CH3)2, -C(O)N(H)CH3, -C(O)N( H)CH2CHF2, -OCH2CH2N(CH3)2, -C(O)N(H)CH2CH2N(CH3)2, -C(O)N(CH3)CH2CH2N(CH3)2, Cyclopropane, cyclobutane, In some embodiments, each R 5independently selected from oxo, -CN, fluoro, chloro, -NH2, -N(CH3)2, -OCH3, -C(O)CH3, -C(O)N(CH3)2, -C(O)N(H)CH3, -CH2C(O)N(H)CH3, -CH2C(O)N(CH3)2, -C(O)N(H)CH2CH2N(CH3)2, -CO2NH2, -SO2CH3, -SO2NH2, -SO2N(H)CH3, -N=S(O)(CH3)2, -P(O)(CH3)2, -CH3, -CH2F, -CHF2, -CH2CHF2, -C H2OH, -CH2CH2OH, -CH2CH2OCH3, -CH2C(CH3)2OH, -C(CH3)2CH2OH, -C(CH3)2OH, -C(CH3)2NH2, -C(CH3)2CN, -CH2N(CH3)2, -CH2CH2 N(CH3)2, -CH2C(CH3)2NH2, -OCH2CH2N(CH3)2, -CH2CH2N(CH3)2, -CH2C(O)NH2, -CH(CH3)2, -CH(CF3)N(H)CH3, and -CH(CF3)N(CH3)2.

[0318] In some embodiments of any of the formulas described herein, each R 5’ independently selected from oxo, =NH, -CN, halogen, -OR, -N(R)2, -SR, -C(O)R, -N(R)C(O)R, -(CH2) x C(O)N(R)2, -(CH2) x C(O)Cy, -OC(O)R, -C(O)OR, -SO2R, -N(R)SO2R, -N=S(O)(R)2, -SO2N(R)2, -P(O)(R)2, -(CH2) x Cy, -O(CH2) x Cy and C 1-6 Aliphatic, C 1-6 The aliphatic group is unsubstituted or substituted with one or more halogens, -CN, -N(R)C(O)R, -N(R)2, or -OR. In some embodiments, each R 5’ independently selected from oxo, =NH, -CN, halogen, -OR, -N(R)2, -SR, -C(O)R, -N(R)C(O)R, -(CH2) x C(O)N(R)2, -OC(O)R, -C(O)OR, -SO2R, -N(R)SO2R, -SO2N(R)2, -(CH2) x Cy and C 1-6 Aliphatic, C 1-6Aliphatic is unsubstituted or substituted with one or more halogen and -OR. In some embodiments, each R 5’ independently selected from -CN, halogen, -OR, -N(R)2, -SR, -C(O)R, -N(R)C(O)R, -C(O)N(R)2, -OC(O)R, -C(O)OR, -SO2R, -N(R)SO2R, -SO2N(R)2, -(CH2) x Cy and optionally substituted C 1-6 Aliphatic (e.g., C substituted with one or more substituents selected from 1-6 Aliphatic: halogen, -OR, -C(O)NR2, and -N(R)2). In some embodiments, each R 5’ independently selected from oxo, =NH, -CN, halogen, -OR, -N(R)2, -SR, -C(O)R, -N(R)C(O)R, -C(O)N(R)2, -OC(O)R, -C(O)OR, -SO2R, -N(R)SO2R, -SO2N(R)2, -(CH2) x Cy and optionally substituted C 1-6 Alkyl (e.g., C substituted with one or more substituents selected from 1-6 Alkyl: halogen, -OR, -C(O)NR2, and -N(R)2). In some embodiments, each R 5’ independently selected from oxo, =NH, -OR, -N(R)2 and optionally substituted C 1-6 Aliphatic (e.g., C substituted with one or more substituents selected from 1-6 Aliphatic: halogen, -OR, -C(O)NR2, and -N(R)2). In some embodiments, each R 5’ independently selected from oxo, =NH, halogen, -OR, -N(R)2 and C 1-6 Aliphatic, C 1-6 The aliphatic group is unsubstituted or substituted with one or more halogens, -N(R)2, or -OR. In some embodiments, each R 5’ independently selected from oxo, =NH, -OH, -NH2, -N(C 1-4 alkyl)2 and optionally one or more -OR o (e.g. -OH) substituted C 1-6 alkyl.

[0319] In some embodiments of any of the formulae described herein, R 5’ In some embodiments, R 5’ =NH. In some embodiments, R 5’ In some embodiments, R 5’is halogen (eg, fluorine or chlorine). In some embodiments, R 5’ In some embodiments, R 5’ is -OR (e.g., -OH or -OCH3). In some embodiments, R 5’ is -N(R)2. In some embodiments, R 5’ In some embodiments, R 5’ -N(C 1-4 In some embodiments, R 5’ In some embodiments, R 5’ In some embodiments, R 5’ In some embodiments, R 5’ -(CH2) x C(O)N(R)2. In some embodiments, R 5’ is -C(O)N(R)2. In some embodiments, R 5’ -C(O)N(R)(CH2) x Cy. In some embodiments, R 5’ -(CH2) x C(O)Cy. In some embodiments, R 5’ In some embodiments, R 5’ In some embodiments, R 5’ In some embodiments, R 5’ In some embodiments, R 5’ is -N=S(O)(R)2. In some embodiments, R 5’ In some embodiments, R 5’ is -P(O)R2. In some embodiments, R 5’ -(CH2) x Cy. In some embodiments, R 5 -(CH2) x Cy, wherein Cy is a 3- to 6-membered carbocyclic ring optionally substituted with one or more halogens. 5 -(CH2) x Cy, wherein Cy is a 4- to 6-membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. 5 -(CH2) x Cy, and x is 0. In some embodiments, R 5 -(CH2) xCy, wherein x is 0 and Cy is a 3- to 6-membered carbocyclic ring optionally substituted with one or more halogens. 5 -(CH2) x Cy, wherein x is 0 and Cy is a 4- to 6-membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. 5’ -O(CH2) x Cy. In some embodiments, R 5’ is an optionally substituted C 1-6 In some embodiments, R 5’ For optional one or more -OR o (e.g. -OH) substituted C 1-6 In some embodiments, R 5’ is optionally substituted with one or more halogens (e.g., F), -OH, or -O(C 1-4 Alkyl) substituted C 1-6 In some embodiments, R 5’ is an optionally substituted C 1-6 In some embodiments, R 5’ is C optionally substituted with one or more -OH 1-6 In some embodiments, R 5’ is optionally substituted with one or more halogens (e.g., F), -OH, or -O(C 1-4 Alkyl) substituted C 1-6 In some embodiments, R 5’ For unsubstituted C 1-6 In some embodiments, R 5’ For unsubstituted C 1-6 In some embodiments, R 5’ is methyl, ethyl or isopropyl.

[0320] In some embodiments of any of the formulas described herein, each R 5’ is independently selected from oxo, =NH, -OH, -OCH3, -NH2, -N(CH3)2, fluoro, cyclopropyl, -CH3, -CD3, -CH2CHF2, -CH2CF3, -CH2CH2CH2F, -CH2CH2N(CH3)2, -CH2CH2OH, -CH2CH2OCH3, and -CH(CH3)2. In some embodiments, each R 5’ Independently selected from oxo, =NH, -OH, -NH2, -N(CH3)2, -CH3, -CH2CH2OH and -CH(CH3)2.

[0321] In some embodiments of any of the formulae described herein, p is 0, 1, or 2. In some embodiments, p is 0 or 1. In some embodiments, p is 1 or 2. In some embodiments, p is 0. In some embodiments, p is 1. In some embodiments, p is 2. In some embodiments, p is 3.

[0322] In some embodiments of any of the formulae described herein, s is 0, 1, or 2. In some embodiments, s is 0 or 1. In some embodiments, s is 1 or 2. In some embodiments, s is 0. In some embodiments, s is 1. In some embodiments, s is 2. In some embodiments, s is 3.

[0323] In some embodiments of any of the formulae described herein, Ring D is selected from phenyl and a 5- to 6-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, Ring D is selected from phenyl and a 5- to 6-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein Ring D is fused to Ring F.

[0324] In some embodiments of any of the formulas described herein, Ring D is not fused to Ring F. In some embodiments, Ring D is fused to Ring F. In some embodiments, when Ring D is fused to Ring F, q is 0.

[0325] In some embodiments of any of the formulae described herein, Ring D is phenyl.

[0326] In some embodiments of any of the formulas described herein, Ring D is a 5- to 6-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, Ring D is a 5-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, Ring D is pyrazole, imidazole, triazole, oxazole, or thiazole. In some embodiments, Ring D is a 6-membered heteroaromatic ring having 1-3 nitrogen atoms. In some embodiments, Ring D is pyridine, pyridone, pyridazinone, or pyrazinone.

[0327] In some embodiments of any of the formulas described herein, Ring D is not fused to Ring F and is fused to Ring F via r R 2 Examples and q R 1 Example substituted ring D is selected from

[0328] In some embodiments of any of the formulae described herein, ring F is selected from phenyl; a 5- to 6-membered saturated or partially unsaturated carbocyclic ring; a 5- to 7-membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and a 5- to 6-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein ring F is substituted by u instances of -LW and y instances of R2’ In some embodiments, ring F is selected from phenyl; a 5- to 6-membered saturated or partially unsaturated carbocyclic ring; a 5- to 6-membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and a 5- to 6-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein ring F is substituted with u instances of -LW.

[0329] In some embodiments of any of the formulae described herein, Ring F is substituted with u instances of -LW and y instances of R 2’ In some embodiments, ring F is phenyl substituted with u instances of —LW.

[0330] In some embodiments of any of the formulae described herein, Ring F is substituted with u instances of -LW and y instances of R 2’ In some embodiments, Ring F is a 5- to 6-membered carbocyclic ring substituted with u -LW instances. In some embodiments, Ring F is a 5- to 6-membered carbocyclic ring substituted with u -LW instances. In some embodiments, Ring F is a 5- to 6-membered saturated or partially unsaturated carbocyclic ring substituted with u -LW instances. In some embodiments, Ring F is a 5-membered carbocyclic ring substituted with u -LW instances. In some embodiments, Ring F is a cyclopentane substituted with u -LW instances. In some embodiments, Ring F is a 6-membered carbocyclic ring substituted with u -LW instances.

[0331] In some embodiments of any of the formulas described herein, Ring F is a 5- to 7-membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein Ring F is substituted by u instances of -LW and y instances of R 2’ In some embodiments, ring F is a 5- to 6-membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein ring F is substituted with u instances of -LW. In some embodiments, ring F is a 5- to 7-membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein ring F is substituted with u instances of -LW and y instances of R. 2’ In some embodiments, ring F is a 5- to 6-membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein ring F is substituted with u instances of -LW. In some embodiments, ring F is a 5-membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein ring F is substituted with u instances of -LW. In some embodiments, ring F is a pyrrolidine substituted with u instances of -LW. In some embodiments, ring F is a 6-membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein ring F is substituted with u instances of -LW and y instances of R. 2’In some embodiments, Ring F is a 6-membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein Ring F is substituted with u instances of -LW. In some embodiments, Ring F is piperidine or piperazine, each substituted with u instances of -LW and y instances of R 2’ In some embodiments, ring F is piperidine or piperazine, each substituted with u instances of -LW.

[0332] In some embodiments of any of the formulas described herein, Ring F is a 5- to 6-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein Ring F is substituted by u instances of -LW and y instances of R 2’ In some embodiments, Ring F is a 5- to 6-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein Ring F is substituted with u instances of -LW. In some embodiments, Ring F is a 5-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein Ring F is substituted with u instances of -LW. In some embodiments, Ring F is a pyrrole substituted with u instances of -LW. In some embodiments, Ring F is a 6-membered heteroaromatic ring having 1-3 nitrogen atoms, substituted with u instances of -LW.

[0333] In some embodiments of any of the formulas described herein, u is 0. In some embodiments, u is 1. In some embodiments, when u is 1, q is 0.

[0334] In some embodiments of any of the formulas described herein, Ring D is fused to Ring F, q is 0, and Selected from

[0335] In some embodiments of any of the formulas described herein, Ring D is fused to Ring F, q is 0, and Selected from

[0336] In some embodiments of any of the formulas described herein, Ring D is fused to Ring F and is fused via u instances of -LW and y instances of R 2’ Example substituted ring F is selected from

[0337] In some embodiments of any of the formulas described herein, Ring D is fused to Ring F, q is 0, and Selected from

[0338] In some embodiments of any of the formulae described herein, R 1 is -LW or ring D'. In some embodiments, R 1 is a divalent C ring D' or a divalent C ring D' 1-6 In some embodiments, R 1 is Ring D' or -CH2-Ring D'. In some embodiments, R 1 In some embodiments, R 1 In some embodiments, R 1 is a divalent C substituted by ring D' 1-6 In some embodiments, R 1 It is –CH2-ring D'.

[0339] In some embodiments of any of the formulae described herein, R 1 Selected from -CH3, -CH(CH3)2, -CH2C(CH3)3, -CH2NH2, -CH2OH, -OCH(CH3)2,

[0340] In some embodiments of any of the formulas described herein, each L is independently a divalent linear or branched C 1-6 An aliphatic chain, wherein one or more methylene units of the aliphatic chain are optionally and independently replaced by a group selected from the group consisting of: -N(R)-, -O-, -S-, -C(O)-, -SO2-, -CH(X)-, -C(X)2-, -C(O)N(R)-, -N(R)C(O)-, -C(O)O-, -OC(O)-, -SON(R)-, and -N(R)SO2-. In some embodiments, each L is independently a divalent linear or branched C 1-4 An aliphatic chain, wherein one or more methylene units of the aliphatic chain are optionally and independently replaced by a group selected from the group consisting of: -N(R)-, -O-, -S-, -C(O)-, -SO2-, -CH(X)-, -C(X)2-, -C(O)N(R)-, -N(R)C(O)-, -C(O)O-, -OC(O)-, -SON(R)-, and -N(R)SO2-.

[0341] In some embodiments of any of the formulas described herein, each L is independently a divalent linear or branched C 1-8An aliphatic chain, wherein one or two methylene units of the aliphatic chain are independently replaced by a group selected from the group consisting of: -N(R)-, -O-, -S-, -C(O)-, -SO2-, -CH(X)-, -C(X)2-, -C(O)N(R)-, -N(R)C(O)-, -C(O)O-, -OC(O)-, -SON(R)-, and -N(R)SO2-. In some embodiments, each L is independently a divalent linear or branched C 1-6 An aliphatic chain, wherein one or two methylene units of the aliphatic chain are independently replaced by a group selected from the group consisting of: -N(R)-, -O-, -S-, -C(O)-, -SO2-, -CH(X)-, -C(X)2-, -C(O)N(R)-, -N(R)C(O)-, -C(O)O-, -OC(O)-, -SON(R)-, and -N(R)SO2-. In some embodiments, each L is independently a divalent linear or branched C 1-4 An aliphatic chain wherein one or two methylene units of the aliphatic chain are independently replaced by a group selected from the group consisting of -N(R)-, -O-, -S-, -C(O)-, -SO2-, -CH(X)-, -C(X)2-, -C(O)N(R)-, -N(R)C(O)-, -C(O)O-, -OC(O)-, -SON(R)-, and -N(R)SO2-.

[0342] In some embodiments of any of the formulas described herein, each L is independently a divalent linear or branched C 1-8 An aliphatic chain, wherein one or two methylene units of the aliphatic chain are independently replaced by a group selected from: -N(R)-, -O-, C(O)-, -C(O)N(R)-, and -N(R)C(O)-. In some embodiments, each L is independently a divalent linear or branched C 1-6 An aliphatic chain, wherein one or two methylene units of the aliphatic chain are independently replaced by a group selected from: -N(R)-, -O-, C(O)-, -C(O)N(R)-, and -N(R)C(O)-. In some embodiments, each L is independently a divalent linear or branched C 1-4 An aliphatic chain, wherein one or two methylene units of the aliphatic chain are independently replaced by a group selected from: -N(R)-, -O-, C(O)-, -C(O)N(R)-, and -N(R)C(O)-.

[0343] In some embodiments of any of the formulas described herein, each L is independently a divalent linear or branched C 1-8An alkyl chain wherein one or more methylene units of the aliphatic chain are optionally and independently replaced by a group selected from the group consisting of: -N(R)-, -O-, -S-, -C(O)-, -SO2-, -CH(X)-, -C(X)2-, -C(O)N(R)-, -N(R)C(O)-, -C(O)O-, -OC(O)-, -SON(R)-, and -N(R)SO2-. In some embodiments, each L is independently a divalent linear or branched C 1-6 An alkyl chain wherein one or more methylene units of the aliphatic chain are optionally and independently replaced by a group selected from the group consisting of: -N(R)-, -O-, -S-, -C(O)-, -SO2-, -CH(X)-, -C(X)2-, -C(O)N(R)-, -N(R)C(O)-, -C(O)O-, -OC(O)-, -SON(R)-, and -N(R)SO2-. In some embodiments, each L is independently a divalent linear or branched C 1-4 An alkyl chain in which one or more methylene units of the aliphatic chain are optionally and independently replaced by a group selected from the group consisting of: -N(R)-, -O-, -S-, -C(O)-, -SO2-, -CH(X)-, -C(X)2-, -C(O)N(R)-, -N(R)C(O)-, -C(O)O-, -OC(O)-, -SON(R)-, and -N(R)SO2-.

[0344] In some embodiments of any of the formulas described herein, each L is independently a divalent linear or branched C 1-8 An aliphatic chain, wherein one or more methylene units of the aliphatic chain are optionally and independently replaced by a group selected from the group consisting of: -N(R)-, -O-, -S-, -C(O)-, -SO2-, -CH(X)-, -C(X)2-, -C(O)N(R)-, -N(R)C(O)-, -C(O)O-, -OC(O)-, -SON(R)-, and -N(R)SO2-. In some embodiments, each L is independently a divalent linear or branched C 1-6 An aliphatic chain, wherein one or more methylene units of the aliphatic chain are optionally and independently replaced by a group selected from the group consisting of: -N(R)-, -O-, -S-, -C(O)-, -SO2-, -CH(X)-, -C(X)2-, -C(O)N(R)-, -N(R)C(O)-, -C(O)O-, -OC(O)-, -SON(R)-, and -N(R)SO2-. In some embodiments, each L is independently a divalent linear or branched C 1-4An aliphatic chain, wherein one or more methylene units of the aliphatic chain are optionally and independently replaced by a group selected from the group consisting of: -N(R)-, -O-, -S-, -C(O)-, -SO2-, -CH(X)-, -C(X)2-, -C(O)N(R)-, -N(R)C(O)-, -C(O)O-, -OC(O)-, -SON(R)-, and -N(R)SO2-.

[0345] In some embodiments of any of the formulas described herein, each L is independently a divalent linear or branched C 1-8 An aliphatic chain, wherein one or more methylene units of the aliphatic chain are optionally and independently replaced by a group selected from the group consisting of: -N(R)-, -O-, -S-, -C(O)-, -SO2-, -CH(X)-, -C(X)2-, -C(O)N(R)-, -N(R)C(O)-, -C(O)O-, -OC(O)-, -SON(R)-, and -N(R)SO2-. In some embodiments, each L is independently a divalent linear or branched C 1-6 An aliphatic chain, wherein one or more methylene units of the aliphatic chain are optionally and independently replaced by a group selected from the group consisting of: -N(R)-, -O-, -S-, -C(O)-, -SO2-, -CH(X)-, -C(X)2-, -C(O)N(R)-, -N(R)C(O)-, -C(O)O-, -OC(O)-, -SON(R)-, and -N(R)SO2-. In some embodiments, each L is independently a divalent linear or branched C 1-4 An aliphatic chain, wherein one or more methylene units of the aliphatic chain are optionally and independently replaced by a group selected from the group consisting of: -N(R)-, -O-, -S-, -C(O)-, -SO2-, -CH(X)-, -C(X)2-, -C(O)N(R)-, -N(R)C(O)-, -C(O)O-, -OC(O)-, -SON(R)-, and -N(R)SO2-.

[0346] In some embodiments of any of the formulas described herein, each L is independently a divalent linear or branched C 1-8 An aliphatic chain, wherein one or more methylene units of the aliphatic chain are optionally and independently replaced by a group selected from the group consisting of: -N(R)-, -O-, -S-, -C(O)-, -SO2-, -CH(X)-, -C(X)2-, -C(O)N(R)-, -N(R)C(O)-, -C(O)O-, -OC(O)-, -SON(R)-, and -N(R)SO2-. In some embodiments, each L is independently a divalent linear or branched C 1-6An aliphatic chain, wherein one or more methylene units of the aliphatic chain are optionally and independently replaced by a group selected from the group consisting of: -N(R)-, -O-, -S-, -C(O)-, -SO2-, -CH(X)-, -C(X)2-, -C(O)N(R)-, -N(R)C(O)-, -C(O)O-, -OC(O)-, -SON(R)-, and -N(R)SO2-. In some embodiments, each L is independently a divalent linear or branched C 1-4 An aliphatic chain, wherein one or more methylene units of the aliphatic chain are optionally and independently replaced by a group selected from the group consisting of: -N(R)-, -O-, -S-, -C(O)-, -SO2-, -CH(X)-, -C(X)2-, -C(O)N(R)-, -N(R)C(O)-, -C(O)O-, -OC(O)-, -SON(R)-, and -N(R)SO2-.

[0347] In some embodiments of any of the formulas described herein, each L is independently a divalent linear or branched C 1-8 An aliphatic chain, wherein one or more methylene units of the aliphatic chain are optionally and independently replaced by a group selected from: -N(R)-, -O-, C(O)-, -C(O)N(R)-, and -N(R)C(O)-. In some embodiments, each L is independently a divalent linear or branched C 1-6 An aliphatic chain, wherein one or more methylene units of the aliphatic chain are optionally and independently replaced by a group selected from: -N(R)-, -O-, C(O)-, -C(O)N(R)-, and -N(R)C(O)-. In some embodiments, each L is independently a divalent linear or branched C 1-4 An aliphatic chain, wherein one or more methylene units of the aliphatic chain are optionally and independently replaced with a group selected from: -N(R)-, -O-, C(O)-, -C(O)N(R)-, and -N(R)C(O)-.

[0348] In some embodiments of any of the formulae described herein, each L is independently selected from -N(R)C(O)CH2CH2-, -N(R)C(O)CH(CH3)CH2-, -OCH(CH3)CH2-, -C(O)-, -C(O)CClH-, -C(O)CClF-, -C(O)CH2CH2-, -C(O)CH(OH)CH(OH)-, -C(O)N(R)CH(CH3)CH2-, -C(O)N(R)CH2CH(CH3)CH2-, -CH2-, -CH(CH3)CH2-, -CH2C(CH3)2CH2 -, -CH2C(O)-, -CH2C(O)N(R)C(CH3)2CH2-, -CH2CH2C(O)N(R)C(CH3)2CH2-, -CH2N(R)-, -CH2N(R)C(O)-, –CH2N(R)C(O)CH2CH2-, – CH2N(R)C(O)CH(CH3)CH2-, –CH2N(R)C(O)C(CH3)2CH2-, –CH2N(R)C(O)CH2C(CH3)2CH2-, –CH2CH2N(R)C(O)CH(CH3)CH2-, and –CH2O-. In some embodiments, each L is independently selected from -N(H)C(O)CH2CH2-, -N(H)C(O)CH(CH3)CH2-, -OCH(CH3)CH2-, -C(O)-, -C(O)CClH-, -C(O)CClF-, -C(O)CH2CH2-, -C(O)CH(OH)CH(OH)-, -C(O)N(H)CH(CH3)CH2-, -C(O)N(H)CH2CH(CH3)CH2-, -CH2-, -CH(CH3)CH2-, -CH2C(CH3)2CH2-, -CH 2C(O)-, -CH2C(O)N(H)C(CH3)2CH2-, -CH2CH2C(O)N(H)C(CH3)2CH2-, -CH2N(H)-, -CH2N(H)C(O)-, –CH2N(H)C(O)CH2CH2-, –CH 2N(H)C(O)CH(CH3)CH2-, –CH2N(H)C(O)C(CH3)2CH2-, –CH2N(H)C(O)CH2C(CH3)2CH2-, –CH2CH2N(H)C(O)CH(CH3)CH2-, and –CH2O-.

[0349] In some embodiments of any of the formulae described herein, each L is independently selected from -N(R)C(O)CH2CH2-, -N(R)C(O)CH(CH3)CH2-, -OCH(CH3)CH2-, -C(O)-, -C(O)CH2CH2-, -C(O)CH(OH)CH(OH)-, -C(O)N(R)CH(CH3)CH2-, -C(O)N(R)CH2CH(CH3)CH2-, -CH2-, -CH(CH3)CH2-, -CH2C(CH3)2CH2-, -CH2C(O)- , -CH2C(O)N(R)C(CH3)2CH2-, -CH2CH2C(O)N(R)C(CH3)2CH2-, -CH2N(R)-, -CH2N(R)C(O)-, –CH2N(R)C(O)CH2CH2-, –CH2N( R)C(O)CH(CH3)CH2-, –CH2N(R)C(O)C(CH3)2CH2-, –CH2N(R)C(O)CH2C(CH3)2CH2-, –CH2CH2N(R)C(O)CH(CH3)CH2-, and –CH2O-. In some embodiments, each L is independently selected from -N(H)C(O)CH2CH2-, -N(H)C(O)CH(CH3)CH2-, -OCH(CH3)CH2-, -C(O)-, -C(O)CH2CH2-, -C(O)CH(OH)CH(OH)-, -C(O)N(H)CH(CH3)CH2-, -C(O)N(H)CH2CH(CH3)CH2-, -CH2-, -CH(CH3)CH2-, -CH2C(CH3)2CH2-, -CH 2C(O)N(H)C(CH3)2CH2-, -CH2CH2C(O)N(H)C(CH3)2CH2-, -CH2N(H)-, -CH2N(H)C(O)-, –CH2N(H)C(O)CH2CH2-, –CH2N(H) C(O)CH(CH3)CH2-, –CH2N(H)C(O)C(CH3)2CH2-, –CH2N(H)C(O)CH2C(CH3)2CH2-, –CH2CH2N(H)C(O)CH(CH3)CH2-, and –CH2O-.

[0350] In some embodiments of any of the formulae described herein, each L is independently selected from —C(O)CH═CH—, —N(R)C(O)CH═CH—, —C(O)C(═CH)—, —C(O)C(═CHCH)—, —C(O)CH═CH—CH—, —C(O)CH═CHCHOCH—, —C(O)CH═CHCHN(R)—, —CHN(R)C(O)CH═CH—, —CHCHN(R)C(O)CH═CH—, —C(O)C≡C—, —C(O)C≡CCH—, and —SOCH═CH—. In some embodiments, each L is independently selected from -C(O)CH=CH-, -NHC(O)CH=CH-, -C(O)C(=CH2)-, -C(O)C(=CHCH3)-, -C(O)CH=CH-CH2-, -C(O)CH=CHCH2OCH2-, -C(O)CH=CHCH2N(CH3)-, -CH2NHC(O)CH=CH-, -CH2CH2NHC(O)CH=CH-, -C(O)C≡C-, -C(O)C≡CCH2-, and -SO2CH=CH-. In some embodiments, each L is independently -C(O)CH=CH-, -C(O)CF=CH-, -NHC(O)CF=CH-, or -NHC(O)CH=CH-. In some embodiments, each L is independently -C(O)CH=CH- or -NHC(O)CH=CH-.

[0351] In some embodiments of any of the formulae described herein, each L is independently selected from -C(O)CClH-, -C(O)CClF-, -C(O)CH=CH-, -N(R)C(O)CH=CH-, -C(O)C(=CH2)-, -C(O)C(=CHCH3)-, -C(O)CH=CH-CH2-, -C(O)CH=CHCH2OCH2-, -C(O)CH=CHCH2N(R)-, -CH2N(R)C(O)CH=CH-, -CH2CH2N(R)C(O)CH=CH-, and -SO2CH=CH-. In some embodiments, each L is independently selected from -C(O)CClF-, -C(O)CH=CH-, -NHC(O)CH=CH-, -C(O)C(=CH2)-, -C(O)C(=CHCH3)-, -C(O)CH=CH-CH2-, -C(O)CH=CHCH2OCH2-, -C(O)CH=CHCH2N(CH3)-, -CH2NHC(O)CH=CH-, -CH2CH2NHC(O)CH=CH-, -C(O)C≡C-, -C(O)C≡CCH2-, and -SO2CH=CH-. In some embodiments, each L is independently -C(O)CH=CH- or -NHC(O)CH=CH-.

[0352] In some embodiments of any of the formulae described herein, each W is independently hydrogen, halogen, -CN, or a 3-10 membered monocyclic or bicyclic, saturated, partially unsaturated, or aromatic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, each W is independently hydrogen, halogen, or a 3-10 membered monocyclic or bicyclic, saturated, partially unsaturated, or aromatic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, each W is independently hydrogen, halogen, or -CN. In some embodiments, W is hydrogen. In some embodiments, W is halogen (e.g., fluorine or chlorine). In some embodiments, W is fluorine. In some embodiments, W is chlorine. In some embodiments, W is -CN. In some embodiments, W is an optionally substituted 3-10 membered monocyclic or bicyclic, saturated, partially unsaturated, or aromatic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, W is an optionally substituted group selected from the following: phenyl; a 5- to 6-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3- to 6-membered carbocyclic ring; and a 4- to 6-membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, W is an optionally substituted 3- to 6-membered carbocyclic ring. In some embodiments, W is cyclopentane. In some embodiments, W is an optionally substituted 4- to 6-membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, W is pyrrolidine.

[0353] In some embodiments of any formula described herein, each X is independently halogen or -CN. In some embodiments, each X is independently halogen (e.g., chlorine or fluorine). In some embodiments, each X is independently chlorine. In some embodiments, each X is independently fluorine. In some embodiments, each X is independently -CN. In some embodiments, each X is independently -OR (e.g., -OH).

[0354] In some embodiments of any of the formulae described herein, each -LW is independently selected from -CH3, -CH(CH3)2, -CH2C(CH3)3, -CH2OH, -CH2NH2, -OCH(CH3)2, -CN,

[0355] In some embodiments of any of the formulae described herein, each -LW is independently selected from -CH3, -CH(CH3)2, -CH2C(CH3)3, -CH2OH, -CH2NH2, -OCH(CH3)2, -CN, -C(O)CH=CH2, -C(O)CF=CH2, -NHC(O)CF=CH2, and -NHC(O)CH=CH2.

[0356] In some embodiments of any of the formulae described herein, each -LW is independently selected from -C(O)CH=CH2 and -NHC(O)CH=CH2. In some embodiments, -LW is independently selected from -C(O)CH=CH2, -C(O)CF=CH2, -NHC(O)CF=CH2, and -NHC(O)CH=CH2. In some embodiments, each -LW is -C(O)CH=CH2. In some embodiments, each -LW is -CN.

[0357] In some embodiments of any of the formulae described herein, each ring D' is independently a 4- to 6-membered saturated or partially unsaturated carbocyclic ring or a 4- to 6-membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein ring D' is substituted with t instances of -LW.

[0358] In some embodiments of any of the formulae described herein, Ring D' is a 4- to 6-membered carbocyclic ring substituted with t -LW instances. In some embodiments, Ring D' is a 4- to 6-membered saturated or partially unsaturated carbocyclic ring substituted with t -LW instances. In some embodiments, Ring D' is a 4- to 6-membered cycloalkyl ring substituted with t -LW instances. In some embodiments, Ring D' is a 4- to 6-membered carbocyclic ring substituted with t -LW instances. In some embodiments, Ring D' is a cyclobutane ring substituted with t -LW instances. In some embodiments, Ring D' is a 5-membered carbocyclic ring substituted with t -LW instances. In some embodiments, Ring D' is a 6-membered carbocyclic ring substituted with t -LW instances.

[0359] In some embodiments of any of the formulas described herein, Ring D' is a 4- to 6-membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein Ring D' is substituted with t instances of -LW. In some embodiments, Ring D' is a 4- to 6-membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein Ring D' is substituted with t instances of -LW. In some embodiments, Ring D' is a 4- to 6-membered saturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein Ring D' is substituted with t instances of -LW. In some embodiments, Ring D' is a 4- to 6-membered saturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein Ring D' is substituted with t instances of -LW. In some embodiments, Ring D' is a 4-membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein Ring D' is substituted with t instances of -LW. In some embodiments, Ring D' is an azetidine substituted with t instances of -LW. In some embodiments, Ring D' is a 5-membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein Ring D' is substituted with t -LW instances. In some embodiments, Ring D' is a pyrrolidine substituted with t -LW instances. In some embodiments, Ring D' is a 6-membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein Ring D' is substituted with t -LW instances. In some embodiments, Ring D' is a piperidine substituted with t -LW instances.

[0360] In some embodiments of any of the formulas described herein, Ring D' substituted with t instances of -LW is selected from

[0361] In some embodiments of any of the formulae described herein, when R 1 is a divalent C ring D' or a divalent C ring D' 1-6 When the chain is aliphatic, it is through r R 2 Example substituted ring D is selected from

[0362] In some embodiments of any of the formulae described herein, Ring D is substituted with 1 R1 Instance replacement, R 1 is a ring D', and Selected from

[0363] In some embodiments of any of the formulas described herein, q is 0. In some embodiments, q is 1.

[0364] In some embodiments of any of the formulae described herein, t is 0 or 1. In some embodiments, t is 1 or 2. In some embodiments, t is 0. In some embodiments, t is 1. In some embodiments, t is 2.

[0365] In some embodiments of any of the formulas described herein, each R 2 independently selected from halogen, -CN, -OR and C 1-6 In some embodiments, each R 2 are independently selected from oxo, halogen, -CN, -O(C 1-4 alkyl) and C 1-6 In some embodiments, R 2 In some embodiments, R 2 is halogen (eg, fluorine or chlorine). In some embodiments, R 2 In some embodiments, R 2 In some embodiments, R 2 -O(C 1-4 In some embodiments, R 2 C 1-6 In some embodiments, each R 2 Independently selected from oxo, fluoro, chloro, -CN, -OCH3, -OCH(CH3)2, -CH3, -CH(CH3)2, and -CH2C(CH3)3.

[0366] In some embodiments of any of the formulae described herein, r is 0 or 1. In some embodiments, r is 1 or 2. In some embodiments, when q is 1, r is 0 or 1. In some embodiments, when q is 0, r is 1 or 2. In some embodiments, r is 0. In some embodiments, r is 1. In some embodiments, r is 2.

[0367] In some embodiments of any of the formulas described herein, each R 2’ independently selected from halogen, -CN, -OR and C 1-6 In some embodiments, R 2’ In some embodiments, R 2’is halogen (eg, fluorine or chlorine). In some embodiments, R 2’ In some embodiments, R 2’ In some embodiments, R 2’ C 1-6 Alkyl (eg, methyl).

[0368] In some embodiments of any of the formulas described herein, y is 0 or 1. In some embodiments, y is 1 or 2. In some embodiments, y is 0. In some embodiments, y is 1. In some embodiments, y is 2.

[0369] In some embodiments of any of the formulae described herein, each Cy is independently a 5- to 6-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3- to 6-membered saturated or partially unsaturated carbocyclic ring; or a 4- to 6-membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein Cy is substituted by 0-2 R 6 In some embodiments, Cy is substituted with 0-1 R 6 In some embodiments, Cy is substituted with 1-2 R 6 In some embodiments, Cy is not substituted by R 6 In some embodiments, Cy is substituted with 1 R 6 In some embodiments, Cy is substituted with 2 R 6 Instance replacement.

[0370] In some embodiments of any of the formulae described herein, Cy is a 5- to 6-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein Cy is substituted by 0-2 R 6 In some embodiments, Cy is a 5-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein Cy is substituted by 0-2 R 6 In some embodiments, Cy is a 6-membered heteroaromatic ring having 1-3 nitrogen atoms, wherein Cy is substituted by 0-2 R 6 In some embodiments, Cy is substituted with 0-2 R 6 Examples are substituted pyridines.

[0371] In some embodiments of any of the formulae described herein, Cy is 6 In some embodiments, Cy is substituted with 0-2 R 6 In some embodiments, Cy is substituted with 0-2 R 6In some embodiments, Cy is substituted with 0-2 R 6 In some embodiments, Cy is substituted with 0-2 R 6 In some embodiments, Cy is substituted with 0-2 R 6 In some embodiments, Cy is substituted with 0-2 R 6 Examples include substituted 6-membered carbocyclic rings.

[0372] In some embodiments of any formula described herein, Cy is a 4- to 6-membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, Cy is a 4- to 6-membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, Cy is a 4-membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, Cy is an azetidine. In some embodiments, Cy is a 5-membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, Cy is a pyrrolidone. In some embodiments, Cy is a 6-membered heterocyclic ring having 1-2 nitrogen atoms. In some embodiments, Cy is a piperidone or piperazine.

[0373] In some embodiments of any of the formulae described herein, 6 Example substituted Cy is selected from

[0374] In some embodiments of any of the formulas described herein, each R 6 independently selected from oxo, -CN, halogen, -OR, -N(R)2, -SR, -C(O)R, -N(R)C(O)R, -C(O)N(R)2, -OC(O)R, -C(O)OR, -SO2R, -N(R)SO2R, -SO2N(R)2, and a group selected from the group consisting of: C 1-6 aliphatic; 3 to 6 membered carbocyclic ring; phenyl; 3 to 6 membered heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur; 5 to 6 membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur; 10 membered aromatic ring; and 9 to 10 membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur. In some embodiments, each R 6 independently selected from oxo, -CN, halogen, -OR, -N(R)2, -SR, -C(O)R, -N(R)C(O)R, -C(O)N(R)2, -OC(O)R, -C(O)OR, -SO2R, -N(R)SO2R, -SO2N(R)2, and an optionally substituted group selected from: C1-6 aliphatic; a 3- to 6-membered saturated or partially unsaturated carbocyclic ring; a phenyl ring; a 3- to 6-membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5- to 6-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 10-membered aromatic ring; and a 9- to 10-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, each R 6 independently selected from -CN, halogen, -OR, -N(R)2, -SR, -C(O)R, -N(R)C(O)R, -C(O)N(R)2, -OC(O)R, -C(O)OR, -SO2R, -N(R)SO2R, -SO2N(R)2, and an optionally substituted group selected from: C 1-6 aliphatic; 3 to 6 membered carbocyclic ring; phenyl; 3 to 6 membered heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur; 5 to 6 membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur; 10 membered aromatic ring; and 9 to 10 membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur. In some embodiments, each R 6 independently selected from oxo, halogen, -OR, -N(R)2, -C(O)N(R)2 and optionally substituted C 1-6 In some embodiments, each R 6 are independently selected from oxo, halogen and optionally substituted C 1-6 In some embodiments, each R 6 are independently selected from oxo, halogen and optionally substituted C 1-6 In some embodiments, each R 6 independently selected from halogen and optionally substituted C 1-6 In some embodiments, each R 6 independently selected from halogen and optionally substituted C 1-6 In some embodiments, R 6 In some embodiments, R 6 is halogen (eg, fluorine or chlorine). In some embodiments, R 6 In some embodiments, R 6 In some embodiments, R 6 For –N(R)2(for example -N(C 1-4 In some embodiments, R 6 is -C(O)N(R)2. In some embodiments, R 6 is an optionally substituted C 1-6 In some embodiments, R 6 is an optionally substituted C1-6 In some embodiments, R 6 C 1-6 Alkyl (eg, methyl).

[0375] In some embodiments of any of the formulae described herein, each v is independently 0 or 1. In some embodiments, each v is independently 1 or 2. In some embodiments, v is 0. In some embodiments, v is 1. In some embodiments, v is 2.

[0376] In some embodiments of any of the formulae described herein, each x is independently 0 or 1. In some embodiments, each x is independently 1 or 2. In some embodiments, x is 0. In some embodiments, x is 1. In some embodiments, x is 2.

[0377] In some embodiments of any of the formulae described herein, each R is independently hydrogen; C 1-6 Aliphatic; C 1-6 haloaliphatic; 3- to 6-membered carbocyclic ring; phenyl; 3- to 6-membered heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; 5- to 6-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; 10-membered aromatic ring; and 9- to 10-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, each R is independently hydrogen or an optionally substituted group selected from: C 1-6 aliphatic; a 3- to 6-membered saturated or partially unsaturated carbocyclic ring; a phenyl ring; a 3- to 6-membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5- to 6-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 10-membered aromatic ring; and a 9- to 10-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, each R is independently hydrogen, an optionally substituted C 1-6 aliphatic or an optionally substituted 4- to 6-membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, each R is independently hydrogen, C optionally substituted with one or more halogens (eg, fluorine), 1-6 Alkyl, or having 1-2 heteroatoms independently selected from nitrogen, oxygen and sulfur and optionally C 1-6 In some embodiments, each R is independently hydrogen or an optionally substituted C 1-6 In some embodiments, each R is independently hydrogen or an optionally substituted C 1-6 In some embodiments, each R is independently hydrogen or C alkyl, optionally substituted with one or more halogens (eg, fluorine). 1-6 In some embodiments, R is hydrogen. In some embodiments, R is optionally substituted C1-6 In some embodiments, R is C 1-6 In some embodiments, R is an optionally substituted C 1-6 In some embodiments, R is C alkyl, optionally substituted with one or more halogens (eg, fluorine). 1-6 alkyl.

[0378] Embodiments are also provided herein, wherein any embodiment described herein can be combined with any one or more of these embodiments, with the proviso that the combinations are not mutually exclusive. As used herein, when an embodiment is defined as something different from another, two embodiments are "mutually exclusive." For example, an embodiment in which two groups combine to form a ring is mutually exclusive with an embodiment in which one group is ethyl and the other group is hydrogen. Similarly, an embodiment in which one group is CH2 is mutually exclusive with an embodiment in which the same group is NH.

[0379] In some embodiments of any of the aforementioned aspects, the compound is a compound included in Table 1 or 2, or a salt (e.g., a pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer thereof. In some embodiments, the compound is a compound included in Table 1, or a salt (e.g., a pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer thereof. In some embodiments, the compound is a compound included in Table 1, or a salt (e.g., a pharmaceutically acceptable salt). In some embodiments, the compound is a compound included in Table 2, or a salt (e.g., a pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer thereof. In some embodiments, the compound is a compound included in Table 2, or a salt (e.g., a pharmaceutically acceptable salt).

[0380] Also provided herein are compounds selected from Table 1 or 2 or any of the examples provided herein, or salts thereof (e.g., pharmaceutically acceptable salts), esters, tautomers, prodrugs, zwitterionic forms, or stereoisomers. In some embodiments, the present disclosure provides compounds selected from Table 1 or 2 or any of the examples provided herein, or salts thereof (e.g., pharmaceutically acceptable salts).

[0381] Compounds of the present disclosure, such as compounds of the formulae included in Table 1 or 2, can be synthesized according to one of the general routes outlined in Synthetic Examples 1-88 or by a variety of other methods known in the art.

[0382] Table 1 includes selected compounds of the present disclosure.

[0383] Table 1. Selected compounds of the present disclosure.

[0384]

[0385]

[0386]

[0387]

[0388]

[0389]

[0390]

[0391]

[0392]

[0393]

[0394]

[0395]

[0396]

[0397]

[0398]

[0399]

[0400]

[0401]

[0402]

[0403]

[0404]

[0405]

[0406]

[0407]

[0408]

[0409]

[0410]

[0411]

[0412]

[0413]

[0414]

[0415]

[0416]

[0417]

[0418]

[0419]

[0420]

[0421]

[0422]

[0423]

[0424]

[0425]

[0426]

[0427]

[0428]

[0429]

[0430]

[0431]

[0432]

[0433]

[0434]

[0435]

[0436]

[0437]

[0438]

[0439]

[0440]

[0441]

[0442]

[0443]

[0444]

[0445]

[0446]

[0447]

[0448]

[0449]

[0450]

[0451]

[0452]

[0453]

[0454]

[0455]

[0456]

[0457]

[0458]

[0459]

[0460]

[0461]

[0462]

[0463]

[0464]

[0465]

[0466] In some embodiments, the present disclosure provides a compound selected from those included in Table 2, or a pharmaceutically acceptable salt thereof.

[0467] Table 2. Selected compounds of the present disclosure.

[0468]

[0469]

[0470]

[0471]

[0472]

[0473]

[0474]

[0475]

[0476]

[0477]

[0478]

[0479]

[0480]

[0481]

[0482]

[0483]

[0484]

[0485]

[0486]

[0487]

[0488]

[0489]

[0490]

[0491]

[0492]

[0493]

[0494]

[0495]

[0496]

[0497]

[0498]

[0499]

[0500]

[0501]

[0502]

[0503]

[0504]

[0505]

[0506]

[0507]

[0508]

[0509]

[0510]

[0511]

[0512]

[0513]

[0514]

[0515]

[0516]

[0517]

[0518]

[0519]

[0520]

[0521]

[0522]

[0523]

[0524]

[0525]

[0526]

[0527]

[0528]

[0529]

[0530]

[0531]

[0532]

[0533]

[0534]

[0535]

[0536]

[0537]

[0538]

[0539]

[0540]

[0541]

[0542]

[0543]

[0544]

[0545]

[0546]

[0547]

[0548]

[0549]

[0550]

[0551]

[0552]

[0553]

[0554]

[0555]

[0556]

[0557]

[0558]

[0559]

[0560]

[0561]

[0562]

[0563]

[0564]

[0565]

[0566]

[0567]

[0568]

[0569]

[0570]

[0571]

[0572]

[0573]

[0574]

[0575]

[0576]

[0577]

[0578]

[0579]

[0580]

[0581]

[0582]

[0583]

[0584]

[0585]

[0586]

[0587]

[0588]

[0589]

[0590]

[0591]

[0592]

[0593]

[0594]

[0595]

[0596]

[0597]

[0598]

[0599]

[0600]

[0601]

[0602]

[0603]

[0604]

[0605]

[0606]

[0607]

[0608]

[0609]

[0610]

[0611]

[0612]

[0613]

[0614]

[0615]

[0616]

[0617]

[0618]

[0619]

[0620]

[0621]

[0622]

[0623]

[0624]

[0625]

[0626]

[0627]

[0628]

[0629]

[0630]

[0631]

[0632]

[0633]

[0634]

[0635]

[0636]

[0637]

[0638]

[0639]

[0640]

[0641]

[0642]

[0643]

[0644]

[0645]

[0646]

[0647]

[0648]

[0649]

[0650]

[0651]

[0652]

[0653]

[0654]

[0655]

[0656]

[0657]

[0658]

[0659]

[0660]

[0661]

[0662]

[0663]

[0664]

[0665]

[0666]

[0667]

[0668]

[0669]

[0670]

[0671]

[0672]

[0673]

[0674]

[0675]

[0676]

[0677]

[0678]

[0679]

[0680]

[0681]

[0682]

[0683]

[0684]

[0685]

[0686]

[0687]

[0688]

[0689]

[0690]

[0691]

[0692]

[0693]

[0694]

[0695]

[0696]

[0697]

[0698]

[0699]

[0700]

[0701]

[0702]

[0703]

[0704]

[0705]

[0706]

[0707]

[0708]

[0709]

[0710]

[0711]

[0712]

[0713]

[0714]

[0715]

[0716]

[0717]

[0718]

[0719]

[0720]

[0721]

[0722]

[0723]

[0724]

[0725]

[0726]

[0727]

[0728]

[0729]

[0730]

[0731]

[0732]

[0733]

[0734]

[0735]

[0736]

[0737]

[0738]

[0739]

[0740]

[0741]

[0742]

[0743]

[0744]

[0745]

[0746]

[0747]

[0748]

[0749]

[0750]

[0751]

[0752]

[0753]

[0754]

[0755]

[0756]

[0757]

[0758]

[0759]

[0760]

[0761]

[0762]

[0763]

[0764]

[0765]

[0766]

[0767]

[0768]

[0769]

[0770]

[0771]

[0772]

[0773]

[0774]

[0775]

[0776]

[0777]

[0778]

[0779]

[0780]

[0781]

[0782]

[0783]

[0784]

[0785]

[0786]

[0787]

[0788]

[0789]

[0790]

[0791]

[0792]

[0793]

[0794]

[0795]

[0796]

[0797]

[0798]

[0799]

[0800]

[0801]

[0802]

[0803]

[0804]

[0805]

[0806]

[0807]

[0808]

[0809]

[0810]

[0811]

[0812]

[0813]

[0814]

[0815]

[0816]

[0817]

[0818]

[0819]

[0820]

[0821]

[0822]

[0823]

[0824]

[0825]

[0826]

[0827]

[0828]

[0829]

[0830]

[0831]

[0832]

[0833]

[0834]

[0835]

[0836]

[0837]

[0838]

[0839]

[0840]

[0841]

[0842]

[0843]

[0844]

[0845]

[0846]

[0847]

[0848]

[0849]

[0850]

[0851]

[0852]

[0853]

[0854]

[0855]

[0856]

[0857]

[0858]

[0859]

[0860]

[0861]

[0862]

[0863]

[0864]

[0865]

[0866]

[0867]

[0868] In some embodiments, the compound provided is provided and / or utilized in salt form (e.g., pharmaceutically acceptable salt form). Unless otherwise indicated, reference to the compound provided herein should be understood to include reference to its salt. Pharmaceutically acceptable salt forms are known in the art. For example, SM Berge et al. describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 66: 1-19 (1977). Examples of pharmaceutically acceptable non-toxic acid addition salts are amino groups with inorganic acids (such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, and perchloric acid) or with organic acids (such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid, or malonic acid) or by using other methods used in the art (such as ion exchange) to form salts. Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, gluconate heptanoate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate, and the like. Salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and N + (C 1-4 Representative alkali metal or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Other pharmaceutically acceptable salts include non-toxic ammonium, quaternary ammonium, and amine cations formed using counterions, such as halides, hydroxides, carboxylates, sulfates, phosphates, nitrates, lower alkyl sulfonates, and aryl sulfonates, as appropriate.

[0869] It should be understood that the compounds described herein can be provided and / or utilized in any useful form (e.g., salt form), and the present disclosure encompasses all such forms. The present disclosure also encompasses forms such as esters, tautomers, prodrugs, zwitterionic forms, and stereoisomers of the compounds provided herein.

[0870] It should be understood that throughout the present disclosure, unless otherwise indicated, reference to a compound of formula I also is intended to include compounds of formulae I-a, I-b, I-c, I-d, I-e, I-f, I-g, I-h, I-i, I-j, I-k, I-a-i, I-b-i, I-c-i, I-d-i, I-e-i, I-f-i, I-g-i, I-h-i, I-i-i, I-j-I, I-k-i, I-a-ii, I-b-ii, I-c-ii, I-d-ii, I-e-ii, I-f-ii, I-g-ii, I-h-ii, I-i-ii, I-j-ii, I-k-ii, I-a-ii’, I-b-ii’, I-c-ii’, I-d-ii’, I-e-ii’, I-f-ii’, I-g-ii’, I-h-ii’, I-i-ii’, I-j-ii’, I-k-ii’, I-a-iii, I-b-iii, I-c-iii, I-d-iii, I-e-iii, I-f-iii, I-g-iii, I-h-iii, I-i-iii, I-j-iii, I-k-iii, I-a-iv, I-b-iv, I-c-iv, I-d-iv, I-e-iv, I-f-iv, I-g-iv, I-h-iv, I-i-iv, I-j-iv, I-k-iv, I-a-v, I-b-v, I-c-v, I-d-v, I-e-v, I-f-v, I-g-v, I-h-v, I-i-v, I-j-v, I-k-v, I-a-v’, I-b-v’, I-c-v’, I-d-v’, I-e-v’, I-f-v’, I-g-v’, I-h-v’, I-i-v’, I-j-v’, I-k-v’, I-l, I-m, I-n, I-p, I-q, I-r, IA, IA1, IB, IB1, IC, IC1, ID, ID1, IE, IE1, IF, and IF1, and species of compounds of such formulae disclosed herein.

[0871] In some embodiments, the provided compounds are prepared as described herein, such as according to any one of Synthesis Examples 1-88.

[0872] Composition

[0873] This publication may include one or more kinds of compounds and other combinations provided by this publication. In one small practical implementation scheme, the provided combinations include sums / or send text-stated compounds (for example, formula I, Ia, Ib, Ic, Id, Ie, If, Ig, Ih, Ii, Ij, Ik, Ia i, Ibi, Ici, Idi, Iei, Ifi, Igi, Ihi, Iii, IjI, Iki, Ia-ii, Ib-ii, Ic-ii, Id-ii, Ie-ii, If -ii, Ig-ii, Ih-ii, Ii-ii, Ij-ii, Ik-ii, Ia-ii', Ib-ii', Ic-ii', Id-ii', Ie-ii', If-i i', Ig-ii', Ih-ii', Ii-ii', Ij-ii', Ik-ii', Ia-iii, Ib-iii, Ic-iii, Id-iii, Ie-iii, I f-iii, Ig-iii, Ih-iii, Ii-iii, Ij-iii, Ik-iii, Ia-iv, Ib-iv, Ic-iv, Id-iv, Ie-iv, If -iv, Ig-iv, Ih-iv, Ii-iv, Ij-iv, Ik-iv, Iav, Ibv, Icv, Idv, Iev, Ifv, Igv, Ihv, Iiv, Ijv, Ikv, Ia-v', Ib-v', Ic-v', Id-v', Ie-v', If-v', Ig-v', Ih-v', Ii-v', Ij-v', Ik-v', Il, I m, In, Ip, Iq, Ir, IA, IA1, IB, IB1, IC, IC1, ID, ID1, IE, IE1, IF or IF1 compounds, or select Table 1 or Table 2 compounds).

[0874] In some embodiments, provided compositions are pharmaceutical compositions that contain and / or deliver a compound provided herein (e.g., Formula I, Ia, Ib, Ic, Id, Ie, If, Ig, Ih, Ii, Ij, Ik, Iai, Ibi, Ici, Idi, Iei, Ifi, Igi, Ihi, Iii, Ijl, Iki, Ia-ii, Ib-ii, Ic-ii, Id-ii, Ie-ii, If-ii, Ig-ii, Ih-ii, Ii-ii, Ij-ii, Ik-ii, Ia-ii', Ib-ii', Ic-ii', Id-ii', Ie-ii', If-ii', Ig-ii', Ih-ii', Ii-ii', Ij-ii', Ik-ii', Ia-iii, Ib-iii, Ic-iii, Id-iii, Ie-iii, If-ii i, Ig-iii, Ih-iii, Ii-iii, Ij-iii, Ik-iii, Ia-iv, Ib-iv, Ic-iv, Id-iv, Ie-iv, If-iv, Ig- iv, Ih-iv, Ii-iv, Ij-iv, Ik-iv, Iav, Ibv, Icv, Idv, Iev, Ifv, Igv, Ihv, Iiv, Ijv, Ikv, Ia-v', Ib-v', Ic-v', Id-v', Ie-v', If-v', Ig-v', Ih-v', Ii-v', Ij-v', Ik-v', Il, Im, In, Ip, Iq, Ir, IA, IA1, IB, IBI, IC, IC1, ID, ID1, IE, IE1, IF or IF1, or a compound selected from Table 1 or Table 2) and further comprising a pharmaceutically acceptable carrier. Pharmaceutical compositions typically contain an effective amount of an active agent (e.g., a compound described herein) to achieve the desired therapeutic effect while avoiding or minimizing adverse side effects. In some embodiments, provided pharmaceutical compositions comprise a compound as described herein and one or more fillers, disintegrants, lubricants, glidants, anti-adherents and / or antistatic agents, etc. The pharmaceutical compositions provided can be in a variety of forms, including oral dosage forms, topical creams, topical patches, iontophoretic forms, suppositories, nasal sprays and / or inhalants, eye drops, intraocular injection forms, reservoir forms, and injectable and infusible solutions. Methods for preparing pharmaceutical compositions are well known in the art.

[0875] In some embodiments, for ease of administration and dosage uniformity, provided compound is formulated into unit dosage form. As used herein, the expression "unit dosage form" refers to a physical discrete unit of an active agent (e.g., a compound described herein) for administration to a subject. Typically, each such unit contains an active agent of predetermined mass. In some embodiments, the unit dosage form contains a complete single dose of an agent. In some embodiments, more than one unit dosage form is administered to achieve a total single dose. In some embodiments, it is necessary or expected that multiple unit dosage forms need to be administered to achieve the desired effect. The unit dosage form can be, for example, a liquid pharmaceutical composition containing one or more active agents of predetermined mass, a solid pharmaceutical composition containing one or more active agents of predetermined amount (e.g., tablets, capsules, etc.), a sustained release formulation containing one or more active agents of predetermined mass, or a drug delivery device containing one or more active agents of predetermined amount, etc.

[0876] Provided compositions can be administered using any amount and any route of administration effective for treating or lessening the severity of any disease or condition described herein.

[0877] use

[0878] The present disclosure provides compounds and compositions described herein (e.g., Formula I, Ia, Ib, Ic, Id, Ie, If, Ig, Ih, Ii, Ij, Ik, Iai, Ibi, Ici, Idi , Iei, Ifi, Igi, Ihi, Iii, IjI, Iki, Ia-ii, Ib-ii, Ic-ii, Id-ii, Ie-ii, If-ii, Ig-ii, I h-ii, Ii-ii, Ij-ii, Ik-ii, Ia-ii', Ib-ii', Ic-ii', Id-ii', Ie-ii', If-ii', Ig-ii', Ih-ii', Ii-ii', Ij-ii', Ik-ii', Ia-iii, Ib-iii, Ic-iii, Id-iii, Ie-iii, If-iii, Ig Ij-v', Ik-v', Ia-v, Ib-iv, Ic-iv, Id-iv, Ie-iv, If-iv, Ig-iv, Ih-iv, Ii-iv, Ij-iv, Ik-iv, Iav, Ibv, Icv, Idv, Iev, Ifv, Igv, Ihv, Iiv, Ijv, Ikv, Ia-v', Ib-v', Ic-v', Id-v', Ie-v', If-v', Ig-v', Ih-v', Ii-v', Ij-v', Ik-v', Il, Im, In, Ip, Iq, Ir, IA, IA1, IIB, IB1, IC, IC1, ID, ID1, IE, IE1, IF or IF1, or a compound selected from Table 1 or 2. In some embodiments, provided compounds and compositions can be used in pharmacy (e.g., as therapeutic agents for treating, ameliorating, delaying the progression of, ameliorating or eliminating the symptoms of, and / or inhibiting a disease or condition as described herein). In some embodiments, provided compounds and compositions can be used as pharmaceutical agents. In some embodiments, provided compounds and compositions can be used in research, for example, as analytical tools and / or control compounds in biological assays.

[0879] In some embodiments, provided compounds can be used to destroy (e.g., inhibit and / or prevent and / or regulate) the interaction between a small GTPase (e.g., Rac1, CDC42 or RAS protein, such as KRAS, NRAS, HRAS, RRAS, RRAS2, MRAS or RIT1) and a PI3K alpha protein. In some embodiments, the disclosure provides methods for destroying, interrupting and / or preventing the interaction between a small GTPase (e.g., Rac1, CDC42 or RAS protein, such as KRAS, NRAS, HRAS, RRAS, RRAS2, MRAS or RIT1) and a PI3K alpha protein in a subject, comprising administering provided compounds or compositions. In some embodiments, the disclosure provides methods for destroying, interrupting and / or preventing the interaction between a small GTPase (e.g., Rac1, CDC42 or RAS protein, such as KRAS, NRAS, HRAS, RRAS, RRAS2, MRAS or RIT1) and a PI3K alpha protein in a biological sample, comprising administering provided compounds or compositions. In some embodiments, the methods provided by the present disclosure include contacting cells containing small GTPases (e.g., Rac1, CDC42, or RAS proteins, such as KRAS, NRAS, HRAS, RRAS, RRAS2, MRAS, or RIT1) and PI3Kα proteins with provided compounds or compositions. In some such embodiments, the small GTPase is capable of binding to the RAS binding domain (RBD) of the PI3Kα protein. In some embodiments, the small GTPase is selected from Rac1, CDC42, and RAS proteins. In some embodiments, the RAS protein is selected from HRAS, NRAS, KRAS, RRAS, RRAS2, MRAS, and RIT1. In some embodiments, the RAS protein is a wild-type RAS protein. In some embodiments, the RAS protein is a mutant RAS protein. In some embodiments, the RAS protein (e.g., HRAS, NRAS, or KRAS) comprises a mutation at codon 12 (e.g., G12), codon 13 (e.g., G13), or codon 61 (e.g., Q61). In some embodiments, the KRAS protein comprises a G12C, G12D, G12S, G12V, G12R, G12A, G13D, G13A, G13C, G13R, G13S, G13V, Q61E, Q61K, Q61L, Q61P, Q61R, and / or Q61H mutation. In some embodiments, the KRAS protein comprises a G12C, G12D, G12S, G12V, G12R, G13D, and / or Q61H mutation.In some embodiments, the NRAS protein comprises a G12C, G12D, G12S, G12V, G12R, G12A, G13D, G13A, G13C, G13R, G13S, G13V, Q61E, Q61K, Q61L, Q61P, Q61R, and / or Q61H mutation. In some embodiments, the NRAS protein comprises a G12D, G12V, G13D, and / or Q61R mutation. In some embodiments, the HRAS protein comprises a G12C, G12D, G12S, G12V, G12R, G12A, G13D, G13C, G13R, G13S, G13V, Q61K, Q61L, Q61P, Q61R, and / or Q61H mutation. In some embodiments, the HRAS protein comprises a G12V, G13R, and / or Q61R mutation. In some embodiments, the PI3Kα protein is a wild-type PI3Kα protein. In some embodiments, the PI3Kα protein is a mutant PI3Kα protein. In some embodiments, the PI3Kα protein comprises an N345K, E726K, C420R, Q546R, G118D, E453K, Q546K, G1049R, M1043I, K111E, K111N, E81K, E545A, E545G, N1044K, E110del, Q546P, E542K, E545K, H1047R, and / or H1047L mutation. In some embodiments, the PI3Kα protein comprises an E542K, E545K, H1047R, and / or H1047L mutation.

[0880] In some embodiments, the disclosure provides a method comprising administering provided compounds or compositions to a subject in need thereof. In some such embodiments, the subject suffers from a disease, disease or illness related to the interaction between a small GTPase (for example, Rac1, CDC42 or RAS protein, such as KRAS, NRAS, HRAS, RRAS, RRAS2, MRAS or RIT1) and PI3K α protein. In some embodiments, the subject suffers from a disease, disease or illness alleviated by destroying the interaction between a small GTPase (for example, Rac1, CDC42 or RAS protein, such as KRAS, NRAS, HRAS, RRAS, RRAS2, MRAS or RIT1) and PI3K α protein. In some embodiments, small GTPase (for example, Rac1, CDC42 or RAS protein, such as KRAS, NRAS, HRAS, RRAS, RRAS2, MRAS or RIT1) can be combined with the RAS binding domain (RBD) of PI3K α protein. In some embodiments, small GTPase is selected from Rac1, CDC42 and RAS protein. In some embodiments, the RAS protein is selected from HRAS, NRAS, KRAS, RRAS, RRAS2, MRAS, and RIT1. In some embodiments, the KRAS protein comprises G12C, G12D, G12S, G12V, G12R, G12A, G13D, G13A, G13C, G13R, G13S, G13V, Q61E, Q61K, Q61L, Q61P, Q61R, and / or Q61H mutations. In some embodiments, the KRAS protein comprises G12C, G12D, G12S, G12V, G12R, G13D, and / or Q61H mutations. In some embodiments, the NRAS protein comprises a G12C, G12D, G12S, G12V, G12R, G12A, G13D, G13A, G13C, G13R, G13S, G13V, Q61E, Q61K, Q61L, Q61P, Q61R, and / or Q61H mutation. In some embodiments, the NRAS protein comprises a G12D, G12V, G13D, and / or Q61R mutation. In some embodiments, the HRAS protein comprises a G12C, G12D, G12S, G12V, G12R, G12A, G13D, G13C, G13R, G13S, G13V, Q61K, Q61L, Q61P, Q61R, and / or Q61H mutation. In some embodiments, the HRAS protein comprises a G12V, G13R, and / or Q61R mutation. In some embodiments, the RAS protein is a wild-type RAS protein. In some embodiments, the PI3Kα protein is a wild-type PI3Kα protein. In some embodiments, the PI3Kα protein is a mutant PI3Kα protein.In some embodiments, the PI3Kα protein comprises N345K, E726K, C420R, Q546R, G118D, E453K, Q546K, G1049R, M1043I, K111E, K111N, E81K, E545A, E545G, N1044K, E110del, Q546P, E542K, E545K, H1047R and / or H1047L mutations. In some embodiments, the PI3Kα protein comprises E542K, E545K, H1047R and / or H1047L mutations. In some embodiments, the subject has a cancer or other indication described herein. In some embodiments, the subject has previously received a cancer treatment regimen. In some embodiments, the subject has previously entered cancer remission.

[0881] In some embodiments, provided methods comprise administering a provided compound or composition to a subject in need thereof according to a regimen such that the subject does not experience hyperglycemia or insulin-driven resistance.

[0882] In some embodiments, the present disclosure provides a method for treating cancer, which includes administering a provided compound or composition to a subject. In some embodiments, cancer is associated with and / or characterized by the abnormal activation of PI3K α. In some embodiments, the characteristic of cancer is a mutation in a RAS protein (e.g., HRAS, NRAS, KRAS, RRAS, RRAS2, MRAS, and RIT1). In some embodiments, the characteristic of cancer is a mutation in a KRAS protein. In some embodiments, KRAS protein includes G12C, G12D, G12S, G12V, G12R, G12A, G13D, G13A, G13C, G13R, G13S, G13V, Q61E, Q61K, Q61L, Q61P, Q61R, and / or Q61H mutations. In some embodiments, KRAS protein includes G12C, G12D, G12S, G12V, G12R, G13D, and / or Q61H mutations. In some embodiments, the cancer is characterized by a mutation in the NRAS protein. In some embodiments, the NRAS protein comprises G12C, G12D, G12S, G12V, G12R, G12A, G13D, G13A, G13C, G13R, G13S, G13V, Q61E, Q61K, Q61L, Q61P, Q61R and / or Q61H mutations. In some embodiments, the NRAS protein comprises G12D, G12V, G13D and / or Q61R mutations. In some embodiments, the cancer is characterized by a mutation in the HRAS protein. In some embodiments, the HRAS protein comprises a G12C, G12D, G12S, G12V, G12R, G12A, G13D, G13C, G13R, G13S, G13V, Q61K, Q61L, Q61P, Q61R, and / or Q61H mutation. In some embodiments, the HRAS protein comprises a G12V, G13R, and / or Q61R mutation. In some embodiments, the cancer is characterized by a mutation in the PI3Kα protein. In some embodiments, the PI3Ka protein comprises N345K, E726K, C420R, Q546R, G118D, E453K, Q546K, G1049R, M1043I, K111E, K111N, E81K, E545A, E545G, N1044K, E110del, Q546P, E542K, E545K, H1047R and / or H1047L mutations. In some embodiments, the PI3Ka protein comprises E542K, E545K, H1047R and / or H1047L mutations.

[0883] As used herein, "cancer" (and also referred to as "malignancy," "neoplasm," "tumor," and "carcinoma") refers to cells that exhibit relatively abnormal, uncontrolled, and / or autonomous growth, such that they exhibit an abnormal growth phenotype characterized by a significant loss of control of cell proliferation. In some embodiments, a tumor can be or comprise precancerous (e.g., benign), malignant, pre-metastatic, metastatic, and / or non-metastatic cells. In some embodiments, a cancer can be characterized as a solid tumor. In some embodiments, a cancer can be characterized as a hematologic tumor. Many different types of cancer are known.

[0884] In some embodiments, the cancer is selected from pancreatic cancer; colon cancer; rectal cancer; colorectal cancer; breast cancer; ovarian cancer; endometrial cancer; lung cancer; prostate cancer; oral and pharyngeal cancer (lip cancer, tongue cancer, mouth cancer, larynx cancer, pharynx cancer), esophageal cancer, stomach cancer, small intestine cancer, large intestine cancer, liver cancer and bile duct cancer, bone cancer, connective tissue cancer, skin cancer, cervical cancer, uterine cancer, endometrial cancer, testicular cancer, bladder cancer, kidney cancer and other urinary tissue cancer, including renal cell carcinoma (RCC); cancer of the eye, brain cancer, spinal cord cancer, and other components of the central and peripheral nervous system and related structures such as the meninges; thyroid cancer and other endocrine gland cancers; Hodgkin's disease (Hodgkin's disease); non-Hodgkin's lymphomas; multiple myeloma; and hematopoietic malignancies, including leukemias (chronic lymphocytic leukemia (CLL), acute lymphocytic leukemia (ALL), chronic myeloid leukemia (CML), acute myeloid leukemia (AML) and lymphomas, including lymphocytic, granulocytic and monocytic lymphomas. Additional exemplary cancer types include, but are not limited to, adenocarcinoma, angiosarcoma, astrocytoma, acoustic neuroma, anaplastic astrocytoma, basal cell carcinoma, blastoma, chondrosarcoma, choriocarcinoma, chordoma, craniopharyngioma, cutaneous melanoma, cystadenocarcinoma, endotheliosarcoma, embryonal carcinoma, ependymoma, Ewing's tumor, epithelial carcinoma, fibrosarcoma, gastric cancer, genitourinary tract cancer, multiple myeloma, sarcoma, ovarian cancer ... glioblastoma, head and neck cancer, hemangioblastoma, hepatocellular carcinoma, hepatoma, Kaposi sarcoma, large cell carcinoma, leiomyosarcoma, leukemia, liposarcoma, lymphatic system cancer, lymphoma, lymphangiosarcoma, lymphangioendothelioma, medullary thyroid cancer, medulloblastoma, meningeomesothelioma, myeloma, myxosarcoma, neuroblastoma, neurofibrosarcoma, oligodendritic glioma, osteosarcoma, epithelial ovarian cancer, papillary carcinoma, papillary adenocarcinoma, paraganglioma, parathyroid tumor, pheochromocytoma, pinealoma, plasmacytoma, retinoblastoma, rhabdomyosarcoma, sebaceous gland carcinoma, seminoma, skin cancer, melanoma, small cell lung cancer, non-small cell lung cancer, squamous cell carcinoma, sweat gland carcinoma, synovioma, thyroid cancer, uveal melanoma, and Wilms' tumor In some embodiments, the cancer is selected from breast cancer, lung cancer (e.g., non-small cell lung cancer), endometrial cancer, esophageal cancer, ovarian cancer, colorectal cancer, gastric cancer, squamous cell carcinoma, prostate cancer, and pancreatic cancer.

[0885] In some embodiments, the feature of cancer is one or more mutations. In some such embodiments, the subject can be diagnosed with cancer and / or selected for therapy based on detecting one or more mutations in a biological sample obtained from the subject. In some embodiments, the feature of cancer is a mutation in a RAS protein (e.g., KRAS, HRAS, or NRAS). In some embodiments, the feature of cancer is a mutation in a KRAS protein. In some embodiments, the KRAS protein comprises G12C, G12D, G12S, G12V, G12R, G12A, G13D, G13A, G13C, G13R, G13S, G13V, Q61E, Q61K, Q61L, Q61P, Q61R, and / or Q61H mutations. In some embodiments, the KRAS protein comprises G12C, G12D, G12S, G12V, G12R, G13D, and / or Q61H mutations. In some embodiments, the feature of cancer is a mutation in a NRAS protein. In some embodiments, the NRAS protein comprises G12C, G12D, G12S, G12V, G12R, G12A, G13D, G13A, G13C, G13R, G13S, G13V, Q61E, Q61K, Q61L, Q61P, Q61R and / or Q61H mutations. In some embodiments, the NRAS protein comprises G12D, G12V, G13D and / or Q61R mutations. In some embodiments, the cancer is characterized by mutations in the HRAS protein. In some embodiments, the HRAS protein comprises G12C, G12D, G12S, G12V, G12R, G12A, G13D, G13C, G13R, G13S, G13V, Q61K, Q61L, Q61P, Q61R and / or Q61H mutations. In some embodiments, the HRAS protein comprises a G12V, G13R, and / or Q61R mutation. In some embodiments, the cancer is characterized by a mutation in the PI3Kα protein. In some embodiments, the PI3Kα protein comprises an N345K, E726K, C420R, Q546R, G118D, E453K, Q546K, G1049R, M1043I, K111E, K111N, E81K, E545A, E545G, N1044K, E110del, Q546P, E542K, E545K, H1047R, and / or H1047L mutation. In some embodiments, the PI3Kα protein comprises an E542K, E545K, H1047R, and / or H1047L mutation. In some embodiments, the cancer is characterized by a mutated, overexpressed, and / or amplified receptor tyrosine kinase (e.g., HER family (e.g., HER2 and / or HER3), Met, FGFR, Alk, PDGF, EGFR, or ROS kinase).In some embodiments, the cancer is characterized by a mutation or deletion of a PTEN protein. In some embodiments, the cancer has demonstrable sensitivity to Avastin. For example, the cancer may be non-small cell lung cancer (NSCLC) or colorectal cancer. In some embodiments, the cancer is ER positive (e.g., having an estrogen receptor). In some embodiments, the cancer is PR positive (e.g., having a progesterone receptor).

[0886] In some embodiments, the present disclosure provides methods of treating metabolic syndrome comprising administering to a subject a provided compound or composition. In some embodiments, metabolic syndrome is selected from hyperinsulinemia and type 2 diabetes.

[0887] In some embodiments, the present disclosure provides a method for treating a RAS disease (e.g., a genetic syndrome caused by germline mutations in genes encoding components or regulators of the RAS / MAPK pathway) comprising administering to a subject a compound or composition provided. In some embodiments, the RAS disease is selected from the group consisting of capillary malformation-arteriovenous malformation syndrome and Legius syndrome. In some embodiments, the RAS disease is neurofibromatosis type 1 (NF1).

[0888] In some embodiments, the disclosure provides a method for treating a vascular disorder, comprising administering to a subject a compound or composition provided. In some embodiments, the vascular disorder is selected from PIK3CA-associated overgrowth syndrome (PROS) and vascular malformations (e.g., venous malformations; lymphatic malformations; congenital lipomatous overgrowth with vascular, epidermal, and skeletal anomalies syndrome (CLOVES); Klippel-Trenaunay syndrome; PTEN hamartoma tumor syndrome (PHTS); and fibrofatty vascular anomaly (FAVA)).

[0889] In some embodiments, the present disclosure provides methods of treating pulmonary hypertension, such as pulmonary arterial hypertension, comprising administering to a subject a provided compound or composition.

[0890] In some embodiments, the present disclosure provides methods of treating age-related macular degeneration or diabetic macular edema, comprising administering to a subject a provided compound or composition.

[0891] In some embodiments, the disclosure provides a compound or composition for the manufacture of a medicament. In some embodiments, the compound or composition provided can be used to manufacture a medicament for treating a disease, disease or illness related to or improved by the interaction between a small GTPase (e.g., Rac1, CDC42 or RAS protein, such as KRAS, NRAS, HRAS, RRAS, RRAS2, MRAS or RIT1) and a PI3K α protein. In some embodiments, a small GTPase (e.g., Rac1, CDC42 or RAS protein, such as KRAS, NRAS, HRAS, RRAS, RRAS2, MRAS or RIT1) can bind to the RAS binding domain (RBD) of PI3K α protein. In some embodiments, a small GTPase is selected from Rac1, CDC42 and a RAS protein. In some embodiments, a RAS protein is selected from HRAS, NRAS, KRAS, RRAS, RRAS2, MRAS and RIT1. In some embodiments, a RAS protein is a wild-type RAS protein. In some embodiments, a RAS protein is a mutant RAS protein. In some embodiments, the RAS protein (e.g., HRAS, NRAS, or KRAS) comprises a mutation in codon 12 (e.g., G12), codon 13 (e.g., G13), or codon 61 (e.g., Q61). In some embodiments, the KRAS protein comprises a G12C, G12D, G12S, G12V, G12R, G12A, G13D, G13A, G13C, G13R, G13S, G13V, Q61E, Q61K, Q61L, Q61P, Q61R, and / or Q61H mutation. In some embodiments, the KRAS protein comprises a G12C, G12D, G12S, G12V, G12R, G13D, and / or Q61H mutation. In some embodiments, the NRAS protein comprises a G12C, G12D, G12S, G12V, G12R, G12A, G13D, G13A, G13C, G13R, G13S, G13V, Q61E, Q61K, Q61L, Q61P, Q61R, and / or Q61H mutation. In some embodiments, the NRAS protein comprises a G12D, G12V, G13D, and / or Q61R mutation. In some embodiments, the HRAS protein comprises a G12C, G12D, G12S, G12V, G12R, G12A, G13D, G13C, G13R, G13S, G13V, Q61K, Q61L, Q61P, Q61R, and / or Q61H mutation. In some embodiments, the HRAS protein comprises a G12V, G13R, and / or Q61R mutation. In some embodiments, the PI3Kα protein is a wild-type PI3Kα protein. In some embodiments, the PI3Kα protein is a mutant PI3Kα protein.In some embodiments, the PI3Kα protein comprises N345K, E726K, C420R, Q546R, G118D, E453K, Q546K, G1049R, M1043I, K111E, K111N, E81K, E545A, E545G, N1044K, E110del, Q546P, E542K, E545K, H1047R and / or H1047L mutations. In some embodiments, the PI3Kα protein comprises E542K, E545K, H1047R and / or H1047L mutations. In some embodiments, the compounds or compositions provided can be used to manufacture a medicament for treating a disease, disorder or condition described herein. In some embodiments, the compounds or compositions provided can be used to manufacture a medicament for treating a cancer or other indication described herein.

[0892] In some embodiments, the disclosure provides a compound or composition for treating a disease, disorder or illness of a subject in need thereof. In some embodiments, the compound or composition provided can be used for treating a disease, disorder or illness related to or improved by the interaction between a small GTPase (such as Rac1, CDC42 or RAS protein, such as KRAS, NRAS, HRAS, RRAS, RRAS2, MRAS or RIT1) and a PI3K α protein. In some embodiments, a small GTPase (such as Rac1, CDC42 or RAS protein, such as KRAS, NRAS, HRAS, RRAS, RRAS2, MRAS or RIT1) can bind to the RAS binding domain (RBD) of PI3K α protein. In some embodiments, a small GTPase is selected from Rac1, CDC42 and RAS protein. In some embodiments, a RAS protein is selected from HRAS, NRAS, KRAS, RRAS, RRAS2, MRAS and RIT1. In some embodiments, a RAS protein is a wild-type RAS protein. In some embodiments, a RAS protein is a mutant RAS protein. In some embodiments, the RAS protein (e.g., HRAS, NRAS, or KRAS) comprises a mutation in codon 12 (e.g., G12), codon 13 (e.g., G13), or codon 61 (e.g., Q61). In some embodiments, the KRAS protein comprises a G12C, G12D, G12S, G12V, G12R, G12A, G13D, G13A, G13C, G13R, G13S, G13V, Q61E, Q61K, Q61L, Q61P, Q61R, and / or Q61H mutation. In some embodiments, the KRAS protein comprises a G12C, G12D, G12S, G12V, G12R, G13D, and / or Q61H mutation. In some embodiments, the NRAS protein comprises a G12C, G12D, G12S, G12V, G12R, G12A, G13D, G13A, G13C, G13R, G13S, G13V, Q61E, Q61K, Q61L, Q61P, Q61R, and / or Q61H mutation. In some embodiments, the NRAS protein comprises a G12D, G12V, G13D, and / or Q61R mutation. In some embodiments, the HRAS protein comprises a G12C, G12D, G12S, G12V, G12R, G12A, G13D, G13C, G13R, G13S, G13V, Q61K, Q61L, Q61P, Q61R, and / or Q61H mutation. In some embodiments, the HRAS protein comprises a G12V, G13R, and / or Q61R mutation. In some embodiments, the PI3Kα protein is a wild-type PI3Kα protein. In some embodiments, the PI3Kα protein is a mutant PI3Kα protein.In some embodiments, the PI3Kα protein comprises N345K, E726K, C420R, Q546R, G118D, E453K, Q546K, G1049R, M1043I, K111E, K111N, E81K, E545A, E545G, N1044K, E110del, Q546P, E542K, E545K, H1047R and / or H1047L mutations. In some embodiments, the PI3Kα protein comprises E542K, E545K, H1047R and / or H1047L mutations. In some embodiments, the compounds or compositions provided can be used to treat diseases, disorders or conditions described herein. In some embodiments, the compounds or compositions provided can be used to treat cancer or other indications as described herein.

[0893] In some embodiments, provided compound or composition is administered as part of a combination therapy. As used herein, the term "combination therapy" refers to those situations in which a subject is simultaneously exposed to two or more treatment or prevention regimens (e.g., two or more therapeutic agents or preventive agents). In some embodiments, two or more regimens can be administered simultaneously. In some embodiments, such regimens can be administered sequentially (e.g., a first regimen of all "dosages" is administered before a second regimen of any dose is administered); in some embodiments, such agents are administered with overlapping dosing regimens. In some embodiments, the "administration" of the combination therapy can be administered to subjects who receive other agents or methods in the combination. For clarity, combination therapy does not require that individual agents be administered together in a single composition (or even must be administered simultaneously), although in some embodiments, two or more agents can be administered together in a combined composition.

[0894] In some embodiments, provided compound or composition is administered to a subject who is receiving or has received one or more additional therapeutic agents (e.g., anticancer agents and / or one or more side effects of such anticancer therapies or otherwise providing palliative care). Exemplary anticancer agents include but are not limited to alkylating agents, antimitotic agents, checkpoint inhibitors, antimetabolites, plant alkaloids, terpenes, cytotoxic agents, antibiotics, topoisomerase inhibitors, aromatase inhibitors, angiogenesis inhibitors, antisteroids, antiandrogens, mTOR inhibitors, monoclonal antibodies, kinase inhibitors, HIF2α inhibitors, or tyrosine kinase inhibitors. Alkylating agents can be, for example, amustine, chlorambucil (LEUKERAN), cisplatin (PLATIN), carboplatin (PARAPLATIN), oxaliplatin (ELOXATIN), streptozocin (ZANOSAR), busulfan (MYLERAN), dacarbazine, ifosfamide, lomustine (CCNU), melphalan (ALKERAN), procarbazine (MATULAN), temozolomide (TEMODAR), thiotepa, or cyclophosphamide (ENDOXAN). Antimetabolites can be, for example, cladribine (LEUSTATIN), mercaptopurine (PURINETHOL), thioguanine, pentostatin (NIPENT), cytosine arabinoside (cytarabine, ARA-C), gemcitabine (GEMZAR), fluorouracil (5-FU, CARAC), capecitabine (XELODA), leucovorin (FUSILEY), methotrexate (RHEUMATREX), or raltitrexed. The anti-mitotic agent may be, for example, a taxane such as docetaxel (TAXITERE) or paclitaxel (ABRAXANE, TAXOL); or a vinca alkaloid such as vincristine (ONCOVIN), vinblastine, vindesine, or vinorelbine (NAVELBINE). Checkpoint inhibitors may be anti-PD-1 or anti-PD-L1 antibodies such as pembrolizumab (KEYTRUDA), nivolumab (OPDIVO), MEDI4736, or MPDL3280A; anti-CTLA-4 antibody ipilimumab (YERVOY); or agents targeting LAG3 (lymphocyte activation gene 3 protein), KIR (killer cell immunoglobulin-like receptor), 4-1BB (tumor necrosis factor receptor superfamily member 9), TIM3 (T cell immunoglobulin and mucin domain-3), or OX40 (tumor necrosis factor receptor superfamily member 4). The topoisomerase inhibitor may be, for example, camptothecin (CTP), irinotecan (CAMPTOSAR), topotecan (HYCAMTIN), teniposide (VUMON), or etoposide (EPOSIN).Cytotoxic antibiotics may be, for example, actinomycin D (dactinomycin, COSMEGEN), bleomycin (BLENOXANE), doxorubicin (ADRIAMYCIN), daunorubicin (CERUBIDINE), epirubicin (ELLENCE), fludarabine (FLUDARA), idarubicin (idarubicin), mitomycin (MITOSOL), mitoxantrone (NOYANTRONE) or plicamycin. Aromatase inhibitors may be, for example, aminoglutethimide, anastrozole (ARIMIDEX), letrozole (FEMARA), vorozole (RIYIZOR) or exemestane (AROMASIN). Angiogenesis inhibitors may be, for example, genistein, sunitinib (SUTENT) or bevacizumab (AYASTIN). Antisteroid or antiandrogen can be, for example, aminoglutethimide (CYTADREN), bicalutamide (CASODEX), cyproterone, flutamide (EULEXIN) or nilutamide (NILANDRON). Tyrosine kinase inhibitors can be, for example, imatinib (GLEEVEC), erlotinib (TARCEVA), afatinib (GILOTRIF), lapatinib (TYKERB), sorafenib (NEXAVAR) or axitinib (INLYTA). mTOR inhibitors can be, for example, everolimus, temsirolimus (TORISEL) or sirolimus. Monoclonal antibodies can be, for example, trastuzumab (HERCEPTIN) or rituximab (RITUXAN). Kinase inhibitors can be, for example, BRAF inhibitors, MEK inhibitors or KRAS inhibitors (for example, KRAS G12C inhibitors, such as sotorasib, adagrasib or BBO-8520).Additional examples of agents that can be used in combination with the compounds provided herein include, but are not limited to, amsacrine; Bacillus Calmette-Guérin (BCG) vaccine; buserelin (ETILAMIDE); chloroquine (ARALEN); clodronate, pamidronate and other bisphosphonates; colchicine; desmethoxyviridin; dichloroacetate; estramustine; filgrastim (NEUPOGEN); fludrocortisone (FLORINEF); goserelin (ZOLADEX); interferon; leucovorin; leuprorelin (LUPRON); levamisole; Lonidamine; mesna; metformin; mitotane (o,r'-DDD, LYSODREN); nocodazole; octreotide (SANDOSTATIN); perifosine; porfibril sodium (especially used in combination with phototherapy and radiation therapy); suramin; tamoxifen; titanium dichloride; tretinoin; anabolic steroids such as fluoxymesterone (HALOTESTIN); estrogens such as estradiol, diethylstilbestrol (DES), and dienstilbestrol; progestins such as medroxyprogesterone acetate (MPA) and megestrol acetate; and testosterone.

[0895] Exemplary Implementation

[0896] The following numbered embodiments, while not limiting, serve as examples of certain aspects of the present disclosure:

[0897] 1. A compound of formula I:

[0898]

[0899] or a salt thereof (e.g., a pharmaceutically acceptable salt), wherein:

[0900] Ring A is selected from phenyl and a 5- to 6-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur;

[0901] Ring B is selected from phenyl, a 6-membered heteroaromatic ring having 1-2 nitrogen atoms, and a 9- to 10-membered bicyclic ring containing at least one 5- or 6-membered heteroaromatic ring;

[0902] Ring C is selected from phenyl; a 5- to 6-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5- to 6-membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and a 9- to 10-membered spiro-fused heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein the phenyl, heteroaromatic, and heterocyclic rings are each optionally fused to Ring E;

[0903] Ring D is selected from phenyl and a 5- to 6-membered heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein the phenyl and heteroaryl ring are each optionally fused to Ring F;

[0904] Ring E is selected from 5 to 6 membered carbocyclic rings; 5 to 7 membered heterocyclic rings having 1-2 heteroatoms independently selected from nitrogen, oxygen and sulfur; and 5 to 6 membered heteroaromatic rings having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur, wherein Ring E is substituted by s R 5′ Instance replacement;

[0905] Ring F is selected from phenyl; a 5- to 6-membered carbocyclic ring; a 5- to 6-membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and a 5- to 6-membered heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein Ring F is substituted with u instances of -LW;

[0906] R 1 Selected from -LW, ring D' or a divalent C substituted by ring D' 1-6 aliphatic chains;

[0907] Each L is independently a divalent linear or branched C 1-8 an aliphatic chain, wherein one or more methylene units of the aliphatic chain are optionally and independently replaced by a group selected from the group consisting of: -N(R)-, -O-, -S-, -C(O)-, -SO2-, -CH(X)-, -C(X)2-, -C(O)N(R)-, -N(R)C(O)-, -C(O)O-, -OC(O)-, -SO2N(R)-, and -N(R)SO2-;

[0908] each W is independently hydrogen, halogen, -CN, or a 3-10 membered monocyclic or bicyclic, saturated, partially unsaturated, or aromatic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

[0909] Each X is independently halogen or -CN;

[0910] each ring D' is independently a 4- to 6-membered carbocyclic ring or a 4- to 6-membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein ring D' is substituted with t instances of -LW;

[0911] Each R 2 are independently selected from oxo, halogen, -CN, -OR and C 1-6 alkyl;

[0912] Each R 3 Independently selected from oxo, halogen, -CN, -OR, -O(CH2) v Cy, -OCH2CH2OR, -CH2CH2OR, C 1-6 Aliphatic and C 1-6 Halogenated fatty acids;

[0913] Each Cy is independently a 5- to 6-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3- to 6-membered carbocyclic ring; or a 4- to 6-membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein Cy is optionally substituted with 0-2 R 6 Instance replacement;

[0914] Each R 4 independently selected from halogen and C 1-6 aliphatic;

[0915] R 5 and R 5′ are each independently selected from oxo, =NH, -CN, halogen, -OR, -N(R)2, -SR, -C(O)R, -N(R)C(O)R, -(CH2) x C(O)N(R)2, -OC(O)R, -C(O)OR, -SO2R, -N(R)SO2R, -SO2N(R)2, -(CH2) x Cy and C 1-6 Aliphatic, C 1-6 aliphatic is unsubstituted or substituted with one or more halogen and -OR;

[0916] Each R 6 independently selected from oxo, -CN, halogen, -OR, -N(R)2, -SR, -C(O)R, -N(R)C(O)R, -C(O)N(R)2, -OC(O)R, -C(O)OR, -SO2R, -N(R)SO2R, -SO2N(R)2, and a group selected from the group consisting of: C 1-6 aliphatic; 3- to 6-membered carbocyclic ring; phenyl; 3- to 6-membered heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; 5- to 6-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; 10-membered aromatic ring; and 9- to 10-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;

[0917] Each R is independently hydrogen; C 1-6 Aliphatic; C 1-6 Halogenated aliphatic; 3- to 6-membered carbocyclic ring; phenyl; 3- to 6-membered heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; 5- to 6-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; 10-membered aromatic ring; and 9- to 10-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;

[0918] m is 0, 1, 2, or 3;

[0919] n is 0, 1, or 2;

[0920] p is 0, 1, or 2;

[0921] q is 0 or 1;

[0922] r is 0, 1, or 2;

[0923] s is 0, 1, or 2;

[0924] t is 0, 1, or 2;

[0925] u is 0 or 1;

[0926] each v is independently 0, 1 or 2; and

[0927] Each x is independently 0, 1 or 2.

[0928] 2. The compound according to embodiment 1, wherein L is a divalent linear or branched C 1-8 An aliphatic chain, wherein one or two methylene units of the aliphatic chain are optionally and independently replaced by a group selected from the group consisting of: -N(R)-, -O-, -S-, -C(O)-, -SO2-, -CH(X)-, -C(X)2-, -C(O)N(R)-, -N(R)C(O)-, -C(O)O-, -OC(O)-, -SON(R)-, and -N(R)SO2-.

[0929] 3. The compound according to embodiment 1 or 2, wherein L is a divalent linear or branched C 1-8 An aliphatic chain, wherein one or two methylene units of the aliphatic chain are optionally and independently replaced with a group selected from: -N(R)-, -O-, C(O)-, -C(O)N(R)-, and -N(R)C(O)-.

[0930] 4. The compound according to any one of embodiments 1 to 3, wherein L is a divalent linear or branched C 1-8 An aliphatic chain, wherein one or more methylene units of the aliphatic chain are optionally and independently replaced by a group selected from the group consisting of: -N(R)-, -O-, -S-, -C(O)-, -SO2-, -CH(X)-, -C(X)2-, -C(O)N(R)-, -N(R)C(O)-, -C(O)O-, -OC(O)-, -SON(R)-, and -N(R)SO2-.

[0931] 5. The compound according to embodiment 4, wherein L is a divalent linear or branched C 1-4An aliphatic chain, wherein one or more methylene units of the aliphatic chain are optionally and independently replaced by a group selected from the group consisting of: -N(R)-, -O-, -S-, -C(O)-, -SO2-, -CH(X)-, -C(X)2-, -C(O)N(R)-, -N(R)C(O)-, -C(O)O-, -OC(O)-, -SON(R)-, and -N(R)SO2-.

[0932] 6. The compound according to embodiment 5, wherein L is a divalent linear or branched C 1-4 An aliphatic chain, wherein one or two methylene units of the aliphatic chain are optionally and independently replaced by a group selected from the group consisting of: -N(R)-, -O-, -C(O)-, -SO2-, -C(O)N(R)-, -N(R)C(O)-, -C(O)O-, -OC(O)-, -SO2N(R)-, and -N(R)SO2-.

[0933] 7. The compound according to embodiment 6, wherein L is a divalent linear or branched C 1-4 An aliphatic chain, wherein one or two methylene units of the aliphatic chain are optionally and independently replaced with a group selected from the group consisting of -N(R)-, -C(O)-, and -N(R)C(O)-.

[0934] 8. A compound according to embodiment 1, wherein L is selected from -C(O)CClF-, -C(O)CH=CH-, -N(R)C(O)CH=CH-, -C(O)C(=CH2)-, -C(O)CH=CH-CH2-, -C(O)CH=CHCH2OCH2-, -C(O)CH=CHCH2N(R)-, -CH2N(R)C(O)CH=CH- and -CH2CH2N(R)C(O)CH=CH-.

[0935] 9. A compound according to embodiment 8, wherein L is selected from -C(O)CClF-, -C(O)CH=CH-, -NHC(O)CH=CH-, -C(O)C(=CH2)-, -C(O)CH=CH-CH2-, -C(O)CH=CHCH2OCH2-, -C(O)CH=CHCH2N(CH3)-, -CH2NHC(O)CH=CH- and -CH2CH2NHC(O)CH=CH-.

[0936] 10. The compound according to embodiment 1 or 2, wherein L is a divalent linear or branched C 1-8An alkyl chain in which one or more methylene units of the aliphatic chain are optionally and independently replaced by a group selected from the group consisting of: -N(R)-, -O-, -S-, -C(O)-, -SO2-, -CH(X)-, -C(X)2-, -C(O)N(R)-, -N(R)C(O)-, -C(O)O-, -OC(O)-, -SON(R)-, and -N(R)SO2-.

[0937] 11. A compound according to embodiment 1, wherein L is selected from -N(R)C(O)CH2CH2-, -N(R)C(O)CH(CH3)CH2-, -OCH(CH3)CH2-, -C(O)-, -C(O)CH2CH2-, -C(O)N(R)CH(CH3)CH2-, -C(O)N(R)CH2CH(CH3)CH2-, -CH2-, -CH(CH3)CH2-, -CH2C(CH3)2CH2-, -CH2C(O)-, -CH2C(O)N(R)CH(CH3)CH2-, -CH2C(O)N(R)CH2CH(CH3)CH2-, -CH2C(O)N(R) )C(CH3)2CH2-, -CH2CH2C(O)N(R)C(CH3)2CH2-, -CH2N(R)-, -CH2N(R)C(O)-, -CH2N(R)C(O)CH2CH2-, -CH2N(R)C(O) CH(CH3)CH2-, -CH2N(R)C(O)C(CH3)2CH2-, -CH2N(R)C(O)CH2C(CH3)2CH2-, -CH2CH2N(R)C(O)CH(CH3)CH2-, and -CH2O-.

[0938] 12. The compound according to embodiment 11, wherein L is selected from -N(H)C(O)CH2CH2-, -N(H)C(O)CH(CH3)CH2-, -OCH(CH3)CH2-, -C(O)-, -C(O)CH2CH2-, -C(O)N(H)CH(CH3)CH2-, -C(O)N(H)CH2CH(CH3)CH2-, -CH2-, -CH(CH3)CH2-, -CH2C(CH3)2CH2-, -CH2C(O)-, -CH2C(O)N( H)C(CH3)2CH2-, -CH2CH2C(O)N(H)C(CH3)2CH2-, -CH2N(H)-, -CH2N(H)C(O)-, -CH2N(H)C(O)CH2CH2-, –CH2N(H)C(O) CH(CH3)CH2-, -CH2N(H)C(O)C(CH3)2CH2-, -CH2N(H)C(O)CH2C(CH3)2CH2-, -CH2CH2N(H)C(O)CH(CH3)CH2-, and -CH2O-.

[0939] 13. The compound according to any one of embodiments 1 to 12, wherein W is hydrogen.

[0940] 14. The compound according to any one of embodiments 1-12, wherein W is halogen.

[0941] 15. The compound according to embodiment 1, wherein -LW is selected from -CH3, -CH(CH3)2, -CH2C(CH3)3, -CH2OH, -CH2NH2, -OCH(CH3)2,

[0942] 16. A compound according to embodiment 1, wherein -LW is selected from -C(O)CH=CH2, -C(O)CF=CH2, -NHC(O)CF=CH2 and -NHC(O)CH=CH2.

[0943] 17. The compound according to embodiment 1, wherein R 1 Selected from -CH3, -CH(CH3)2, -CH2C(CH3)3, -CH2NH2, -CH2OH, -OCH(CH3)2,

[0944] 18. The compound according to any one of embodiments 1 to 17, wherein ring B is a 9- to 10-membered bicyclic ring comprising at least one 5- or 6-membered heteroaromatic ring comprising at least one nitrogen atom.

[0945] 19. The compound according to any one of embodiments 1-18, wherein n R 4 Example substituted ring B is selected from

[0946]

[0947] 20. The compound according to any one of embodiments 1-19, wherein the compound is selected from Formula Ia, Ib, Ic, Id, Ie, If, Ig and Ih:

[0948]

[0949]

[0950] or a pharmaceutically acceptable salt thereof.

[0951] 21. A compound according to any one of embodiments 1-20, wherein each R 4 It is a halogen.

[0952] 22. The compound according to any one of embodiments 1-20, wherein n is 0.

[0953] 23. The compound according to any one of embodiments 1-22, wherein ring A is phenyl.

[0954] 24. The compound according to any one of embodiments 1-23, wherein ring A is

[0955] 25. The compound according to embodiment 24, wherein ring A is selected from

[0956]

[0957] 26. The compound according to embodiment 25, wherein ring A is selected from

[0958]

[0959] 27. The compound according to embodiment 26, wherein R 3 Selected from halogen, -OR, -O(CH2) v Cy and -OCH2CH2OR.

[0960] 28. The compound according to any one of embodiments 1-27, wherein m R 3 Example substituted ring A is selected from

[0961]

[0962] 29. The compound according to any one of embodiments 1-22, wherein Ring A is a 5- to 6-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur.

[0963] 30. The compound according to embodiment 29, wherein m R 3 Example substituted ring A is selected from

[0964]

[0965] 31. The compound according to any one of embodiments 1 to 30, wherein m is 1, 2 or 3.

[0966] 32. The compound according to any one of embodiments 1-31, wherein at least one R 3 Selected from halogen, -OR, -O(CH2) v Cy and -OCH2CH2OR.

[0967] 33. The compound according to any one of embodiments 1-32, wherein ring C is phenyl.

[0968] 34. The compound according to any one of embodiments 1-32, wherein Ring C is a 5- to 6-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur.

[0969] 35. The compound according to any one of embodiments 1-32, wherein Ring C is a 5- to 6-membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen and sulfur.

[0970] 36. The compound according to any one of embodiments 1-32, wherein Ring C is a 9- to 10-membered spiro-fused heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur.

[0971] 37. The compound according to any one of embodiments 1-32, wherein 5 Example substituted ring C is selected from

[0972]

[0973]

[0974] 38. The compound according to any one of embodiments 1 to 36, wherein ring C is fused to ring E.

[0975] 39. The compound according to embodiment 38, wherein the compound is selected from the group consisting of formula Iai, Ibi, Ici, Idi, Iei, Ifi, Igi and Ihi:

[0976]

[0977]

[0978] or a pharmaceutically acceptable salt thereof.

[0979] 40. The compound according to embodiment 39, wherein Selected from

[0980]

[0981] 41. The compound according to any one of embodiments 38-40, wherein Ring E is a 5- to 7-membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen and sulfur, wherein Ring E is substituted by s R 5′ Instance replacement.

[0982] 42. The compound according to embodiment 41, wherein 5’ Example substituted ring E is selected from

[0983]

[0984] 43. The compound according to any one of embodiments 38-40, wherein ring E is a 5- to 6-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur, wherein ring E is substituted by s R 5′ Instance replacement.

[0985] 44. The compound according to embodiment 19, wherein 5’ Example substituted ring E is selected from

[0986]

[0987] 45. The compound according to any one of embodiments 38-40, wherein ring E is substituted with 3 R 5’ Examples include substituted 5- to 6-membered carbocyclic rings.

[0988] 46. ​​The compound according to embodiment 45, wherein 5’ Example substituted ring E is selected from

[0989]

[0990] 47. A compound according to any one of embodiments 38-40, wherein Selected from

[0991]

[0992] 48. The compound according to any one of embodiments 1-47, wherein p is 1 or 2.

[0993] 49. A compound according to any one of embodiments 1-48, wherein each R 5 independently selected from oxo, -CN, halogen, -N(R)2, -(CH2) x C(O)N(R)2, -SO2R, -SO2N(R)2, -(CH2) x Cy and C 1-6 Aliphatic, C 1-6 Aliphatic groups are unsubstituted or substituted with one or more halogen and -OR.

[0994] 50. A compound according to any one of embodiments 1-49, wherein each R 5’ independently selected from oxo, =NH, -OR, -N(R)2 and C 1-6 Aliphatic, C 1-6 Aliphatic groups are unsubstituted or substituted with one or more halogen and -OR.

[0995] 51. The compound according to any one of embodiments 1-50, wherein ring D is phenyl.

[0996] 52. The compound according to any one of embodiments 1-50, wherein ring D is a 5- to 6-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur.

[0997] 53. A compound according to any one of embodiments 1-52, wherein 2 Examples and q R 1 Example substituted ring D is selected from

[0998]

[0999] 54. The compound according to any one of embodiments 1-52, wherein ring D is fused to ring F.

[1000] 55. The compound according to embodiment 54, wherein q is 0.

[1001] 56. The compound according to any one of embodiments 1-52, 54 and 55, wherein the compound is selected from formula Ia-ii, Ib-ii, Ic-ii, Id-ii, Ie-ii, If-ii, Ig-ii and Ih-ii:

[1002]

[1003] or a pharmaceutically acceptable salt thereof.

[1004] 57. The compound according to embodiment 56, wherein Selected from

[1005]

[1006] 58. The compound according to any one of embodiments 1-52 and 54-57, wherein ring F is phenyl substituted with u instances of -LW.

[1007] 59. The compound according to embodiment 58, wherein the ring F substituted with u instances of -LW is selected from

[1008]

[1009] 60. The compound according to embodiment 56, wherein Selected from

[1010]

[1011] 61. The compound according to any one of embodiments 1-52, 54-57 and 60, wherein Ring F is a 5- to 6-membered carbocyclic ring substituted with u instances of —LW.

[1012] 62. The compound according to embodiment 61, wherein the ring F substituted with u instances of -LW is

[1013] 63. The compound according to any one of embodiments 1-52, 54-57 and 60, wherein Ring F is a 5- to 6-membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen and sulfur, wherein Ring F is substituted with u instances of -LW.

[1014] 64. The compound according to embodiment 63, wherein the ring F substituted with u instances of -LW is selected from

[1015]

[1016] 65. The compound according to any one of embodiments 1-52, 54-57 and 60, wherein Ring F is a 5- to 6-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur, wherein Ring F is substituted with u instances of -LW.

[1017] 66. The compound according to embodiment 65, wherein ring F substituted with u instances of -LW is

[1018] 67. The compound according to embodiment 56, wherein Selected from

[1019]

[1020] 68. A compound according to any one of embodiments 1-52, wherein R 1 is ring D'.

[1021] 69. The compound according to embodiment 68, wherein ring D is not fused to ring F.

[1022] 70. The compound according to any one of embodiments 1-52, wherein the compound is selected from formula Ia-iii, Ib-iii, Ic-iii, Id-iii, Ie-iii, If-iii, Ig-iii and Ih-iii:

[1023]

[1024] or a pharmaceutically acceptable salt thereof.

[1025] 71. The compound according to embodiment 70, wherein 2 Example substituted ring D is selected from

[1026]

[1027] 72. The compound according to any one of embodiments 1-52 and 68-71, wherein Ring D' is a 4- to 6-membered carbocyclic ring substituted with t instances of -LW.

[1028] 73. The compound according to any one of embodiments 1-52 and 68-71, wherein Ring D' is a 4- to 6-membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen and sulfur, wherein Ring D' is substituted with t instances of -LW.

[1029] 74. The compound according to any one of embodiments 1-52 and 68-71, wherein the ring D′ substituted with t instances of —LW is selected from

[1030]

[1031] 75. The compound according to embodiment 70, wherein Selected from

[1032]

[1033] 76. The compound according to any one of embodiments 1-52 and 68-75, wherein the compound is selected from formula Ia-iv, Ib-iv, Ic-iv, Id-iv, Ie-iv, If-iv, Ig-iv and Ih-iv:

[1034]

[1035] or a pharmaceutically acceptable salt thereof.

[1036] 77. The compound according to any one of embodiments 1-36, 38-52 and 54-67, wherein the compound is selected from the group consisting of formula Iav, Ibv, Icv, Idv, Iev, Ifv, Igv and Ihv:

[1037]

[1038] or a pharmaceutically acceptable salt thereof.

[1039] 78. The compound according to any one of embodiments 1-52 and 68-76, wherein the compound is selected from formula II, Im, In, Ip and Iq:

[1040]

[1041] or a pharmaceutically acceptable salt thereof.

[1042] 79. The compound according to any one of embodiments 1-78, wherein t is 1.

[1043] 80. The compound according to any one of embodiments 1-79, wherein q is 1.

[1044] 81. The compound according to any one of embodiments 1-80, wherein v is 0 or 1.

[1045] 82. The compound according to any one of embodiments 1-81, wherein x is 0 or 1.

[1046] 83. A compound according to any one of embodiments 1-82, wherein each R is independently hydrogen, C 1-6 Aliphatic or C 1-6 Halogenated fatty acids.

[1047] 84. A compound selected from Table 1 or a pharmaceutically acceptable salt thereof.

[1048] 85. A pharmaceutical composition comprising a compound according to any one of embodiments 1-84 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

[1049] 86. A method comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to any one of embodiments 1-84, or a pharmaceutically acceptable salt thereof.

[1050] 87. The method of embodiment 86, wherein the subject suffers from a disease, disorder or condition that is ameliorated by disrupting, inhibiting and / or preventing the interaction between a small GTPase and a PI3K alpha protein.

[1051] 88. The method of embodiment 87, wherein the small GTPase is Racl, CDC42 or RAS protein.

[1052] 89. The method of embodiment 88, wherein the small GTPase is a RAS protein.

[1053] 90. The method of embodiment 89, wherein the RAS protein is KRAS, NRAS, HRAS, RRAS, RRAS2, MRAS, or RIT1.

[1054] 91. The method of any one of embodiments 86-90, wherein the subject has cancer.

[1055] 92. A method of treating cancer comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to any one of embodiments 1-84, or a pharmaceutically acceptable salt thereof.

[1056] 93. The method according to embodiment 91 or 92, wherein the cancer is associated with and / or characterized by aberrant activation of PI3Kα and / or mutations in PI3Kα.

[1057] 94. The method of claim 93, wherein the PI3Kα protein comprises N345K, E726K, C420R, Q546R, G118D, E453K, Q546K, G1049R, M1043I, K111E, K111N, E81K, E545A, E545G, N1044K, E110del, Q546P, E542K, E545K, H1047R and / or H1047L mutations.

[1058] 95. The method according to any one of embodiments 91-94, wherein the cancer is characterized by a mutation in a RAS protein.

[1059] 96. The method of embodiment 95, wherein the RAS protein comprises a mutation in codon 12, 13, or 61.

[1060] 97. The method according to embodiment 95 or 96, wherein the RAS protein is KRAS.

[1061] 98. The method of embodiment 97, wherein the KRAS protein comprises G12C, G12D, G12S, G12V, G12R, G12A, G13D, G13A, G13C, G13R, G13S, G13V, Q61E, Q61K, Q61L, Q61P, Q61R and / or Q61H mutations.

[1062] 99. The method of embodiment 95 or 96, wherein the RAS protein is HRAS.

[1063] 100. The method of claim 99, wherein the HRAS protein comprises G12C, G12D, G12S, G12V, G12R, G12A, G13D, G13C, G13R, G13S, G13V, Q61K, Q61L, Q61P, Q61R, and / or Q61H mutations.

[1064] 101. The method of embodiment 95 or 96, wherein the RAS protein is NRAS.

[1065] 102. The method of claim 101, wherein the NRAS protein comprises a G12C, G12D, G12S, G12V, G12R, G12A, G13D, G13A, G13C, G13R, G13S, G13V, Q61E, Q61K, Q61L, Q61P, Q61R, and / or Q61H mutation.

[1066] 103. The method according to any one of embodiments 91-102, wherein the cancer is selected from pancreatic cancer; colon cancer; rectal cancer; colorectal cancer; breast cancer; ovarian cancer; endometrial cancer; lung cancer; prostate cancer; oral and pharyngeal cancer (lip cancer, tongue cancer, mouth cancer, larynx cancer, pharynx cancer), esophageal cancer, stomach cancer, small intestine cancer, large intestine cancer, liver cancer and bile duct cancer, bone cancer, connective tissue cancer, skin cancer, cervical cancer, uterine cancer, endometrial cancer, testicular cancer, bladder cancer, kidney cancer and other urinary tissue cancers, including renal cell carcinoma (RCC); Cancers of the eye, brain, spinal cord, and other components of the central and peripheral nervous systems, and related structures such as the meninges; thyroid and other endocrine gland cancers; Hodgkin's disease; non-Hodgkin's lymphoma; multiple myeloma; and hematopoietic malignancies, including leukemias (chronic lymphocytic leukemia (CLL), acute lymphocytic leukemia (ALL), chronic myeloid leukemia (CML), acute myeloid leukemia (AML)) and lymphomas, including lymphocytic, granulocytic, and monocytic lymphomas.

[1067] 104. The method of claim 103, wherein the cancer is selected from breast cancer, lung cancer (e.g., non-small cell lung cancer), endometrial cancer, esophageal cancer, ovarian cancer, colorectal cancer, gastric cancer, squamous cell carcinoma, prostate cancer, and pancreatic cancer.

[1068] 105. The method according to any one of embodiments 91-104, wherein the cancer is characterized by a mutated, overexpressed and / or amplified receptor tyrosine kinase (e.g., HER family, Met, FGFR, Alk, PDGF, EGFR, or ROS kinase).

[1069] 106. The method according to any one of embodiments 91-105, wherein the cancer is characterized by a mutation or deletion in the PTEN protein.

[1070] 107. The method according to any one of embodiments 86-106, wherein the subject has previously received a cancer treatment regimen.

[1071] 108. The method according to any one of embodiments 86-107, wherein the subject has previously entered cancer remission.

[1072] 109. A method of treating a metabolic disorder comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to any one of embodiments 1-84, or a pharmaceutically acceptable salt thereof.

[1073] 110. The method according to embodiment 109, wherein the metabolic disorder is selected from hyperinsulinemia and type 2 diabetes.

[1074] 111. A method of treating a RASopathy, comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to any one of embodiments 1-84, or a pharmaceutically acceptable salt thereof.

[1075] 112. The method according to embodiment 111, wherein the RASopathy is selected from neurofibromatosis type 1 (NF1), capillary malformation-arteriovenous malformation syndrome, and Legius syndrome.

[1076] 113. A method of treating a vascular condition or disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to any one of embodiments 1-84, or a pharmaceutically acceptable salt thereof.

[1077] 114. The method of claim 113, wherein the vascular disorder or condition is selected from PIK3CA-associated overgrowth syndrome (PROS) and vascular malformations (e.g., venous malformations; lymphatic malformations; congenital lipomatous overgrowth with vascular, epidermal, and skeletal anomalies syndrome (CLOVES); Klippel-Trenaunay syndrome; PTEN hamartoma tumor syndrome (PHTS); and fibrofatty vascular anomaly (FAVA)).

[1078] 115. A method of disrupting the interaction between a small GTPase and a PI3Kα protein in a subject, comprising administering to the subject a compound according to any one of embodiments 1-84, or a pharmaceutically acceptable salt thereof.

[1079] 116. A method of disrupting the interaction between a small GTPase and a PI3Kα protein, comprising contacting a cell containing a small GTPase and a PI3Kα protein with a compound according to any one of embodiments 1-84 or a pharmaceutically acceptable salt thereof.

[1080] 117. A method comprising contacting a cell containing a small GTPase and a PI3K alpha protein with a compound according to any one of embodiments 1-84, or a pharmaceutically acceptable salt thereof.

[1081] 118. The method of embodiment 116 or 117, wherein the cell is comprised in a subject.

[1082] 119. The method according to any one of embodiments 115-118, wherein the small GTPase is selected from Racl, CDC42 and RAS proteins.

[1083] 120. The method of embodiment 119, wherein the small GTPase is a RAS protein.

[1084] 121. The method of embodiment 120, wherein the RAS protein is selected from HRAS, NRAS, KRAS, RRAS, RRAS2, MRAS and RIT1.

[1085] 122. The method of embodiment 121, wherein the RAS protein is KRAS.

[1086] 123. The method of claim 122, wherein the KRAS protein comprises a G12C, G12D, G12S, G12V, G12R, G12A, G13D, G13A, G13C, G13R, G13S, G13V, Q61E, Q61K, Q61L, Q61P, Q61R, and / or Q61H mutation.

[1087] 124. The method of embodiment 121, wherein the RAS protein is HRAS.

[1088] 125. The method of embodiment 124, wherein the HRAS protein comprises G12C, G12D, G12S, G12V, G12R, G12A, G13D, G13C, G13R, G13S, G13V, Q61K, Q61L, Q61P, Q61R and / or Q61H mutations.

[1089] 126. The method of embodiment 121, wherein the RAS protein is NRAS.

[1090] 127. The method of claim 126, wherein the NRAS protein comprises G12C, G12D, G12S, G12V, G12R, G12A, G13D, G13A, G13C, G13R, G13S, G13V, Q61E, Q61K, Q61L, Q61P, Q61R, and / or Q61H mutations.

[1091] 128. A compound according to any one of embodiments 1-84, or a pharmaceutically acceptable salt thereof, for use as a medicament.

[1092] 129. Use of a compound according to any one of embodiments 1-84 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament.

[1093] 130. The compound or use according to embodiment 128 or 129, wherein the medicament is for the treatment of cancer.

[1094] 131. The compound or use according to embodiment 130, wherein the cancer is associated with and / or characterized by aberrant activation of PI3Kα and / or mutations in PI3Kα.

[1095] 132. The compound or use according to embodiment 131, wherein the PI3Kα protein comprises N345K, E726K, C420R, Q546R, G118D, E453K, Q546K, G1049R, M1043I, K111E, K111N, E81K, E545A, E545G, N1044K, E110del, Q546P, E542K, E545K, H1047R and / or H1047L mutations.

[1096] 133. The compound or use according to any one of embodiments 130-132, wherein the cancer is characterized by a mutation in a RAS protein.

[1097] 134. The compound or use according to embodiment 133, wherein the RAS protein comprises a mutation in codon 12, 13 or 61.

[1098] 135. The compound or use according to embodiment 133 or 134, wherein the RAS protein is KRAS.

[1099] 136. The compound or use according to embodiment 135, wherein the KRAS protein comprises a G12C, G12D, G12S, G12V, G12R, G12A, G13D, G13A, G13C, G13R, G13S, G13V, Q61E, Q61K, Q61L, Q61P, Q61R and / or Q61H mutation.

[1100] 137. The compound or use according to embodiment 133 or 134, wherein the RAS protein is HRAS.

[1101] 138. The compound of embodiment 137, wherein the HRAS protein comprises G12C, G12D, G12S, G12V, G12R, G12A, G13D, G13C, G13R, G13S, G13V, Q61K, Q61L, Q61P, Q61R and / or Q61H mutations.

[1102] 139. The compound or use according to embodiment 133 or 134, wherein the RAS protein is NRAS.

[1103] 140. The compound or use according to embodiment 139, wherein the NRAS protein comprises a G12C, G12D, G12S, G12V, G12R, G12A, G13D, G13A, G13C, G13R, G13S, G13V, Q61E, Q61K, Q61L, Q61P, Q61R and / or Q61H mutation.

[1104] 141. The compound or use according to any one of embodiments 130-140, wherein the cancer is selected from pancreatic cancer; colon cancer; rectal cancer; colorectal cancer; breast cancer; ovarian cancer; endometrial cancer; lung cancer; prostate cancer; oral and pharyngeal cancer (lip cancer, tongue cancer, mouth cancer, larynx cancer, pharyngeal cancer), esophageal cancer, stomach cancer, small intestine cancer, large intestine cancer, liver cancer and bile duct cancer, bone cancer, connective tissue cancer, skin cancer, cervical cancer, uterine cancer, endometrial cancer, testicular cancer, bladder cancer, kidney cancer and other urinary tissue cancers, including renal cell carcinoma (RCC) ); cancers of the eye, brain, spinal cord, and other components of the central and peripheral nervous systems, and related structures such as the meninges; thyroid and other endocrine gland cancers; Hodgkin's disease; non-Hodgkin's lymphoma; multiple myeloma; and hematopoietic malignancies, including leukemias (chronic lymphocytic leukemia (CLL), acute lymphocytic leukemia (ALL), chronic myeloid leukemia (CML), acute myeloid leukemia (AML)) and lymphomas, including lymphocytic, granulocytic, and monocytic lymphomas.

[1105] 142. The compound or use according to embodiment 141, wherein the cancer is selected from breast cancer, lung cancer (e.g., non-small cell lung cancer), endometrial cancer, esophageal cancer, ovarian cancer, colorectal cancer, gastric cancer, squamous cell carcinoma, prostate cancer, and pancreatic cancer.

[1106] 143. The compound or use according to any one of embodiments 130-142, wherein the cancer is characterized by a mutated, overexpressed and / or amplified receptor tyrosine kinase (e.g., HER family, Met, FGFR, Alk, PDGF, EGFR or ROS kinase).

[1107] 144. The compound or use according to any one of embodiments 130-143, wherein the cancer is characterized by a mutation or deletion in the PTEN protein.

[1108] 145. The compound or use according to embodiment 128 or 129, wherein the medicament is for treating a metabolic disorder, a RASopathy, or a vascular disorder.

[1109] 146. A compound or use according to embodiment 145, wherein: (i) the metabolic disorder is selected from hyperinsulinemia and type 2 diabetes; (ii) the RASopathy is selected from neurofibromatosis type 1 (NF1), capillary malformation-arteriovenous malformation syndrome, and Legius syndrome; or (iii) the vascular disorder or condition is selected from PIK3CA-associated overgrowth syndrome (PROS) and vascular malformations (e.g., venous malformations; lymphatic malformations; congenital lipomatous overgrowth with vascular, epidermal, and skeletal anomalies syndrome (CLOVES); Klippel-Trenaunay syndrome; PTEN hamartoma tumor syndrome (PHTS); or fibrofatty vascular dysplasia (FAVA)).

[1110] 147. A compound according to any one of embodiments 1-84, or a pharmaceutically acceptable salt thereof, for use in treating a disease, disorder or condition.

[1111] 148. A compound for use according to embodiment 147 for the treatment of cancer.

[1112] 149. The compound for use according to embodiment 148, wherein the cancer is associated with and / or characterized by aberrant activation of PI3Kα and / or mutations in PI3Kα.

[1113] 150. The compound for use according to embodiment 149, wherein the PI3Kα protein comprises N345K, E726K, C420R, Q546R, G118D, E453K, Q546K, G1049R, M1043I, K111E, K111N, E81K, E545A, E545G, N1044K, E110del, Q546P, E542K, E545K, H1047R and / or H1047L mutations.

[1114] 151. A compound for use according to any one of embodiments 148-150, wherein the cancer is characterized by a mutation in a RAS protein.

[1115] 152. The compound for use according to embodiment 151, wherein the RAS protein comprises a mutation in codon 12, 13 or 61.

[1116] 153. The compound for use according to embodiment 151 or 152, wherein the RAS protein is KRAS.

[1117] 154. A compound for use according to embodiment 153, wherein the KRAS protein comprises a G12C, G12D, G12S, G12V, G12R, G12A, G13D, G13A, G13C, G13R, G13S, G13V, Q61E, Q61K, Q61L, Q61P, Q61R and / or Q61H mutation.

[1118] 155. The compound for use according to embodiment 151 or 152, wherein the RAS protein is HRAS.

[1119] 156. A compound for use according to embodiment 155, wherein the HRAS protein comprises G12C, G12D, G12S, G12V, G12R, G12A, G13D, G13C, G13R, G13S, G13V, Q61K, Q61L, Q61P, Q61R and / or Q61H mutations.

[1120] 157. The compound for use according to embodiment 151 or 152, wherein the RAS protein is NRAS.

[1121] 158. The compound for use according to embodiment 157, wherein the NRAS protein comprises a G12C, G12D, G12S, G12V, G12R, G12A, G13D, G13A, G13C, G13R, G13S, G13V, Q61E, Q61K, Q61L, Q61P, Q61R and / or Q61H mutation.

[1122] 159. A compound for use according to any one of embodiments 148-158, wherein the cancer is selected from pancreatic cancer; colon cancer; rectal cancer; colorectal cancer; breast cancer; ovarian cancer; endometrial cancer; lung cancer; prostate cancer; oral and pharyngeal cancer (lip cancer, tongue cancer, mouth cancer, larynx cancer, pharyngeal cancer), esophageal cancer, stomach cancer, small intestine cancer, large intestine cancer, liver cancer and bile duct cancer, bone cancer, connective tissue cancer, skin cancer, cervical cancer, uterine cancer, endometrial cancer, testicular cancer, bladder cancer, kidney cancer and other urinary tissue cancers, including renal cell carcinoma (RCC) ); cancers of the eye, brain, spinal cord, and other components of the central and peripheral nervous systems, and related structures such as the meninges; thyroid and other endocrine gland cancers; Hodgkin's disease; non-Hodgkin's lymphoma; multiple myeloma; and hematopoietic malignancies, including leukemias (chronic lymphocytic leukemia (CLL), acute lymphocytic leukemia (ALL), chronic myeloid leukemia (CML), acute myeloid leukemia (AML)) and lymphomas, including lymphocytic, granulocytic, and monocytic lymphomas.

[1123] 160. A compound for use according to embodiment 159, wherein the cancer is selected from breast cancer, lung cancer (e.g., non-small cell lung cancer), endometrial cancer, esophageal cancer, ovarian cancer, colorectal cancer, gastric cancer, squamous cell carcinoma, prostate cancer, and pancreatic cancer.

[1124] 161. A compound for use according to any one of embodiments 148-160, wherein the cancer is characterized by a mutated, overexpressed and / or amplified receptor tyrosine kinase (e.g., HER family, Met, FGFR, Alk, PDGF, EGFR or ROS kinase).

[1125] 162. A compound for use according to any one of embodiments 148-161, wherein the cancer is characterized by a mutation or deletion in the PTEN protein.

[1126] 163. A compound for use according to embodiment 147 for the treatment of a metabolic disorder, a RASopathy or a vascular disorder.

[1127] 164. A compound for use according to embodiment 163, wherein: (i) the metabolic disorder is selected from hyperinsulinemia and type 2 diabetes; (ii) the RASopathy is selected from neurofibromatosis type 1 (NF1), capillary malformation-arteriovenous malformation syndrome, and Legius syndrome; or (iii) the vascular disorder or condition is selected from PIK3CA-associated overgrowth syndrome (PROS) and vascular malformations (e.g., venous malformations; lymphatic malformations; congenital lipomatous overgrowth with vascular, epidermal, and skeletal anomalies syndrome (CLOVES); Klippel-Trenaunay syndrome; PTEN hamartoma tumor syndrome (PHTS); and fibrofatty vascular dysplasia (FAVA)).

[1128] 165. A compound capable of disrupting the interaction between a small GTPase and a PI3Kα protein.

[1129] 166. A compound according to embodiment 165, wherein the compound is capable of binding to PI3Kα such that (i) the interaction between the small GTPase and PI3Kα is at least partially disrupted, prevented or inhibited; and / or (ii) the kinase activity of PI3Kα is not significantly inhibited.

[1130] 167. The compound according to embodiment 165 or 166, wherein the compound has the following activity:

[1131] (i) <5 μM or ≥5 μM and ≤25 μM in an assay of Biological Example 1 (e.g., a surface plasmon resonance (SPR) binding assay assessing inhibition of KRAS-PI3Kα interaction);

[1132] (ii) ≥75%, <75% and ≥50%, or <50% and ≥25%, as determined in Biological Example 2 (e.g., matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) analysis with covalent modification of Cys242 in human PIK3CA(157-299));

[1133] (iii) <1 μM or ≥1 μM and ≤10 μM in an assay of Biological Example 3 (e.g., a matrix-assisted cell-based pAKT homogeneous time-resolved fluorescence (HTRF) assay in Tet-on KRASG12D HeLa cells); and / or

[1134] (iv) <0.1 μM, ≥0.1 μM and ≤1 μM, or ≥1 μM and ≤3 μM in an assay of Biological Example 4 (eg, a matrix-assisted cell-based pAKT HTRF assay in BT474 cells).

[1135] 168. The compound according to any one of embodiments 165-167, wherein the compound comprises an electrophilic moiety.

[1136] 169. The compound according to any one of embodiments 165-168, wherein said compound is capable of interacting with the Cys242 residue in the catalytic subunit of PI3Kα.

[1137] 170. The compound according to any one of embodiments 165-169, wherein the compound is capable of irreversibly binding to PI3Kα protein.

[1138] 171. The compound according to any one of embodiments 165-169, wherein the compound is capable of reversibly binding to PI3Kα protein.

[1139] 172. The compound according to any one of embodiments 165-171, wherein the small GTPase is Racl, CDC42 or a RAS protein.

[1140] 173. A compound according to embodiment 172, wherein the RAS protein is KRAS, NRAS, HRAS, RRAS, RRAS2, MRAS or RIT1.

[1141] 174. A compound according to embodiment 173, wherein the RAS protein comprises a mutation in codon 12, 13 or 61.

[1142] 175. The compound according to embodiment 173 or 174, wherein the RAS protein is KRAS.

[1143] 176. The compound of embodiment 175, wherein the KRAS protein comprises G12C, G12D, G12S, G12V, G12R, G12A, G13D, G13A, G13C, G13R, G13S, G13V, Q61E, Q61K, Q61L, Q61P, Q61R and / or Q61H mutations.

[1144] 177. The compound according to embodiment 173 or 174, wherein the RAS protein is HRAS.

[1145] 178. The compound of embodiment 177, wherein the HRAS protein comprises G12C, G12D, G12S, G12V, G12R, G12A, G13D, G13C, G13R, G13S, G13V, Q61K, Q61L, Q61P, Q61R and / or Q61H mutations.

[1146] 179. The compound according to embodiment 173 or 174, wherein the RAS protein is NRAS.

[1147] 180. The compound of embodiment 179, wherein the NRAS protein comprises G12C, G12D, G12S, G12V, G12R, G12A, G13D, G13A, G13C, G13R, G13S, G13V, Q61E, Q61K, Q61L, Q61P, Q61R and / or Q61H mutations.

[1148] 181. The compound of any one of embodiments 165-180, wherein the compound is according to any one of embodiments 1-84.

[1149] 182. A method of disrupting, inhibiting or preventing the interaction between a small GTPase and a PI3Kα protein, comprising contacting a cell containing a small GTPase and a PI3Kα protein with a compound according to any one of embodiments 165-181 or a pharmaceutically acceptable salt thereof.

[1150] 183. The method of embodiment 182, wherein the cell is within a subject.

[1151] 184. The method according to embodiment 182 or 183, wherein the small GTPase is Racl, CDC42 or RAS protein.

[1152] 185. The method of embodiment 184, wherein the RAS protein is KRAS, NRAS, HRAS, RRAS, RRAS2, MRAS, or RIT1.

[1153] 186. The method of embodiment 185, wherein the RAS protein comprises a mutation in codon 12, 13, or 61.

[1154] 187. The method of embodiment 185 or 186, wherein the RAS protein is KRAS.

[1155] 188. The method of embodiment 187, wherein the KRAS protein comprises G12C, G12D, G12S, G12V, G12R, G12A, G13D, G13A, G13C, G13R, G13S, G13V, Q61E, Q61K, Q61L, Q61P, Q61R and / or Q61H mutations.

[1156] 189. The method of embodiment 185 or 186, wherein the RAS protein is HRAS.

[1157] 190. The method of embodiment 189, wherein the HRAS protein comprises G12C, G12D, G12S, G12V, G12R, G12A, G13D, G13C, G13R, G13S, G13V, Q61K, Q61L, Q61P, Q61R and / or Q61H mutations.

[1158] 191. The method of embodiment 185 or 186, wherein the RAS protein is NRAS.

[1159] 192. The method of claim 191, wherein the NRAS protein comprises G12C, G12D, G12S, G12V, G12R, G12A, G13D, G13A, G13C, G13R, G13S, G13V, Q61E, Q61K, Q61L, Q61P, Q61R, and / or Q61H mutations.

[1160] Example

[1161] As described in the examples below, in certain exemplary embodiments, compounds are prepared according to the following general procedures. It should be understood that although the general methods describe the synthesis of certain compounds of the present disclosure, the following general methods and other methods known to those of ordinary skill in the art can be applied to all compounds as described herein and subclasses and species of each of these compounds.

[1162] Table 3 summarizes selected abbreviations used in the preceding sections and examples.

[1163] Table 3. Abbreviations.

[1164]

[1165]

[1166] Materials and methods

[1167] Preparative thin layer chromatography (PTLC) separations described herein were typically performed on 20 x 20 cm plates (500-μm thick silica gel).

[1168] Chromatographic purification is typically performed using Biotage Isolera. An automated system (Biotage LLC, Charlotte, NC) running Biotage Isolera One 2.0.6 software is used. Flow rates are the default values ​​specified for the columns used. Reverse phase chromatography is performed using an elution gradient of water and acetonitrile on KP-C18-HS Flash+ columns (Biotage LLC) of various sizes. Typical loadings are between 1:50 and 1:1000 crude sample:RP SiO2 by weight. Normal phase chromatography is performed using an elution gradient of various solvents (e.g., hexane, ethyl acetate, dichloromethane, methanol, acetone, chloroform, MTBE, etc.). The column is a SNAP column (Biotage LLC) containing KP-SIL or SNAP Ultra (25 μm spherical particles) of various sizes. Typical loadings are between 1:10 and 1:150 crude sample:SiO2 by weight. Alternatively, silica gel chromatography is performed on a Biotage Horizon flash chromatography system.

[1169] Intermediates and exemplary compounds 1 HNMR analysis was typically performed on a Bruker Ascend™ 400 spectrometer (running at 400 MHz), a Bruker Ascend 500 MHz Avance Neo spectrometer (Bruker-Biospin), or a Bruker Avance Neo Nanobay (running at 400 MHz) at 298 K following the manufacturer's recommended standard operating procedures. TMS was used as an internal standard to set the reference frequency. Chemical shift values ​​(δ) were reported in parts per million (ppm), with the splitting patterns abbreviated as: s (singlet), br.s (broad singlet), d (doublet), dd (two doublets), t (triplet), and m (multiplet). Coupling constants (J) were given in Hz. Typical deuterated solvents were used as shown in the individual examples.

[1170] LCMS analysis is typically performed using one of the following conditions:

[1171] (1) LCMS spectra were acquired on an Agilent Technologies 6120B quadrupole spectrometer. The LC mobile phase consisted of acetonitrile containing 0.1% formic acid (A) and water containing 0.1% formic acid (B), with an eluent gradient of 5-95% A in 6.0 min, 5%-40% A in 6.0 min, and 80-100% A in 6.0 min, using a poroshell 120EC-C18 50 mm x 3.0 mm x 2.7 μM capillary column; flow rate: 0.7 mL / min. Mass spectra (MS) were measured by electrospray ionization mass spectrometry (ESI). All temperatures are in degrees Celsius (°C) unless otherwise stated.

[1172] (2) LCMS spectra were acquired on an Agilent Technologies 1290-6420 triple quadrupole spectrometer: the LC mobile phase consisted of acetonitrile (A) containing 0.05% formic acid and water (B) containing 0.05% formic acid, with a gradient of 5–95% A in 5.0 min, using a ZORBAX SB-C18 50 mm x 2.1 mm x 1.8 μM capillary column; flow rate: 0.3 mL / min. Mass spectra (MS) were measured by electrospray ionization (ESI). All temperatures are in degrees Celsius unless otherwise stated.

[1173] (3) LC-MS analysis was performed using an Agilent 6120b single quadrupole mass spectrometer equipped with an Agilent 1260 infinity II chromatographic separation module and an Agilent 1260 infinity II photodiode array detector controlled by Agilent Chemstation software. The HPLC column used was an Agilent ZORBAX Eclipse XDB-C18 4.6 mm x 150 mm x 3.5 μM RapidResol column with a mobile phase of water (0.1% formic acid) / MeCN (0.1% formic acid) and a gradient of 5-95% MeCN over 10 minutes at a flow rate of 1 mL / min. Accurate mass data were obtained using a Thermo Fisher extractiveplus EMR orbitrap LCMS system. Accurate mass values ​​were calculated using ChemCalc.

[1174] (4) LCMS spectra were collected on an alliance Waters 2695 coupled to a Waters 2487 dual-wavelength absorbance detector and a Waters Micromass-ZQ-2000 single quadrupole spectrometer. The LC mobile phase was acetonitrile (A) and water containing 0.01% formic acid (B), with a gradient of 5-100% A in 10.0 minutes, using a Kromasil 100-5-C18 150 mm x 4.6 mm x 5 μm column. Mass spectra (MS) were measured by electrospray ionization mass spectrometry (ESI). All temperatures are in degrees Celsius unless otherwise stated.

[1175] (5) LCMS spectra were collected on a Waters Micromass-ZQ 2000 quadrupole spectrometer. The LC mobile phase was (A) 0.1% formic acid in water; (B) 100% acetonitrile, with an eluent gradient of 10-90% B over 10.0 min, 90% B until 12 min, 90-10% B from 12-13 min, and 90-10% B from 13-15 min, using a Phenomenex Gemini-C18 (50 mm x 4.6 mm x 5 μm); flow rate: 0.5 mL / min. Mass spectra (MS) were measured by electrospray ionization mass spectrometry (ESI).

[1176] Typically, analytical HPLC spectroscopy conditions are as follows:

[1177] LC1: Agilent Technologies 1260 Infinity coupled, column: poroshell 120EC-C18 150 mm x 4.6 mm x 4 μm; temperature: 40°C; eluent: 5:95 v / v acetonitrile / water + 0.02% trifluoroacetic acid in 20 min; flow rate: 1.2 mL / min; detection: VWD, 190-600 nm.

[1178] LC2: Shimadzu 2010CHT, Waters X-select CSH C18 column (150 x 4.6 mm x 3.5 μm), temperature: 30°C; MP-A: 10 mM ammonium acetate buffer, MP-B: acetonitrile (100%), flow rate: 1.0 mL / min; detection: VWD, 270 nm. Gradient height: Time / B concentration: 0 / 5, 2 / 5, 20 / 50, 25 / 50, 30 / 90, 35 / 90, 37 / 05, 40 / 05.

[1179] LC3: Shimadzu LC-2010A HT, column: XBRIDGE-C18 3.5μm 2.1x50mm; temperature: 45°C; mobile phase: water (0.05% TFA)-ACN (0.05% TFA), ACN from 0 to 60% over 7 minutes, ACN from 60% to 100% over 7-8 minutes; flow rate: 0.8 mL / min; detection: PDA, 214 nm, 254 nm.

[1180] LC4: Shimadzu LC-2050c, column: XBRIDGE-C18 3.5μm 2.1x50mm; temperature: 45°C; mobile phase: water (0.05% TFA)-ACN (0.05% TFA), ACN from 0 to 60% over 7 minutes, 7-8 minutes, ACN from 60% to 100%; flow rate: 0.8 mL / min; detection: VWD, PDA, 214 nm, 254 nm. PDA, 214 nm, 254 nm.

[1181] Preparative HPLC was performed under one of the following conditions:

[1182] Condition 1: GILSON preparative HPLC system; column: Ultimate XB-C18, 21.2 mm x 250 mm, 5 μm; mobile phase: water containing 0.1% trifluoroacetic acid; MeCN containing 0.1% trifluoroacetic acid; method: 15-min gradient elution; initial organic matter: 10% to 30%; final organic matter: 60% to 80%; UV1: 240; UV2: 230; flow rate: 15 mL / min.

[1183] Condition 2: C18-reverse phase preparative HPLC was performed using a Waters purification system with a 2489 UV / Vis detector, a 2545 gradient module and a fraction collector III controlled by a Waters Chromescope v1.6. The preparative HPLC column used was a Waters Prep C18 5uM OBD TM 19x250 mm column, where the mobile phase is water / MeCN or water (0.1% TFA) / MeCN (0.1% TFA).

[1184] Condition 3: Shimadzu preparative HPLC system; column: Phenomenex Luna C18, 21.1 mm × 250 mm, 10 μm; mobile phase: MP-A 10 mM ammonium acetate buffer, MP-B: methanol (100%), 35-minute gradient elution, UV: 254; flow rate: 10 mL / min. Gradient height: time / B concentration: 0 / 50, 25 / 90, 30 / 90, 32 / 50, 35 / 50.

[1185] Chiral supercritical fluid chromatography (SFC) was performed under one of the following conditions:

[1186] Condition 1: SFC Thar prep 80; column: AD-H 250 mm x 20 mm, 5 μm; mobile phase: 40% EtOH / CO2 (containing 0.2% NH4OH); 40 g / min.

[1187] Condition 2: SFC Thar prep 80; column: OD-H 250 mm x 20 mm, 5 μm; mobile phase: 40% MeOH / CO2 (containing 0.2% NH4OH); 40 g / min.

[1188] Condition 3: SFC Thar prep 80; column: IC 250mmx20mm, 5μm; mobile phase: 40% IPA / CO2 (containing 0.2% DEA); 40g / min.

[1189] Compound names were generated using ChemDraw Professional.

[1190] The compounds provided herein, including various forms such as salts, esters, tautomers, prodrugs, zwitterionic forms, stereoisomers, and the like, can be prepared according to a variety of methods, including those listed in the Examples below.

[1191] Synthesis of provided compounds

[1192] Synthesis Example 1: Synthesis of N-(3-(4-(2-(2-methoxyethoxy)phenyl)-1-(1,2,3,4-tetrahydroisoquinolin-6-yl)-6,7-dihydro-5H-cyclopenta[c]pyridin-3-yl)benzyl)acrylamide (Compound 1)

[1193]

[1194] Step A: Preparation of N-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)acrylamide: To a stirred solution of [3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methanamine hydrochloride (100 mg, 0.371 mmol) and triethylamine (0.16 mL, 1.1 mmol) in DCM (5 mL) was added acrylic anhydride (70 mg, 0.56 mmol). The solution was stirred at 25 °C for 1 h. The mixture was concentrated and purified by preparative TLC (petroleum ether / EtOAc: 3 / 1) to give N-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)acrylamide (100 mg, 94% yield) as a colorless oil. LCMS ESI (+) m / z 288.2 (M+H).

[1195] Step B: Preparation of 1-Benzyloxy-4-bromo-3-methoxy-6,7-dihydro-5H-cyclopenta[c]pyridine: To a solution of benzyl alcohol (3.80 mL, 36.3 mmol) stirred in DMF (50 mL) at 0°C was added sodium hydride (0.870 g, 36.3 mmol) portionwise. The mixture was stirred at 0°C for 30 min. 4-Bromo-3-methoxy-1-methylsulfonyl-6,7-dihydro-5H-cyclopenta[c]pyridine (3.70 g, 12.1 mmol) was added, and the resulting mixture was stirred at 0°C to 25°C for an additional 4 hours. The mixture was diluted with water and extracted with EtOAc. The organic layer was dried over Na2SO4 and concentrated. The residue was purified by silica gel column (EtOAc / petroleum ether: 0 to 10%) to give 1-benzyloxy-4-bromo-3-methoxy-6,7-dihydro-5H-cyclopenta[c]pyridine (3.90 g, 97% yield). LCMS ESI (+) m / z 334.0 (M+H).

[1196] Step C: Preparation of 1-(benzyloxy)-3-methoxy-4-(2-(2-methoxyethoxy)phenyl)-6,7-dihydro-5H-cyclopenta[c]pyridine: A mixture of 1-benzyloxy-4-bromo-3-methoxy-6,7-dihydro-5H-cyclopenta[c]pyridine (1.00 g, 2.99 mmol), [2-(2-methoxyethoxy)phenyl]boronic acid (0.65 g, 3.29 mmol), 1,1'-bis(diphenylphosphino)ferrocenedichloropalladium(II) (219 mg, 0.299 mmol) and sodium carbonate (634 mg, 5.98 mmol) in 1,4-dioxane (30 mL) / water (3 mL) was stirred at 85 °C for 6 hours. The mixture was concentrated and purified by silica gel column chromatography (petroleum ether:EtOAc=10:1) to give 1-benzyloxy-3-methoxy-4-[2-(2-methoxyethoxy)phenyl]-6,7-dihydro-5H-cyclopenta[c]pyridine (1.10 g, 91% yield). LCMS ESI(+) m / z 406.2 (M+H).

[1197] Step D: Preparation of 3-methoxy-4-[2-(2-methoxyethoxy)phenyl]-6,7-dihydro-5H-cyclopenta[c]pyridin-1-ol: A mixture of 1-benzyloxy-3-methoxy-4-[2-(2-methoxyethoxy)phenyl]-6,7-dihydro-5H-cyclopenta[c]pyridin-1-ol (1.10 g, 2.71 mmol) and Pd / C (100 mg) in methanol (10 mL) / THF (10 mL) was stirred at 12 ° C for 12 hours. The mixture was filtered and concentrated. The residue was purified by silica gel column (petroleum ether: EtOAc = 1: 1) to give 3-methoxy-4-[2-(2-methoxyethoxy)phenyl]-6,7-dihydro-5H-cyclopenta[c]pyridin-1-ol (870 mg, 100% yield). LCMS ESI (+) m / z 316.2 (M+H).

[1198] Step E: Preparation of [3-methoxy-4-[2-(2-methoxyethoxy)phenyl]-6,7-dihydro-5H-cyclopenta[c]pyridin-1-yl] trifluoromethanesulfonate: To a stirred solution of 3-methoxy-4-[2-(2-methoxyethoxy)phenyl]-6,7-dihydro-5H-cyclopenta[c]pyridin-1-ol (870 mg, 2.76 mmol) and N,N-diisopropylethylamine (1.40 mL, 8.28 mmol) in DCM (10 mL) was added trifluoromethanesulfonic anhydride (0.560 mL, 3.31 mmol) at 0° C. The mixture was stirred at 10° C. for 1 hour. The mixture was diluted with EtOAc and washed with brine, dried over NaSO, filtered, concentrated, and purified on a silica gel column (petroleum ether:EtOAc=20:1 to 10:1) to give [3-methoxy-4-[2-(2-methoxyethoxy)phenyl]-6,7-dihydro-5H-cyclopenta[c]pyridin-1-yl] trifluoromethanesulfonate (690 mg, 56% yield). LCMS ESI(+) m / z 448.2 (M+H).

[1199] Step F: Preparation of tert-butyl 6-[3-methoxy-4-[2-(2-methoxyethoxy)phenyl]-6,7-dihydro-5H-cyclopenta[c]pyridin-1-yl]-3,4-dihydro-1H-isoquinoline-2-carboxylate: To a stirred mixture of [3-methoxy-4-[2-(2-methoxyethoxy)phenyl]-6,7-dihydro-5H-cyclopenta[c]pyridin-1-yl] trifluoromethanesulfonate (300 mg, 0.670 mmol), 6-(4 To a solution of tert-butyl 3,4-dihydro-1H-isoquinoline-2-carboxylate (289 mg, 0.805 mmol) and potassium carbonate (185 mg, 1.34 mmol) in MeCN (10 mL) / water (1.2 mL) were added palladium (II) acetate (15 mg, 0.067 mmol) and X-PHOS (64 mg, 0.13 mmol). The mixture was stirred at 100 ° C for 12 hours. The mixture was poured into water and extracted with EtOAc. The combined organic layers were washed with brine, dried and concentrated. The residue was purified by silica gel column chromatography (petroleum ether:EtOAc=10:1 to 4:1) to give tert-butyl 6-[3-methoxy-4-[2-(2-methoxyethoxy)phenyl]-6,7-dihydro-5H-cyclopenta[c]pyridin-1-yl]-3,4-dihydro-1H-isoquinoline-2-carboxylate (312 mg, 88% yield). LCMS ESI(+) m / z 531.4 (M+H).

[1200] Step G: Preparation of 4-(2-(2-methoxyethoxy)phenyl)-1-(1,2,3,4-tetrahydroisoquinolin-6-yl)-6,7-dihydro-5H-cyclopenta[c]pyridin-3-ol: To a stirred solution of tert-butyl 6-[3-methoxy-4-[2-(2-methoxyethoxy)phenyl]-6,7-dihydro-5H-cyclopenta[c]pyridin-1-yl]-3,4-dihydro-1H-isoquinoline-2-carboxylate (280 mg, 0.528 mmol) in MeCN (4 mL) was added sodium iodide (237 mg, 1.58 mmol) and trimethylsilyl chloride (0.67 mL, 5.3 mmol). The mixture was stirred at 80 °C for 2 hours. The mixture was cooled to ambient temperature and quenched with water. The product was extracted with DCM, dried over NaSO, and concentrated to dryness to give crude 4-(2-(2-methoxyethoxy)phenyl)-1-(1,2,3,4-tetrahydroisoquinolin-6-yl)-6,7-dihydro-5H-cyclopenta[c]pyridin-3-ol (208 mg), which was used directly in the next step. LCMS ESI (+) m / z 417.2 (M+H).

[1201] Step H: Preparation of tert-butyl 6-[3-hydroxy-4-[2-(2-methoxyethoxy)phenyl]-6,7-dihydro-5H-cyclopenta[c]pyridin-1-yl]-3,4-dihydro-1H-isoquinoline-2-carboxylate: To a solution of 4-(2-(2-methoxyethoxy)phenyl)-1-(1,2,3,4-tetrahydroisoquinolin-6-yl)-6,7-dihydro-5H-cyclopenta[c]pyridin-3-ol (208 mg, 0.600 mmol) and potassium carbonate (219 mg, 1.58 mmol) in ethanol (4 mL) and H2O (2 mL) was added di-tert-butyl dicarbonate (0.25 mL, 1.1 mmol). The mixture was stirred at ambient temperature for 2 hours. The mixture was diluted with water and the product was extracted with EtOAc. The combined organic layers were washed with brine, dried over Na2SO4, filtered, concentrated, and purified on a silica gel column (EtOAc) to give tert-butyl 6-[3-hydroxy-4-[2-(2-methoxyethoxy)phenyl]-6,7-dihydro-5H-cyclopenta[c]pyridin-1-yl]-3,4-dihydro-1H-isoquinoline-2-carboxylate (280 mg, 90%). LCMS ESI (+) m / z 517.3.

[1202] Step I: Preparation of tert-butyl 6-[4-[2-(2-methoxyethoxy)phenyl]-3-(trifluoromethylsulfonyloxy)-6,7-dihydro-5H-cyclopenta[c]pyridin-1-yl]-3,4-dihydro-1H-isoquinoline-2-carboxylate: To a solution of tert-butyl 6-[3-hydroxy-4-[2-(2-methoxyethoxy)phenyl]-6,7-dihydro-5H-cyclopenta[c]pyridin-1-yl]-3,4-dihydro-1H-isoquinoline-2-carboxylate (260 mg, 0.503 mmol) and N,N-diisopropylethylamine (0.260 mL, 1.51 mmol) in DCM (5 mL) was added trifluoromethanesulfonic anhydride (0.100 mL, 0.604 mmol). The mixture was stirred at 7° C. for 1 hour. The mixture was poured into aqueous NaHCO 3 . The product was extracted with EtOAc, washed with brine, dried over NaSO, and concentrated. The residue was purified by silica gel column (petroleum ether:EtOAc=4:1) to give tert-butyl 6-[4-[2-(2-methoxyethoxy)phenyl]-3-(trifluoromethylsulfonyloxy)-6,7-dihydro-5H-cyclopenta[c]pyridin-1-yl]-3,4-dihydro-1H-isoquinoline-2-carboxylate (180 mg, 55% yield). LCMS ESI(+) m / z 649.3 (M+H).

[1203] Step J: Preparation of tert-butyl 6-[4-[2-(2-methoxyethoxy)phenyl]-3-[3-[(prop-2-enoylamino)methyl]phenyl]-6,7-dihydro-5H-cyclopenta[c]pyridin-1-yl]-3,4-dihydro-1H-isoquinoline-2-carboxylate: To tert-butyl 6-[4-[2-(2-methoxyethoxy)phenyl]-3-(trifluoromethylsulfonyloxy)-6,7-dihydro-5H-cyclopenta[c]pyridin-1-yl]-3,4-dihydro-1H-isoquinoline-2-carboxylate To a solution of 4-[[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methyl]prop-2-enamide (40 mg, 0.062 mmol) and N-[[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methyl]prop-2-enamide (35 mg, 0.12 mmol) in acetonitrile (2 mL) and water (0.2 mL) were added X-Phos (5.9 mg, 0.012 mmol), K2CO3 (17 mg, 0.12 mmol) and palladium(II) acetate (1.4 mg, 0.0062 mmol). The solution was stirred at 100°C under N2 for 2 hours. The mixture was concentrated and purified by preparative TLC (petroleum ether:EtOAc=1:1) to give tert-butyl 6-[4-[2-(2-methoxyethoxy)phenyl]-3-[3-[(prop-2-enoylamino)methyl]phenyl]-6,7-dihydro-5H-cyclopenta[c]pyridin-1-yl]-3,4-dihydro-1H-isoquinoline-2-carboxylate (30 mg, 70% yield) as a pale yellow oil. LCMS ESI(+) m / z 660.2 (M+H).

[1204] Step K: Preparation of N-[[3-[4-[2-(2-methoxyethoxy)phenyl]-1-(1,2,3,4-tetrahydroisoquinolin-6-yl)-6,7-dihydro-5H-cyclopenta[c]pyridin-3-yl]phenyl]methyl]prop-2-enamide: To a solution of tert-butyl 6-[4-[2-(2-methoxyethoxy)phenyl]-3-[3-[(prop-2-enoylamino)methyl]phenyl]-6,7-dihydro-5H-cyclopenta[c]pyridin-1-yl]-3,4-dihydro-1H-isoquinoline-2-carboxylate (30 mg, 0.043 mmol) in DCM (2 mL) was added trifluoroacetic acid (1.0 mL, 13 mmol). The solution was stirred at ambient temperature for 1 h. The solution was concentrated and purified by reverse phase preparative HPLC to give N-[[3-[4-[2-(2-methoxyethoxy)phenyl]-1-(1,2,3,4-tetrahydroisoquinolin-6-yl)-6,7-dihydro-5H-cyclopenta[c]pyridin-3-yl]phenyl]methyl]prop-2-enamide (11 mg, 0.44% yield) as a trifluoroacetate salt. LCMS ESI (+) m / z 560.2 (M+H). 1H NMR(400MHz, CD3OD)δ:7.74-7.76(m,2H),7.48-7.50(d,J=8.4Hz,1H),7.40(s,1H),7.26-7.35(m, 4H),7.02-7.04(d,J=8.4Hz,1H),6.96-6.98(d,J=7.6Hz,1H),6.86-6.90(t,J=7.2Hz,1H),6.24-6 .25(d,J=7.2Hz,2H),5.69-5.72(t,J=5.2Hz,1H),4.50(s,2H),4.33-4.61(m,2H),4.12-4.15(m,1 H),3.95-3.98(m,1H),3.57-3.61(m,4H),3.06-3.28(m,8H),2.85-2.93(m,1H),2.18-2.24(m,2H).

[1205] Synthesis Example 2: Synthesis of 7-[2-(2-methoxyethoxy)phenyl]-6-phenyl-4-(1,2,3,4-tetrahydroisoquinolin-6-yl)thieno[3,2-c]pyridine (Compound 4)

[1206]

[1207] Step A: Preparation of 1-(2-methoxyethoxy)-2-(phenylethynyl)benzene: To a solution of 1-iodo-2-(2-methoxyethoxy)benzene (300 mg, 1.08 mmol), phenylacetylene (0.120 mL, 1.13 mmol), triethylamine (0.75 mL, 5.4 mmol) and CuI (41 mg, 0.22 mmol) in THF (7.5 mL) was added Pd(PPh ) Cl (76 mg, 0.11 mmol). The reaction mixture was stirred at ambient temperature for 2 hours. The reaction was then heated to 50 ° C and stirred under nitrogen for 4 hours. The reaction was quenched with water and extracted with EtOAc (x 3). The combined organic layer was washed with brine, dried over Na SO , filtered and the filtrate was concentrated by rotary evaporation. The product was purified by silica gel column chromatography (EtOAc / petroleum ether: 1 / 15) to give 1-(2-methoxyethoxy)-2-(2-phenylethynyl)benzene (237 mg, yield 87%). 1 H NMR (400MHz, CDCl3): δ7.47-7.50(m,3H), 7.25-7.36(m,4H), 6.90-6.97(m,2H), 4.22(t,J=4.8Hz,2H), 3.84(t,J=4.8Hz,2H), 3.51(s,3H).

[1208] Step B: Preparation of 6-[2-(2-methoxyethoxy)phenyl]-7-phenyl-5H-thieno[3,2-c]pyridin-4-one and 7-[2-(2-methoxyethoxy)phenyl]-6-phenyl-5H-thieno[3,2-c]pyridin-4-one: To a solution of 1-(2-methoxyethoxy)-2-(2-phenylethynyl)benzene (230 mg, 0.912 mmol), thiophene-3-carbonitrile (99 mg, 0.91 mmol), potassium hexafluorophosphate (34 mg, 0.18 mmol) and copper acetate monohydrate (50 mg, 0.27 mmol) in acetic acid (10 mL) was added [{RuCl2(p-isopropyltoluene)}2] (28 mg, 0.046 mmol). The reaction was stirred at 120°C for 10 hours. The reaction was concentrated to dryness and the residue was taken up in EtOAc. The organic layer was washed with water and brine, dried, and concentrated. The crude product was purified by column chromatography (5% MeOH in DCM) to yield a mixture of 6-[2-(2-methoxyethoxy)phenyl]-7-phenyl-5H-thieno[3,2-c]pyridin-4-one and 7-[2-(2-methoxyethoxy)phenyl]-6-phenyl-5H-thieno[3,2-c]pyridin-4-one (201 mg, 58% yield). LCMS ESI(+) m / z 378.1 (M+H).

[1209] Step C: Preparation of 4-chloro-6-[2-(2-methoxyethoxy)phenyl]-7-phenyl-thieno[3,2-c]pyridine and 4-chloro-7-[2-(2-methoxyethoxy)phenyl]-6-phenyl-thieno[3,2-c]pyridine: A solution of 6-[2-(2-methoxyethoxy)phenyl]-7-phenyl-5H-thieno[3,2-c]pyridin-4-one and 7-[2-(2-methoxyethoxy)phenyl]-6-phenyl-5H-thieno[3,2-c]pyridin-4-one (201 mg, 0.533 mmol) in POCl3 (5.0 mL) was stirred at 100°C for 3 hours. The reaction was concentrated to dryness and the residue was taken up in EtOAc. The organic layer was washed with saturated sodium bicarbonate solution and saturated brine solution, dried and concentrated. The crude product was then purified by column chromatography (20% EtOAc in hexanes) to give a mixture of two isomers, which was further purified by reverse phase HPLC to give 4-chloro-6-[2-(2-methoxyethoxy)phenyl]-7-phenyl-thieno[3,2-c]pyridine (41 mg, 19% yield) and 4-chloro-7-[2-(2-methoxyethoxy)phenyl]-6-phenyl-thieno[3,2-c]pyridine (64 mg, 30% yield). LCMS ESI(+) m / z 396.1 (M+H).

[1210] Step D: Preparation of tert-butyl 6-[7-[2-(2-methoxyethoxy)phenyl]-6-phenyl-thieno[3,2-c]pyridin-4-yl]-3,4-dihydro-1H-isoquinoline-2-carboxylate: To a solution of 4-chloro-6-[2-(2-methoxyethoxy)phenyl]-7-phenyl-thieno[3,2-c]pyridine and 4-chloro-7-[2-(2-methoxyethoxy)phenyl]-6-phenyl-thieno[3,2-c]pyridine (18 mg, 0.046 mmol) was added. To the mixture, tert-butyl 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydro-1H-isoquinoline-2-carboxylate (20 mg, 0.056 mmol) and sodium carbonate (14 mg, 0.13 mmol) in 1,4-dioxane (2 mL) and water (0.2 mL) was added 1,1'-bis(diphenylphosphino)ferrocenedichloropalladium(II) dichloromethane complex (4.0 mg, 0.0055 mmol). The mixture was stirred at 85° C. under Ar for 4 hours. The mixture was concentrated and purified by preparative TLC (EtOAc / petroleum ether: 1 / 4) to give tert-butyl 6-[7-[2-(2-methoxyethoxy)phenyl]-6-phenyl-thieno[3,2-c]pyridin-4-yl]-3,4-dihydro-1H-isoquinoline-2-carboxylate (22 mg, 82%) as a light yellow solid.

[1211] Step E: Preparation of 7-[2-(2-methoxyethoxy)phenyl]-6-phenyl-4-(1,2,3,4-tetrahydroisoquinolin-6-yl)thieno[3,2-c]pyridine: To a solution of tert-butyl 6-[7-[2-(2-methoxyethoxy)phenyl]-6-phenyl-thieno[3,2-c]pyridin-4-yl]-3,4-dihydro-1H-isoquinoline-2-carboxylate (22 mg, 0.037 mmol) in DCM (3 mL) was added TFA (1 mL). The mixture was stirred at 10° C. for 2 hours. The mixture was concentrated and purified by reverse phase preparative-HPLC to give 7-[2-(2-methoxyethoxy)phenyl]-6-phenyl-4-(1,2,3,4-tetrahydroisoquinolin-6-yl)thieno[3,2-c]pyridine (15 mg, 83% yield) as a trifluoroacetate salt. LCMS ESI (+) m / z 493.2 (M+H). 1H NMR(400MHz,CD3OD)δ:7.95(d,J=4.8Hz,1H),7.85-7.88(m,2H),7.72(d,J =5.6Hz,1H),7.47-7.55(m,3H),7.42(t,J=8.0Hz,1H),7.24-7.38(m,4H),7 .08(d,J=8.4Hz,1H),7.02(t,J=7.4Hz,1H),4.52(s,2H),4.00-4.08(m,1H) ,3.84-3.88(m,1H),3.60(t,J=6.2Hz,2H),3.42-3.53(m,2H),3.15(s,3H).

[1212] Synthesis Example 3: Synthesis of 3-[7-[4-fluoro-2-(2-methoxyethoxy)phenyl-4-(1,2,3,4-tetrahydroisoquinolin-6-yl)thieno[3,2-c]pyridin-6-yl]benzonitrile (Compound 8)

[1213]

[1214] Step A: Preparation of 6-(3-iodophenyl)-5H-thieno[3,2-c]pyridin-4-one: To a solution of 2-methylthiophene-3-carboxylic acid (2.00 g, 14.1 mmol) in THF (20 mL) was added n-butyllithium (12.0 mL, 2.5 M in hexanes, 30.0 mmol) dropwise at -78 °C under Ar. The mixture was stirred at -60 °C under Ar for 0.5 h. 3-iodobenzonitrile (3.50 g, 15.3 mmol) was then added at -60 °C. The temperature was allowed to rise to 0 °C, and the resulting mixture was stirred at 0 °C for an additional hour. The mixture was poured into water and the pH was adjusted to 5 with 1 N HCl. The mixture was concentrated to remove THF and diluted with water. The solid was filtered, washed with water (20 mL) and EtOAc (20 mL), and dried in vacuo to give the crude product 6-(3-iodophenyl)-5H-thieno[3,2-c]pyridin-4-one (2.30 g, 46% yield) as a yellow solid. 1 H NMR (400MHz, CDCl3): δ8.14 (s, 1H), 7.77-7.83 (m, 2H), 7.64 (d, J = 5.2Hz, 1H), 7.51 (d, J = 5.2Hz, 1H), 7.27-7.31 (m, 2H).

[1215] Step B: Preparation of 3-(4-oxo-5H-thieno[3,2-c]pyridin-6-yl)benzonitrile: A suspension of copper(I) cyanide (76 mg, 0.85 mmol) and 6-(3-iodophenyl)-5H-thieno[3,2-c]pyridin-4-one (200 mg, 0.566 mmol) in DMF (5 mL) was stirred at 130 ° C for 16 hours. The mixture was allowed to cool to ambient temperature. Ammonia (1 mL) was added and the mixture was stirred for another 2 hours. The pH was adjusted to 6 with 3N HCl. The solid was collected by filtration and then washed with water and EtOAc / petroleum ether (1 / 1). The solid was dried in vacuo to give 3-(4-oxo-5H-thieno[3,2-c]pyridin-6-yl)benzonitrile (110 mg, 77% yield) as a yellow solid. LCMS ESI (+) m / z 253.0 (M+H).

[1216] Step C: Preparation of 3-(7-bromo-4-oxo-5H-thieno[3,2-c]pyridin-6-yl)benzonitrile: To a solution of crude 3-(4-oxo-5H-thieno[3,2-c]pyridin-6-yl)benzonitrile (1.27 g, 5.03 mmol) in DMF (15 mL) was added N-bromosuccinimide (941 mg, 5.29 mmol) at 0°C. The mixture was stirred at 0°C for 1 h. The mixture was poured into water and the solid was filtered, washed with water and EtOAc / petroleum ether (1 / 1), and dried under vacuum to afford 3-(7-bromo-4-oxo-5H-thieno[3,2-c]pyridin-6-yl)benzonitrile (870 mg, 52% yield) as a yellow solid. LCMS ESI (+) m / z 331, 333 (M+H).

[1217] Step D: Preparation of 3-(7-bromo-4-methoxy-thieno[3,2-c]pyridin-6-yl)benzonitrile: To a suspension of 3-(7-bromo-4-oxo-5H-thieno[3,2-c]pyridin-6-yl)benzonitrile (870 mg, 2.63 mmol) and silver carbonate (761 mg, 2.76 mmol) in toluene (20 mL) was added iodomethane (0.41 mL, 6.6 mmol). The mixture was stirred at 90 °C in a sealed tube for 16 hours. The mixture was then purified by The mixture was filtered and washed with EtOAc. The filtrate was concentrated and the residue was purified by column chromatography (EtOAc / petroleum ether: 1 / 5) to give 3-(7-bromo-4-methoxy-thieno[3,2-c]pyridin-6-yl)benzonitrile (592 mg, 65% yield) as a light yellow solid.

[1218] Step E: Preparation of 3-[7-[4-fluoro-2-(2-methoxyethoxy)phenyl]-4-methoxy-thieno[3,2-c]pyridin-6-yl]benzonitrile: To a solution of 3-(7-bromo-4-methoxy-thieno[3,2-c]pyridin-6-yl)benzonitrile (290 mg, 0.840 mmol) in 1,4-dioxane (5 mL) and water (1 mL) was added [4-fluoro-2-(2-methoxyethyl)phenyl]boronic acid (216 mg, 1.09 mmol), 1,1'-bis(diphenylphosphino)ferrocenedichloropalladium(II) dichloromethane complex (61 mg, 0.084 mmol) and sodium carbonate (178 mg, 1.68 mmol). The mixture was stirred at 100°C for 4 hours. After cooling, the mixture was poured into water (20 mL) and the product was extracted with ethyl acetate (40 mL). The combined organic layers were washed with brine, dried over NaSO, filtered, and concentrated. The residue was purified by preparative TLC (petroleum ether:EtOAc=3:1) to give 3-[7-[4-fluoro-2-(2-methoxyethoxy)phenyl]-4-methoxy-thieno[3,2-c]pyridin-6-yl]benzonitrile (280 mg, 77% yield). LCMS ESI(+) m / z 435 (M+H).

[1219] Step F: Preparation of 3-[7-[4-fluoro-2-(2-methoxyethoxy)phenyl]-4-oxo-5H-thieno[3,2-c]pyridin-6-yl]benzonitrile: To a solution of 3-[7-[4-fluoro-2-(2-methoxyethoxy)phenyl]-4-methoxy-thieno[3,2-c]pyridin-6-yl]benzonitrile (205 mg, 0.472 mmol) in acetonitrile (20 mL) was added sodium iodide (212 mg, 1.42 mmol) and trimethylsilyl chloride (0.180 mL, 1.42 mmol). The mixture was stirred at 0° C. for 2 hours. The mixture was poured into water (20 mL), and the solid was filtered to give 3-[7-[4-fluoro-2-(2-methoxyethoxy)phenyl]-4-oxo-5H-thieno[3,2-c]pyridin-6-yl]benzonitrile (150 mg, 76% yield). LCMS ESI(+) m / z 421 (M+H).

[1220] Step G: Preparation of 3-[4-chloro-7-[4-fluoro-2-(2-methoxyethoxy)phenyl]thieno[3,2-c]pyridin-6-yl]benzonitrile: A solution of 3-[7-[4-fluoro-2-(2-methoxyethoxy)phenyl]-4-oxo-5H-thieno[3,2-c]pyridin-6-yl]benzonitrile (150 mg, 0.357 mmol) in phosphorus oxychloride (3.00 mL, 32.2 mmol) was stirred at 90 ° C for 1 hour. After cooling, the mixture was poured into ice water (20 mL). NaHCO3 was carefully added to adjust the pH to 8. The product was extracted with EtOAc (50 mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated. The residue was purified by preparative TLC (petroleum ether:EA=5:1) to give 3-[4-chloro-7-[4-fluoro-2-(2-methoxyethoxy)phenyl]thieno[3,2-c]pyridin-6-yl]benzonitrile (130 mg, 83% yield). LCMS ESI(+) m / z 439.0 (M+H).

[1221] Step H: Preparation of tert-butyl 6-[6-(3-cyanophenyl)-7-[4-fluoro-2-(2-methoxyethoxy)phenyl]thieno[3,2-c]pyridin-4-yl]-3,4-dihydro-1H-isoquinoline-2-carboxylate: To 3-[4-chloro-7-[4-fluoro-2-(2-methoxyethoxy)phenyl]thieno[3,2-c]pyridin-6-yl]benzonitrile (130 mg, 0.296 mmol) in 1,4-dioxane ( To a solution of 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester (138 mg, 0.385 mmol), sodium carbonate (63 mg, 0.59 mmol) and 1,1'-bis(diphenylphosphino)ferrocenedichloropalladium(II) dichloromethane complex (22 mg, 0.030 mmol) was added (2 mL) and water (0.2 mL). The mixture was stirred at 95 ° C under Ar for 2 hours. After cooling, the mixture was poured into water (20 mL) and extracted with ethyl acetate (40 mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated. The residue was purified by preparative TLC (petroleum ether:EA=3:1) to give tert-butyl 6-[6-(3-cyanophenyl)-7-[4-fluoro-2-(2-methoxyethoxy)phenyl]thieno[3,2-c]pyridin-4-yl]-3,4-dihydro-1H-isoquinoline-2-carboxylate (160 mg, 85% yield). LCMS ESI(+) m / z 636 (M+H).

[1222] Step I: Preparation of 3-[7-[4-fluoro-2-(2-methoxyethoxy)phenyl-4-(1,2,3,4-tetrahydroisoquinolin-6-yl)thieno[3,2-c]pyridin-6-yl]benzonitrile: To a solution of tert-butyl 6-[6-(3-cyanophenyl)-7-[4-fluoro-2-(2-methoxyethoxy)phenyl]thieno[3,2-c]pyridin-4-yl]-3,4-dihydro-1H-isoquinoline-2-carboxylate (17 mg, 0.027 mmol) in DCM (4 mL) was added trifluoroacetic acid (1.0 mL, 13 mmol). The mixture was stirred at 25° C. for 1 hour. The mixture was concentrated and the residue was purified by reverse phase preparative HPLC to give 3-[7-[4-fluoro-2-(2-methoxyethoxy)phenyl-4-(1,2,3,4-tetrahydroisoquinolin-6-yl)thieno[3,2-c]pyridin-6-yl]benzonitrile (4.5 mg, 31% yield) as a trifluoroacetate salt. LCMS ESI(+) m / z 536 (M+H). 1H NMR(400MHz,CD3OD)δ7.89(s,1H),7.81-7.86(m,3H),7.68-7.72(m,2H),7.6 3(d,J=8Hz,1H),7.39-7.47(m,2H),7.32-7.35(m,1H),6.90(dd,J=11.1,2.2 Hz,1H),6.79-6.83(m,1H),4.49(s,2H),3.98-4.01(m,1H),3.83-3.86(m,1H ), 3.60 (t, J = 6.4Hz, 2H), 3.44 (t, J = 4.8, 2H), 3.26-3.30 (m, 2H), 3.15 (s, 3H).

[1223] Synthesis Example 4: Synthesis of N-[[3-[7-[4-fluoro-2-(2-methoxyethoxy)phenyl]-4-(1,2,3,4-tetrahydroisoquinolin-6-yl)thieno[3,2-c]pyridin-6-yl]phenyl]methyl]prop-2-enamide (Compound 11)

[1224]

[1225] Step A: Preparation of tert-butyl 6-[6-[3-(aminomethyl)phenyl]-7-[4-fluoro-2-(2-methoxyethoxy)phenyl]thieno[3,2-c]pyridin-4-yl]-3,4-dihydro-1H-isoquinoline-2-carboxylate: To a solution of tert-butyl 6-[6-(3-cyanophenyl)-7-[4-fluoro-2-(2-methoxyethoxy)phenyl]thieno[3,2-c]pyridin-4-yl]-3,4-dihydro-1H-isoquinoline-2-carboxylate (178 mg, 0.280 mmol) in methanol (5 mL) was added cobaltous chloride (73 mg, 0.56 mmol) and sodium borohydride (106 mg, 2.80 mmol). The mixture was stirred at 25° C. for 12 hours. The mixture was poured into water (20 mL) and extracted with ethyl acetate (40 mL). The combined organic layers were washed with brine, dried over NaSO, and concentrated. The residue was purified by preparative TLC (DCM:MeOH = 20:1) to give tert-butyl 6-[6-[3-(aminomethyl)phenyl]-7-[4-fluoro-2-(2-methoxyethoxy)phenyl]thieno[3,2-c]pyridin-4-yl]-3,4-dihydro-1H-isoquinoline-2-carboxylate (135 mg, 75% yield). LCMS ESI (+) m / z 640.3 (M+H).

[1226] Step B: Preparation of tert-butyl 6-[7-[4-fluoro-2-(2-methoxyethoxy)phenyl]-6-[3-[(prop-2-enoylamino)methyl]phenyl]thieno[3,2-c]pyridin-4-yl]-3,4-dihydro-1H-isoquinoline-2-carboxylate: To a solution of tert-butyl 6-[6-[3-(aminomethyl)phenyl]-7-[4-fluoro-2-(2-methoxyethoxy)phenyl]thieno[3,2-c]pyridin-4-yl]-3,4-dihydro-1H-isoquinoline-2-carboxylate (12 mg, 0.019 mmol) in DCM (2 mL) was added triethylamine (0.0078 mL, 0.056 mmol). The mixture was cooled to -20°C. To this was added a solution of prop-2-enoylprop-2-enoate (2.8 mg, 0.023 mmol) in DCM. The mixture was stirred at -20 ° C for 15 min. The reaction was quenched with H2O (10 mL) and extracted with EtOAc (15 mLx3). The organic layer was concentrated and the residue was purified by preparative TLC (EtOAc / petroleum ether: 50 to 100% EtOAc) to give 6- [7- [4-fluoro-2- (2-methoxyethoxy) phenyl] -6- [3- [(prop-2-enoylamino) methyl] phenyl] thieno [3,2-c] pyridin-4-yl] -3,4-dihydro -1H-isoquinoline-2-carboxylic acid tert-butyl ester (12 mg, 92% yield). LCMS ESI (+) m / z 694.3 (M + H).

[1227] Step C: Preparation of N-[[3-[7-[4-fluoro-2-(2-methoxyethoxy)phenyl]-4-(1,2,3,4-tetrahydroisoquinolin-6-yl)thieno[3,2-c]pyridin-6-yl]phenyl]methyl]prop-2-enamide: To a solution of tert-butyl 6-[7-[4-fluoro-2-(2-methoxyethoxy)phenyl]-6-[3-[(prop-2-enoylamino)methyl]phenyl]thieno[3,2-c]pyridin-4-yl]-3,4-dihydro-1H-isoquinoline-2-carboxylate (14 mg, 0.020 mmol) in dichloromethane (3 mL) was added trifluoroacetic acid (1 mL). The resulting mixture was stirred for 1 hour. The solvent was concentrated under reduced pressure and the residue was purified by reverse phase preparative HPLC to give N-[[3-[7-[4-fluoro-2-(2-methoxyethoxy)phenyl]-4-(1,2,3,4-tetrahydroisoquinolin-6-yl)thieno[3,2-c]pyridin-6-yl]phenyl]methyl]prop-2-enamide (2.3 mg, 19% yield) as a trifluoroacetate salt. LCMS ESI(+) m / z 593.2 (M+H). 1 H NMR (400MHz, CD3OD) δ7.91(d,J=5.6Hz,1H),7.84-7.87(m,2H),7.70(d,J=5.6Hz,1H),7.45-7.51(m,2H),7.36-7.40(m,1H),7.22 -7.32(m,3H),6.88(dd,J=11.1,2.2Hz,1H),6.75(td,J=8.3,2.3Hz,1H),6.25(d,J=6.0Hz,2H),5.70(t,J=6.0Hz,1H), 4.51(s,2H),4.40(s,2H),3.96–4.08(m,1H),3.78–3.91(m,1H),3.60(t,J=6.3Hz,1H),3.44-3.47(m,2H),3.13(s,3H).

[1228] Synthesis Example 5: Synthesis of N-[3-[7-[4-fluoro-2-(2-methoxyethoxy)phenyl]-4-(1,2,3,4-tetrahydroisoquinolin-6-yl)thieno[3,2-c]pyridin-6-yl]phenyl]prop-2-enamide (Compound 12)

[1229]

[1230] Step A: Preparation of 3-[4-(2-tert-Butyloxycarbonyl-3,4-dihydro-1H-isoquinolin-6-yl)-7-[4-fluoro-2-(2-methoxyethoxy)phenyl]thieno[3,2-c]pyridin-6-yl]benzoic acid: A solution of tert-butyl 6-[6-(3-cyanophenyl)-7-[4-fluoro-2-(2-methoxyethoxy)phenyl]thieno[3,2-c]pyridin-4-yl]-3,4-dihydro-1H-isoquinoline-2-carboxylate (350 mg, 0.551 mmol) in ethanol (3 mL) and NaOH (2 N, 3 mL) was stirred at 95° C. for 12 h. The mixture was diluted with water (20 mL) and 1 N HCl was added to adjust the pH to 2. The product was extracted with EtOAc, washed with brine, dried over NaSO, filtered, and concentrated to dryness to afford 3-[4-(2-tert-butoxycarbonyl-3,4-dihydro-1H-isoquinolin-6-yl)-7-[4-fluoro-2-(2-methoxyethoxy)phenyl]thieno[3,2-c]pyridin-6-yl]benzoic acid (310 mg, 86% yield) as a white solid. LCMS ESI(+) m / z 655.3 (M+H).

[1231]

[0264] Step B: Preparation of tert-butyl 6-[6-[3-(benzyloxycarbonylamino)phenyl]-7-[4-fluoro-2-(2-methoxyethoxy)phenyl]thieno[3,2-c]pyridin-4-yl]-3,4-dihydro-1H-isoquinoline-2-carboxylate: To a solution of 3-[4-(2-tert-butoxycarbonyl-3,4-dihydro-1H-isoquinolin-6-yl)-7-[4-fluoro-2-(2-methoxyethoxy)phenyl]thieno[3,2-c]pyridin-6-yl]benzoic acid (42 mg, 0.064 mmol), triethylamine (0.090 mL, 0.64 mmol) and benzyl alcohol (0.033 mL, 0.32 mmol) in dry toluene (3 mL) was added [azido(phenoxy)phosphoryl]oxybenzene (89 mg, 0.32 mmol). The mixture was stirred at 90° C. for 2 hours. The mixture was concentrated and purified by preparative TLC (EtOAc / petroleum ether: 1 / 2) to give tert-butyl 6-[6-[3-(benzyloxycarbonylamino)phenyl]-7-[4-fluoro-2-(2-methoxyethoxy)phenyl]thieno[3,2-c]pyridin-4-yl]-3,4-dihydro-1H-isoquinoline-2-carboxylate (36 mg, 74% yield). LCMS ESI(+) m / z 760.2 (M+H).

[1232] Step C: Preparation of tert-butyl 6-[6-(3-aminophenyl)-7-[4-fluoro-2-(2-methoxyethoxy)phenyl]thieno[3,2-c]pyridin-4-yl]-3,4-dihydro-1H-isoquinoline-2-carboxylate: A solution of tert-butyl 6-[6-[3-(benzyloxycarbonylamino)phenyl]-7-[4-fluoro-2-(2-methoxyethoxy)phenyl]thieno[3,2-c]pyridin-4-yl]-3,4-dihydro-1H-isoquinoline-2-carboxylate (36 mg, 0.047 mmol) and lithium hydroxide monohydrate (40 mg, 0.95 mmol) in 1,4-dioxane (1 mL) and water (1 mL) was stirred at 95° C. under Ar for 16 hours. The mixture was poured into water. The mixture was extracted with EtOAc, dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by preparative TLC (EtOAc / petroleum ether: 1 / 2) to give tert-butyl 6-[6-(3-aminophenyl)-7-[4-fluoro-2-(2-methoxyethoxy)phenyl]thieno[3,2-c]pyridin-4-yl]-3,4-dihydro-1H-isoquinoline-2-carboxylate (24 mg, 81% yield) as a white solid. LCMS ESI (+) m / z 626.3 (M+H).

[1233] Step D: Preparation of tert-butyl 6-[7-[4-fluoro-2-(2-methoxyethoxy)phenyl]-6-[3-(prop-2-enoylamino)phenyl]thieno[3,2-c]pyridin-4-yl]-3,4-dihydro-1H-isoquinoline-2-carboxylate: To a solution of tert-butyl 6-[6-(3-aminophenyl)-7-[4-fluoro-2-(2-methoxyethoxy)phenyl]thieno[3,2-c]pyridin-4-yl]-3,4-dihydro-1H-isoquinoline-2-carboxylate (12 mg, 0.019 mmol) and N,N-diisopropylethylamine (0.015 mL, 0.085 mmol) in DCM (2 mL) was added acryloyl chloride (0.0045 mL, 0.055 mmol) at -30°C. The mixture was stirred at 0°C for 1 hour. The mixture was poured into aqueous NaHCO 3 and extracted with EtOAc. The combined organic layers were dried over anhydrous Na 2 SO 4 , concentrated, and purified by preparative TLC (EtOAc / petroleum ether: 1 / 2) to give tert-butyl 6-[7-[4-fluoro-2-(2-methoxyethoxy)phenyl]-6-[3-(prop-2-enoylamino)phenyl]thieno[3,2-c]pyridin-4-yl]-3,4-dihydro-1H-isoquinoline-2-carboxylate (12 mg, 92% yield).

[1234] Step E: Preparation of N-[3-[7-[4-fluoro-2-(2-methoxyeth...

Claims

1. A compound of formula I: or a salt thereof (e.g., a pharmaceutically acceptable salt), wherein: Ring A is selected from phenyl and a 5- to 6-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur; Ring B is selected from a 9- to 10-membered bicyclic ring containing at least one 5- or 6-membered heteroaromatic ring, a 6-membered heteroaromatic ring having 1-2 nitrogen atoms, and a phenyl group; Ring C is selected from phenyl; a 5- to 6-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur; a 5- to 8-membered bicyclic carbocyclic ring; a 4- to 8-membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen and sulfur; and a 7- to 10-membered spiro-fused heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur; wherein the phenyl, heteroaromatic ring and heterocyclic ring are each optionally fused to Ring E; Ring D is selected from a 5- to 6-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur, and phenyl, wherein the heteroaromatic ring and the phenyl ring are each optionally fused to Ring F; Ring E is selected from a 5- to 6-membered carbocyclic ring; a 5- to 7-membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen and sulfur; a 7- to 10-membered spiro-fused heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur; and a 5- to 6-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur, wherein Ring E is substituted by s R 5′ Instance replacement; Ring F is selected from phenyl; 5- to 6-membered carbocyclic ring; 5- to 7-membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen and sulfur; and 5- to 6-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur, wherein Ring F is substituted by u instances of -LW and y instances of R 2’ Instance replacement; R 1 is selected from -LW, ring D' or a divalent C substituted by ring D' 1-6 Aliphatic chain; Each -LW is -CN, or: Each L is independently a divalent straight or branched chain C 1-8 an aliphatic chain, wherein one or more methylene units of the aliphatic chain are optionally and independently replaced by a group selected from the group consisting of -N(R)-, -O-, -S-, -C(O)-, -SO2-, -CH(X)-, -C(X)2-, -C(O)N(R)-, -N(R)C(O)-, -C(O)O-, -OC(O)-, -SO2N(R)-, and -N(R)SO2-; each W is independently hydrogen, halogen, -CN, or an optionally substituted 3-10 membered monocyclic or bicyclic, saturated, partially unsaturated or aromatic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen or sulfur; Each X is independently halogen, -OR or -CN; each ring D' is independently a 4- to 6-membered carbocyclic ring or a 4- to 6-membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen and sulfur, wherein ring D' is substituted with t instances of -LW; Each R 2 and R 2’ are independently selected from oxo, halogen, -CN, -OR and C 1-6 alkyl; Each R 3 independently selected from oxo, halogen, -CN, -OR, -O(CH2) v Cy, -OCH2CH2OR and optionally substituted C 1-6 Fat; Each Cy is independently a 5- to 6-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur; a 3- to 6-membered carbocyclic ring; or a 4- to 6-membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen and sulfur, wherein Cy is substituted by 0-2 R 6 Instance replacement; Each R 4 are independently selected from halogen and optionally substituted C 1-6 Fat; R 5 and R 5’ Each is independently selected from oxo, =NH, -CN, halogen, -OR, -N(R)2, -SR, -C(O)R, -N(R)C(O)R, -(CH2) x C(O)N(R)2, -C(O)N(R)2, -C(O)N(R)(CH2) x Cy, -(CH2) x C(O)Cy, -OC(O)R, -C(O)OR, -SO2R, -N(R)SO2R, -N=S(O)(R)2, -SO2N(R)2, -P(O)R2, -(CH2) x Cy, -O(CH2) x Cy and optionally substituted C 1-6 Fat; Each R 6 independently selected from oxo, -CN, halogen, -OR, -N(R)2, -SR, -C(O)R, -N(R)C(O)R, -C(O)N(R)2, -OC(O)R, -C(O)OR, -SO2R, -N(R)SO2R, -SO2N(R)2, and an optionally substituted group selected from the group consisting of: C 1-6 aliphatic; 3 to 6 membered carbocyclic ring; phenyl; 3 to 6 membered heterocyclic ring having 1 to 3 heteroatoms independently selected from nitrogen, oxygen and sulfur; 5 to 6 membered heteroaromatic ring having 1 to 3 heteroatoms independently selected from nitrogen, oxygen and sulfur; 10 membered aromatic ring; and 9 to 10 membered heteroaromatic ring having 1 to 3 heteroatoms independently selected from nitrogen, oxygen and sulfur; Each R is independently hydrogen or an optionally substituted group selected from: C 1-6 aliphatic; 3 to 6 membered carbocyclic ring; phenyl; 3 to 6 membered heterocyclic ring having 1 to 3 heteroatoms independently selected from nitrogen, oxygen and sulfur; 5 to 6 membered heteroaromatic ring having 1 to 3 heteroatoms independently selected from nitrogen, oxygen and sulfur; 10 membered aromatic ring; and 9 to 10 membered heteroaromatic ring having 1 to 3 heteroatoms independently selected from nitrogen, oxygen and sulfur; m is 0, 1, 2 or 3; n is 0, 1 or 2; p is 0, 1, 2 or 3; q is 0 or 1; r is 0, 1, or 2; s is 0, 1, 2, or 3; t is 0, 1, or 2; u is 0 or 1; Each v is independently 0, 1 or 2; each x is independently 0, 1 or 2; and y is 0, 1, or 2.

2. The compound according to claim 1, wherein the compound is according to formula IA: or a salt thereof (eg, a pharmaceutically acceptable salt).

3. The compound according to claim 2, wherein the compound is a compound according to formula IA1: or a salt thereof (eg, a pharmaceutically acceptable salt).

4. The compound according to claim 1, wherein the compound is according to formula IB: or a salt thereof (eg, a pharmaceutically acceptable salt).

5. The compound according to claim 4, wherein the compound is a compound according to formula IB1: or a salt thereof (eg, a pharmaceutically acceptable salt).

6. The compound according to claim 1, wherein the compound is according to formula IC: or a salt thereof (eg, a pharmaceutically acceptable salt).

7. The compound according to claim 6, wherein the compound is a compound according to formula IC1: or a salt thereof (eg, a pharmaceutically acceptable salt).

8. The compound according to claim 1, wherein the compound is according to formula ID: or a salt thereof (eg, a pharmaceutically acceptable salt).

9. The compound according to claim 8, wherein the compound is a compound according to formula ID1: or a salt thereof (eg, a pharmaceutically acceptable salt).

10. The compound according to claim 1, wherein the compound is according to Formula IE: or a salt thereof (eg, a pharmaceutically acceptable salt).

11. The compound according to claim 10, wherein the compound is a compound according to formula IE1: or a salt thereof (eg, a pharmaceutically acceptable salt).

12. The compound according to claim 1, wherein the compound is according to formula IF: or a salt thereof (eg, a pharmaceutically acceptable salt).

13. The compound according to claim 12, wherein the compound is a compound according to formula IF1: or a salt thereof (eg, a pharmaceutically acceptable salt).

14. The compound of claim 1, wherein the compound is according to one of Formulas Ia, Ib, Ic, Id, Ie, If, Ig, Ih, Ii, Ij or Ik: or a salt thereof (eg, a pharmaceutically acceptable salt).

15. The compound of claim 1, wherein the compound is a compound according to one of formula Iai, Ibi, Ici, Idi, Iei, Ifi, Igi, Ihi, Iii, Iji or Iki: or a salt thereof (eg, a pharmaceutically acceptable salt).

16. The compound of claim 1, wherein the compound is a compound according to one of formula Ia-ii', Ib-ii', Ic-ii', Id-ii', Ie-ii', If-ii', Ig-ii', Ih-ii', Ii-ii', Ij-ii' or Ik-ii': or a salt thereof (eg, a pharmaceutically acceptable salt).

17. The compound of claim 1, wherein the compound is a compound according to one of Formulas Ia-iii, Ib-iii, Ic-iii, Id-iii, Ie-iii, If-iii, Ig-iii, Ih-iii, Ii-iii, Ij-iii or Ik-iii: or a salt thereof (eg, a pharmaceutically acceptable salt).

18. The compound of claim 1, wherein the compound is according to one of formulas Ia-iv, Ib-iv, Ic-iv, Id-iv, Ie-iv, If-iv, Ig-iv, Ih-iv, Ii-iv, Ij-iv, or Ik-iv: or a salt thereof (eg, a pharmaceutically acceptable salt).

19. The compound of claim 1, wherein the compound is according to one of formula Ia-v', Ib-v', Ic-v', Id-v', Ie-v', If-v', Ig-v', Ih-v', Ii-v', Ij-v' or Ik-v': or a salt thereof (eg, a pharmaceutically acceptable salt).

20. The compound according to claim 1, wherein the compound is a compound according to one of formulas Il, Im, In, Ip, Iq or Ir: or a salt thereof (eg, a pharmaceutically acceptable salt).

21. The compound according to any one of claims 1 to 20, wherein Ring A is phenyl.

22. The compound according to claim 21, wherein ring A is 23. The compound according to claim 22, wherein ring A is selected from 24. The compound according to claim 23, wherein ring A is selected from 25. The compound according to any one of claims 21 to 24, wherein m R 3 Example substituted ring A is selected from 26. The compound according to any one of claims 1-20, wherein Ring A is a 5- to 6-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur.

27. The compound according to claim 26, wherein m R 3 Example substituted ring A is selected from 28. The compound according to any one of claims 1-27, wherein m is 1, 2 or 3.

29. A compound according to any one of claims 1 to 28, wherein at least one R 3 Selected from halogen, -OR, -O(CH2) v Cy and -O-(C 1-4 Alkylene)-OR.

30. The compound according to any one of claims 1-29, wherein Ring B is selected from a 9- to 10-membered bicyclic ring comprising at least one 5- or 6-membered heteroaromatic ring comprising at least one nitrogen atom.

31. The compound according to claim 30, wherein n R 4 Example substituted ring B is selected from 32. The compound according to any one of claims 1-29, wherein Ring B is selected from a 6-membered heteroaromatic ring having 1-2 nitrogen atoms.

33. The compound according to claim 32, wherein n R 4 Example substituted Ring B is selected from:

34. The compound according to any one of claims 1-29, wherein Ring B is phenyl.

35. according to the compound described in any one of claims 1-34, wherein each R 4 It is a halogen.

36. A compound according to any one of claims 1-35, wherein n is 0.

37. The compound according to any one of claims 1-36, wherein Ring C is phenyl.

38. The compound according to any one of claims 1-36, wherein Ring C is selected from a 5- to 6-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur.

39. The compound according to any one of claims 1-36, wherein Ring C is selected from a 5- to 8-membered bicyclic carbocycle.

40. The compound according to any one of claims 1-36, wherein Ring C is selected from a 4 to 8 membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen and sulfur.

41. The compound according to any one of claims 1-36, wherein Ring C is selected from a 7- to 10-membered spiro-fused heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur.

42. The compound according to any one of claims 1 to 41, wherein Ring C is not fused to Ring E, and is fused to Ring E via p R 5 Example substituted Ring C is selected from:

43. The compound according to any one of claims 1-41, wherein Ring C is fused to Ring E.

44. The compound according to claim 43, wherein Selected from 45. The compound according to claim 43 or 44, wherein ring E is selected from a 5- to 6-membered carbocyclic ring, wherein ring E is substituted by s R 5’ Instance replacement.

46. ​​The compound according to claim 43 or 44, wherein ring E is selected from a 5- to 7-membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen and sulfur, wherein ring E is substituted by s R 5′ Instance replacement.

47. The compound according to claim 43 or 44, wherein ring E is selected from a 7- to 10-membered spiro-fused heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur, wherein ring E is fused to ... 5′ Instance replacement.

48. The compound according to claim 43 or 44, wherein ring E is selected from a 5- to 6-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur, wherein ring E is substituted by s R 5′ Instance replacement.

49. The compound according to any one of claims 43-48, wherein Ring C is fused to Ring E and is fused to Ring E via s R 5’ Example substituted Ring E is selected from:

50. A compound according to any one of claims 43-49, wherein Selected from:

51. according to the compound described in any one of claims 1-50, wherein each R 5 independently selected from oxo, =NH, -CN, halogen, -OR, -N(R)2, -SR, -C(O)R, -N(R)C(O)R, -(CH2) x C(O)N(R)2, -C(O)N(R)(CH2) x Cy, -(CH2) x C(O)Cy, -OC(O)R, -C(O)OR, -SO2R, -N(R)SO2R, -N=S(O)(R)2, -SO2N(R)2, -P(O)(R)2, -(CH2) x Cy, -O(CH2) x Cy and C 1-6 Aliphatic, C 1-6 Aliphatic is unsubstituted or substituted with one or more halogen, -CN, -N(R)C(O)R, -N(R)2 or -OR.

52. A compound according to any one of claims 1-51, wherein p is 0.

53. A compound according to any one of claims 1-51, wherein p is 1 or 2.

54. according to the compound described in any one of claims 1-53, wherein each R 5’ independently selected from oxo, =NH, -CN, halogen, -OR, -N(R)2, -SR, -C(O)R, -N(R)C(O)R, -(CH2) x C(O)N(R)2, -(CH2) x C(O)Cy, -OC(O)R, -C(O)OR, -SO2R, -N(R)SO2R, -N=S(O)(R)2, -SO2N(R)2, -P(O)(R)2, -(CH2) x Cy, -O(CH2) x Cy and C 1-6 Aliphatic, C 1-6 Aliphatic is unsubstituted or substituted with one or more halogen, -CN, -N(R)C(O)R, -N(R)2 or -OR.

55. The compound of any one of claims 1-54, wherein s is 0.

56. A compound according to any one of claims 1-54, wherein s is 1 or 2.

57. The compound according to any one of claims 1-56, wherein Ring D is phenyl.

58. The compound according to any one of claims 1-56, wherein ring D is a 5- to 6-membered heteroaromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur.

59. The compound according to any one of claims 1-58, wherein Ring D is fused to Ring F.

60. The compound of claim 59, wherein q is 0.

61. The compound according to claim 60, wherein Selected from:

62. The compound according to claim 60 or 61, wherein u instances of -LW and y instances of R 2’ Example substituted Ring F is selected from:

63. A compound according to any one of claims 60-62, wherein Selected from:

64. A compound according to any one of claims 59-63, wherein u is 1.

65. according to the compound described in any one of claims 59-64, wherein each R 2’ Independently selected from C 1-6 alkyl.

66. A compound according to any one of claims 59-65, wherein y is 0.

67. A compound according to any one of claims 59-65, wherein y is 1 or 2.

68. The compound of any one of claims 1-58, wherein Ring D is not fused to Ring F.

69. The compound according to claim 68, wherein 2 Examples and q R 1 Example substituted ring D is selected from:

70. The compound according to claim 68, wherein R 1 For -LW.

71. The compound according to claim 68, wherein R 1 is a divalent C ring D' or a divalent C ring substituted by D' 1-6 Aliphatic chain.

72. The compound of claim 71, wherein Ring D' is selected from a 4- to 6-membered carbocyclic ring, wherein Ring D' is substituted with t instances of -LW.

73. The compound of claim 71, wherein Ring D' is selected from a 4 to 6 membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen and sulfur, wherein Ring D' is substituted with t instances of -LW.

74. The compound of any one of claims 71-73, wherein the ring D' substituted with t instances of -LW is selected from:

75. according to the compound described in any one of claims 71-74, wherein through r R 2 Example substituted ring D is selected from:

76. A compound according to any one of claims 71-73, wherein ring D is substituted with 1 R 1 Instance replacement, R 1 is a ring D', and Selected from:

77. A compound according to any one of claims 68-76, wherein q is 1.

78. A compound according to any one of claims 1-77, wherein r is 0.

79. A compound according to any one of claims 1-77, wherein r is 1 or 2.

80. The compound of any one of claims 1-79, wherein t is 0.

81. The compound of any one of claims 1-79, wherein t is 1.

82. According to the compound described in any one of claims 1-81, wherein each L is independently selected from divalent straight chain or branched C 1-8 An aliphatic chain, wherein one or two methylene units of the aliphatic chain are optionally and independently replaced by a group selected from the group consisting of -N(R)-, -O-, -S-, -C(O)-, -SO2-, -CH(X)-, -C(X)2-, -C(O)N(R)-, -N(R)C(O)-, -C(O)O-, -OC(O)-, -SO2N(R)- and -N(R)SO2-.

83. A compound according to claims 1-82, wherein each L is independently selected from a divalent straight or branched C 1-8 An aliphatic chain, wherein one or more methylene units of the aliphatic chain are optionally and independently replaced by a group selected from the group consisting of -N(R)-, -O-, -S-, -C(O)-, -SO2-, -CH(X)-, -C(X)2-, -C(O)N(R)-, -N(R)C(O)-, -C(O)O-, -OC(O)-, -SO2N(R)- and -N(R)SO2-.

84. The compound according to claim 83, wherein each L is independently selected from a divalent straight or branched chain C having one double bond. 1-8 An aliphatic chain, wherein one or two methylene units of the aliphatic chain are optionally and independently replaced by a group selected from the group consisting of -N(R)-, -O-, -C(O)-, -SO2-, -C(O)N(R)-, -N(R)C(O)-, -C(O)O-, -OC(O)-, -SO2N(R)- and -N(R)SO2-.

85. according to the compound described in any one of claims 1-84, wherein each L is independently selected from divalent straight chain or branched C 1-8 An aliphatic chain, wherein one or two methylene units of the aliphatic chain are optionally and independently replaced by a group selected from the group consisting of -N(R)-, -O-, C(O)-, -C(O)N(R)-, and -N(R)C(O)-.

86. According to the compound described in any one of claims 1-85, wherein each L is independently selected from divalent straight chain or branched C 1-4 Aliphatic chain.

87. According to the compound described in any one of claims 1-86, wherein each L is independently selected from a divalent straight or branched chain C having one double bond. 1-4 An aliphatic chain, wherein one or two methylene units of the aliphatic chain are optionally and independently replaced by a group selected from the group consisting of -N(R)-, -C(O)-, and -N(R)C(O)-.

88. A compound according to any one of claims 1-87, wherein each L is independently selected from -C(O)CClF-, -C(O)CH=CH-, -N(R)C(O)CH=CH-, -C(O)C(=CH2)-, -C(O)CH=CH-CH2-, -C(O)CH=CHCH2OCH2-, -C(O)CH=CHC H2N(R)-, -CH2N(R)C(O)CH=CH- and -CH2CH2N(R)C(O)CH=CH-.

89. A compound according to any one of claims 1-88, wherein each W is hydrogen.

90. A compound according to any one of claims 1-88, wherein each W is halogen.

91. A compound according to any one of claims 1-90, wherein each -LW is independently selected from -CH3, -CH(CH3)2, -CH2C(CH3)3, -CH2OH, -CH2NH2, -OCH(CH3)2, -CN, 92. A compound according to any one of claims 1-91, wherein each -LW is independently selected from -C(O)CH=CH2, -C(O)CF=CH2, -NHC(O)CF=CH2 and -NHC(O)CH=CH2.

93. according to the compound described in any one of claims 1-92, wherein R 1 Selected from -CH3, -CH(CH3)2, -CH2C(CH3)3, -CH2NH2, -CH2OH, -OCH(CH3)2, 94. according to the compound described in any one of claims 1-93, wherein each R is independently hydrogen, C 1-6 Aliphatic or C 1-6 Halogenated fatty acids.

95. A compound selected from Table 1 or a salt (eg, a pharmaceutically acceptable salt) thereof.

96. A compound selected from Table 2 or a salt (eg, a pharmaceutically acceptable salt) thereof.

97. A pharmaceutical composition comprising a compound according to any one of claims 1-96 or a salt thereof (eg, a pharmaceutically acceptable salt) and a pharmaceutically acceptable carrier or excipient.

98. A method comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to any one of claims 1-96, or a pharmaceutically acceptable salt thereof.

99. The method of claim 98, wherein the subject suffers from a disease, disorder or condition that is ameliorated by disrupting, inhibiting and / or preventing the interaction between a small GTPase and a PI3K alpha protein.

100. The method of claim 99, wherein the small GTPase is Racl, CDC42 or a RAS protein.

101. The method of claim 100, wherein the small GTPase is a RAS protein.

102. The method of claim 101, wherein the RAS protein is KRAS, NRAS, HRAS, RRAS, RRAS2, MRAS, or RIT1.

103. The method of any one of claims 98-102, wherein the subject has cancer.

104. A method of treating cancer comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to any one of claims 1-96 or a pharmaceutically acceptable salt thereof.

105. The method of claim 103 or 104, wherein the cancer is associated with and / or characterized by aberrant activation of PI3Kα and / or mutations in PI3Kα.

106. The method of claim 105, wherein the PI3Kα protein comprises N345K, E726K, C420R, Q546R, G118D, E453K, Q546K, G1049R, M1043I, K111E, K111N, E81K, E545A, E545G, N1044K, E110del, Q546P, E542K, E545K, H1047R and / or H1047L mutations.

107. The method of claim 106, wherein the PI3Kα protein comprises E542K, E545K, H1047R and / or H1047L mutations.

108. The method of any one of claims 103-107, wherein the cancer is characterized by a mutation in a RAS protein.

109. The method of claim 108, wherein the RAS protein comprises a mutation in codon 12, 13, or 61.

110. The method of claim 108 or 109, wherein the RAS protein is KRAS.

111. The method of claim 110, wherein the KRAS protein comprises a G12C, G12D, G12S, G12V, G12R, G12A, G13D, G13A, G13C, G13R, G13S, G13V, Q61E, Q61K, Q61L, Q61P, Q61R and / or Q61H mutation.

112. The method of claim 111, wherein the KRAS protein comprises a G12C or G12D mutation.

113. The method of claim 108 or 109, wherein the RAS protein is HRAS.

114. The method of claim 113, wherein the HRAS protein comprises a G12C, G12D, G12S, G12V, G12R, G12A, G13D, G13C, G13R, G13S, G13V, Q61K, Q61L, Q61P, Q61R and / or Q61H mutation.

115. The method of claim 108 or 109, wherein the RAS protein is NRAS.

116. The method of claim 115, wherein the NRAS protein comprises a G12C, G12D, G12S, G12V, G12R, G12A, G13D, G13A, G13C, G13R, G13S, G13V, Q61E, Q61K, Q61L, Q61P, Q61R and / or Q61H mutation.

117. The method of any one of claims 103-116, wherein the cancer is selected from pancreatic cancer; colon cancer; rectal cancer; colorectal cancer; intestinal cancer; breast cancer; ovarian cancer; endometrial cancer; lung cancer; prostate cancer; oral and pharyngeal cancer (lip cancer, tongue cancer, mouth cancer, larynx cancer, pharynx cancer), esophageal cancer, stomach cancer, small intestine cancer, large intestine cancer, liver cancer and bile duct cancer, bone cancer, connective tissue cancer, skin cancer, cervical cancer, uterine cancer, endometrial cancer, testicular cancer, bladder cancer, kidney cancer and other urinary tissue cancers, including renal cell carcinoma (RCC) C); cancers of the eye, brain, spinal cord, and other components of the central and peripheral nervous systems, and associated structures such as the meninges; thyroid and other endocrine gland cancers; Hodgkin's disease; non-Hodgkin's lymphoma; multiple myeloma; and hematopoietic malignancies, including leukemias (chronic lymphocytic leukemia (CLL), acute lymphocytic leukemia (ALL), chronic myeloid leukemia (CML), acute myeloid leukemia (AML)) and lymphomas, including lymphocytic, granulocytic, and monocytic lymphomas.

118. The method of claim 117, wherein the cancer is selected from breast cancer, lung cancer (e.g., non-small cell lung cancer), endometrial cancer, esophageal cancer, ovarian cancer, colorectal cancer, gastric cancer, squamous cell carcinoma, prostate cancer, and pancreatic cancer.

119. The method of any one of claims 103-118, wherein the cancer is characterized by a mutated, overexpressed and / or amplified receptor tyrosine kinase (e.g., HER family, Met, FGFR, Alk, PDGF, EGFR, or ROS kinase).

120. The method of any one of claims 103-119, wherein the cancer is characterized by a mutation or deletion in the PTEN protein.

121. The method of any one of claims 98-120, wherein the subject has previously received a cancer treatment regimen.

122. The method of any one of claims 98-121, wherein the subject has previously entered cancer remission.

123. A method of treating a metabolic disorder comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to any one of claims 1-96, or a pharmaceutically acceptable salt thereof.

124. The method of claim 123, wherein the metabolic disorder is selected from hyperinsulinemia and type 2 diabetes.

125. A method for treating RASopathy, comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to any one of claims 1-96 or a pharmaceutically acceptable salt thereof.

126. The method of claim 125, wherein the RASopathy is selected from neurofibromatosis type 1 (NF1), capillary malformation-arteriovenous malformation syndrome, and Legius syndrome.

127. A method of treating a vascular condition or disorder comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to any one of claims 1-96, or a pharmaceutically acceptable salt thereof.

128. The method of claim 127, wherein the vascular disorder or condition is selected from PIK3CA-associated overgrowth syndrome (PROS) and vascular malformations (e.g., venous malformations; lymphatic malformations; congenital lipomatous overgrowth with vascular, epidermal, and skeletal anomalies syndrome (CLOVES); Klippel-Trenaunay syndrome; PTEN hamartoma tumor syndrome (PHTS); and fibrofatty vascular anomaly (FAVA)).

129. A method for disrupting, inhibiting and / or preventing the interaction between a small GTPase and a PI3Kα protein in a subject, comprising administering to the subject a compound according to any one of claims 1-96 or a pharmaceutically acceptable salt thereof.

130. A method for disrupting, inhibiting and / or preventing the interaction between a small GTPase and a PI3Kα protein, comprising contacting a cell containing the small GTPase and the PI3Kα protein with a compound according to any one of claims 1-96 or a pharmaceutically acceptable salt thereof.

131. A method comprising contacting a cell containing a small GTPase and a PI3Kα protein with a compound according to any one of claims 1-96, or a pharmaceutically acceptable salt thereof.

132. The method of claim 130 or 131, wherein the cell is comprised in a subject.

133. The method of any one of claims 129-132, wherein the small GTPase is selected from Racl, CDC42 and RAS proteins.

134. The method of claim 133, wherein the small GTPase is a RAS protein.

135. The method of claim 134, wherein the RAS protein is selected from HRAS, NRAS, KRAS, RRAS, RRAS2, MRAS, and RIT1.

136. The method of claim 135, wherein the RAS protein is KRAS.

137. The method of claim 136, wherein the KRAS protein comprises a G12C, G12D, G12S, G12V, G12R, G12A, G13D, G13A, G13C, G13R, G13S, G13V, Q61E, Q61K, Q61L, Q61P, Q61R and / or Q61H mutation.

138. The method of claim 137, wherein the KRAS protein comprises a G12C or G12D mutation.

139. The method of claim 135, wherein the RAS protein is HRAS.

140. The method of claim 139, wherein the HRAS protein comprises a G12C, G12D, G12S, G12V, G12R, G12A, G13D, G13C, G13R, G13S, G13V, Q61K, Q61L, Q61P, Q61R and / or Q61H mutation.

141. The method of claim 135, wherein the RAS protein is NRAS.

142. The method of claim 141, wherein the NRAS protein comprises a G12C, G12D, G12S, G12V, G12R, G12A, G13D, G13A, G13C, G13R, G13S, G13V, Q61E, Q61K, Q61L, Q61P, Q61R and / or Q61H mutation.

143. A compound according to any one of claims 1-96, or a pharmaceutically acceptable salt thereof, for use as a medicament.

144. Use of a compound according to any one of claims 1-96 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament.

145. The compound or use according to claim 143 or 144, wherein the medicament is for treating cancer.

146. The compound or use according to claim 145, wherein the cancer is associated with and / or characterized by aberrant activation of PI3K alpha and / or mutations in PI3K alpha.

147. The compound or use of claim 146, wherein the PI3Kα protein comprises N345K, E726K, C420R, Q546R, G118D, E453K, Q546K, G1049R, M1043I, K111E, K111N, E81K, E545A, E545G, N1044K, E110del, Q546P, E542K, E545K, H1047R and / or H1047L mutations.

148. The compound or use of claim 147, wherein the PI3Kα protein comprises E542K, E545K, H1047R and / or H1047L mutations.

149. The compound or use of any one of claims 145-148, wherein the cancer is characterized by a mutation in a RAS protein.

150. The compound or use of claim 149, wherein the RAS protein comprises a mutation in codon 12, 13, or 61.

151. The compound or use of claim 149 or 150, wherein the RAS protein is KRAS.

152. The compound or use of claim 151, wherein the KRAS protein comprises a G12C, G12D, G12S, G12V, G12R, G12A, G13D, G13A, G13C, G13R, G13S, G13V, Q61E, Q61K, Q61L, Q61P, Q61R and / or Q61H mutation.

153. The compound or use of claim 152, wherein the KRAS protein comprises a G12C or G12D mutation.

154. The compound or use of claim 149 or 150, wherein the RAS protein is HRAS.

155. The compound of claim 154, wherein the HRAS protein comprises a G12C, G12D, G12S, G12V, G12R, G12A, G13D, G13C, G13R, G13S, G13V, Q61K, Q61L, Q61P, Q61R and / or Q61H mutation.

156. The compound or use of claim 149 or 150, wherein the RAS protein is NRAS.

157. A compound or use according to claim 156, wherein the NRAS protein comprises a G12C, G12D, G12S, G12V, G12R, G12A, G13D, G13A, G13C, G13R, G13S, G13V, Q61E, Q61K, Q61L, Q61P, Q61R and / or Q61H mutation.

158. A compound or use according to any one of claims 145-157, wherein the cancer is selected from pancreatic cancer; colon cancer; rectal cancer; colorectal cancer; intestinal cancer; breast cancer; ovarian cancer; endometrial cancer; lung cancer; prostate cancer; oral cancer and pharyngeal cancer (lip cancer, tongue cancer, mouth cancer, larynx cancer, pharynx cancer), esophageal cancer, stomach cancer, small intestine cancer, large intestine cancer, liver cancer and bile duct cancer, bone cancer, connective tissue cancer, skin cancer, cervical cancer, uterine cancer, endometrial cancer, testicular cancer, bladder cancer, kidney cancer and other urinary tissue cancers, including renal cell carcinoma ( cancers of the eye, brain, spinal cord, and other components of the central and peripheral nervous systems, and associated structures such as the meninges; thyroid and other endocrine gland cancers; Hodgkin's disease; non-Hodgkin's lymphoma; multiple myeloma; and hematopoietic malignancies, including leukemias (chronic lymphocytic leukemia (CLL), acute lymphocytic leukemia (ALL), chronic myeloid leukemia (CML), acute myeloid leukemia (AML)) and lymphomas, including lymphocytic, granulocytic, and monocytic lymphomas.

159. The compound or use of claim 158, wherein the cancer is selected from breast cancer, lung cancer (e.g., non-small cell lung cancer), endometrial cancer, esophageal cancer, ovarian cancer, colorectal cancer, gastric cancer, squamous cell carcinoma, prostate cancer, and pancreatic cancer.

160. A compound or use according to any one of claims 145-159, wherein the cancer is characterized by a mutated, overexpressed and / or amplified receptor tyrosine kinase (e.g., HER family, Met, FGFR, Alk, PDGF, EGFR or ROS kinase).

161. The compound or use of any one of claims 145-159, wherein the cancer is characterized by a mutation or deletion in the PTEN protein.

162. The compound or use according to claim 143 or 144, wherein the medicament is for treating a metabolic disorder, a RASopathy, or a vascular disorder.

163. The compound or use according to claim 162, wherein: (i) the metabolic disorder is selected from hyperinsulinemia and type 2 diabetes; (ii) the RASopathy is selected from neurofibromatosis type 1 (NF1), capillary malformation-arteriovenous malformation syndrome and Legius syndrome; and / or (iii) the vascular disorder or condition is selected from PIK3CA-associated overgrowth syndrome (PROS) and vascular malformations (e.g., venous malformations; lymphatic malformations; congenital lipomatous overgrowth with vascular, epidermal and skeletal anomalies syndrome (CLOVES); Klippel-Trenaunay syndrome; PTEN hamartoma tumor syndrome (PHTS); or fibrofatty vascular anomaly (FAVA)).

164. A compound according to any one of claims 1-96, or a pharmaceutically acceptable salt thereof, for use in treating a disease, disorder or condition.

165. A compound for use according to claim 164 for use in the treatment of cancer.

166. The compound for use according to claim 165, wherein the cancer is associated with and / or characterized by aberrant activation of PI3K alpha and / or mutations in PI3K alpha.

167. The compound for use according to claim 166, wherein the PI3Kα protein comprises N345K, E726K, C420R, Q546R, G118D, E453K, Q546K, G1049R, M1043I, K111E, K111N, E81K, E545A, E545G, N1044K, E110del, Q546P, E542K, E545K, H1047R and / or H1047L mutations.

168. The compound for use according to claim 167, wherein the PI3Kα protein comprises E542K, E545K, H1047R and / or H1047L mutations.

169. A compound for use according to any one of claims 165-168, wherein the cancer is characterized by a mutation in a RAS protein.

170. The compound for use according to claim 169, wherein the RAS protein comprises a mutation in codon 12, 13 or 61.

171. The compound for use according to claim 169 or 170, wherein the RAS protein is KRAS.

172. The compound for use according to claim 171, wherein the KRAS protein comprises a G12C, G12D, G12S, G12V, G12R, G12A, G13D, G13A, G13C, G13R, G13S, G13V, Q61E, Q61K, Q61L, Q61P, Q61R and / or Q61H mutation.

173. The compound for use according to claim 172, wherein the KRAS protein comprises a G12C or G12D mutation.

174. The compound for use according to claim 169 or 170, wherein the RAS protein is HRAS.

175. The compound for use according to claim 174, wherein the HRAS protein comprises a G12C, G12D, G12S, G12V, G12R, G12A, G13D, G13C, G13R, G13S, G13V, Q61K, Q61L, Q61P, Q61R and / or Q61H mutation.

176. A compound for use according to claim 169 or 170, wherein the RAS protein is NRAS.

177. The compound for use according to claim 176, wherein the NRAS protein comprises a G12C, G12D, G12S, G12V, G12R, G12A, G13D, G13A, G13C, G13R, G13S, G13V, Q61E, Q61K, Q61L, Q61P, Q61R and / or Q61H mutation.

178. A compound for use according to any one of claims 165-177, wherein the cancer is selected from pancreatic cancer; colon cancer; rectal cancer; colorectal cancer; intestinal cancer; breast cancer; ovarian cancer; endometrial cancer; lung cancer; prostate cancer; oral and pharyngeal cancer (lip cancer, tongue cancer, mouth cancer, larynx cancer, pharynx cancer), esophageal cancer, stomach cancer, small intestine cancer, large intestine cancer, liver cancer and bile duct cancer, bone cancer, connective tissue cancer, skin cancer, cervical cancer, uterine cancer, endometrial cancer, testicular cancer, bladder cancer, kidney cancer and other urinary tissue cancers, including renal cell carcinoma (RCC). The invention relates to cancers of the eye, brain, spinal cord, and other components of the central and peripheral nervous systems, and related structures such as the meninges; thyroid and other endocrine glands; Hodgkin's disease; non-Hodgkin's lymphoma; multiple myeloma; and hematopoietic malignancies, including leukemias (chronic lymphocytic leukemia (CLL), acute lymphocytic leukemia (ALL), chronic myeloid leukemia (CML), acute myeloid leukemia (AML)) and lymphomas, including lymphocytic, granulocytic, and monocytic lymphomas.

179. The compound for use according to claim 178, wherein the cancer is selected from breast cancer, lung cancer (e.g., non-small cell lung cancer), endometrial cancer, esophageal cancer, ovarian cancer, colorectal cancer, gastric cancer, squamous cell carcinoma, prostate cancer, and pancreatic cancer.

180. A compound for use according to any one of claims 165-179, wherein the cancer is characterized by a mutated, overexpressed and / or amplified receptor tyrosine kinase (e.g., HER family, Met, FGFR, Alk, PDGF, EGFR or ROS kinase).

181. A compound for use according to any one of claims 165-180, wherein the cancer is characterized by a mutation or deletion in the PTEN protein.

182. A compound for use according to claim 164 for use in the treatment of a metabolic disorder, a RASopathy or a vascular disorder.

183. A compound for use according to claim 182, wherein: (i) the metabolic disorder is selected from hyperinsulinemia and type 2 diabetes; (ii) the RASopathy is selected from neurofibromatosis type 1 (NF1), capillary malformation-arteriovenous malformation syndrome and Legius syndrome; and / or (iii) the vascular disorder or condition is selected from PIK3CA-associated overgrowth syndrome (PROS) and vascular malformations (e.g., venous malformations; lymphatic malformations; congenital lipomatous overgrowth with vascular, epidermal and skeletal anomalies syndrome (CLOVES); Klippel-Trenaunay syndrome; PTEN hamartoma tumor syndrome (PHTS); and fibrofatty vascular anomaly (FAVA)).

184. A compound capable of disrupting, inhibiting and / or preventing the interaction between a small GTPase and a PI3Kα protein.

185. The compound of claim 184, wherein the compound is capable of binding to PI3Kα such that (i) the interaction between the small GTPase and PI3Kα is at least partially disrupted, prevented or inhibited; and / or (ii) the kinase activity of PI3Kα is not significantly inhibited.

186. The compound of claim 184 or 185, wherein the compound has the following activity: (i) <5 μM or ≥5 μM and ≤25 μM in an assay of Biological Example 1 (e.g., a surface plasmon resonance (SPR) binding assay assessing inhibition of KRAS-PI3Kα interaction); (ii) ≥75%, <75% and ≥50%, or <50% and ≥25%, in an assay of Biological Example 2 (e.g., matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) analysis, covalent modification of Cys242 in human PIK3CA (157-299)); (iii) <1 μM or ≥1 μM and ≤10 μM in an assay of Biological Example 3 (e.g., a matrix-assisted cell-based pAKT homogeneous time-resolved fluorescence (HTRF) assay in Tet-on KRAS G12D HeLa cells); and / or (iv) <0.1 μM, ≥0.1 μM and <1 μM, or ≥1 μM and ≤3 μM in an assay of Biological Example 4 (eg, a matrix-assisted cell-based pAKT HTRF assay in BT474 cells).

187. A compound according to any one of claims 184-186, wherein the compound comprises an electrophilic portion.

188. The compound according to any one of claims 184-187, wherein the compound is capable of interacting with the Cys242 residue in the catalytic subunit of PI3Kα.

189. The compound of any one of claims 184-188, wherein the compound is capable of irreversibly binding to the PI3Kα protein.

190. The compound of any one of claims 184-189, wherein the compound is capable of reversibly binding to the PI3Kα protein.

191. The compound of any one of claims 184-190, wherein the small GTPase is Racl, CDC42 or RAS protein.

192. The compound of claim 191, wherein the RAS protein is KRAS, NRAS, HRAS, RRAS, RRAS2, MRAS or RIT1.

193. The compound of claim 191 or 192, wherein the RAS protein comprises a mutation in codon 12, 13 or 61.

194. The compound of claim 192 or 193, wherein the RAS protein is KRAS.

195. The compound of claim 194, wherein the KRAS protein comprises a G12C, G12D, G12S, G12V, G12R, G12A, G13D, G13A, G13C, G13R, G13S, G13V, Q61E, Q61K, Q61L, Q61P, Q61R and / or Q61H mutation.

196. The compound of claim 195, wherein the KRAS protein comprises a G12C or G12D mutation.

197. The compound of claim 192 or 193, wherein the RAS protein is HRAS.

198. The compound of claim 197, wherein the HRAS protein comprises a G12C, G12D, G12S, G12V, G12R, G12A, G13D, G13C, G13R, G13S, G13V, Q61K, Q61L, Q61P, Q61R and / or Q61H mutation.

199. The compound of claim 192 or 193, wherein the RAS protein is NRAS.

200. The compound of claim 199, wherein the NRAS protein comprises a G12C, G12D, G12S, G12V, G12R, G12A, G13D, G13A, G13C, G13R, G13S, G13V, Q61E, Q61K, Q61L, Q61P, Q61R and / or Q61H mutation.

201. The compound of any one of claims 184-200, wherein the compound is a compound of any one of claims 1-96.

202. A method for disrupting, inhibiting and / or preventing the interaction between a small GTPase and a PI3Kα protein, comprising contacting a cell containing the small GTPase and the PI3Kα protein with a compound according to any one of claims 184-201 or a pharmaceutically acceptable salt thereof.

203. The method of claim 202, wherein the cell is within a subject.

204. The method of claim 202 or 203, wherein the small GTPase is Racl, CDC42 or RAS protein.

205. The method of claim 204, wherein the RAS protein is KRAS, NRAS, HRAS, RRAS, RRAS2, MRAS or RIT1.

206. The method of claim 205, wherein the RAS protein comprises a mutation in codon 12, 13, or 61.

207. The method of claim 205 or 206, wherein the RAS protein is KRAS.

208. The method of claim 207, wherein the KRAS protein comprises a G12C, G12D, G12S, G12V, G12R, G12A, G13D, G13A, G13C, G13R, G13S, G13V, Q61E, Q61K, Q61L, Q61P, Q61R and / or Q61H mutation.

209. The method of claim 208, wherein the KRAS protein comprises a G12C or G12D mutation.

210. The method of claim 205 or 206, wherein the RAS protein is HRAS.

211. The method of claim 210, wherein the HRAS protein comprises G12C, G12D, G12S, G12V, G12R, G12A, G13D, G13C, G13R, G13S, G13V, Q61K, Q61L, Q61P, Q61R and / or Q61H mutations.

212. The method of claim 205 or 206, wherein the RAS protein is NRAS.

213. The method of claim 212, wherein the NRAS protein comprises a G12C, G12D, G12S, G12V, G12R, G12A, G13D, G13A, G13C, G13R, G13S, G13V, Q61E, Q61K, Q61L, Q61P, Q61R and / or Q61H mutation.

Citation Information

Cited By

  • Phosphoinositide 3-kinase modulators and uses thereof

    WO2026210384A1